| Entries |
| Document | Title | Date |
|---|
| 20080206148 | Method for radiographic targeting of malignant tumors and apparatus for focusing rays - A method and apparatus for immunoimaging and destruction of malignant tumors using immunoimaging agents comprising nanoclusters incorporating monoclonal antibodies that selectively bind to the cell membrane of tumor cells, and conjugated payloads comprising an encapsulated near-infrared (NIR) fluorescing crystal. The encapsulated fluorescing crystal compound provides excellent non-radiometric imaging of the tumor, and the non-antigenic metal coating encapsulating the fluorescing crystal particles provides a non-destructive necrotic killing of the tumor cells by low-level radiometric amplification and heating of the tumor cell membrane. Thus the very same nanoclusters used during imaging also serve to kill the tumor cells by necrosis, damaging the cell membrane by overheating as a result of secondary irradiation (not by harmful radiometric-induced apoptosis). Also included is a radiometric treatment platform for that better focuses the marked tumor by articulating the patient (180 degrees along one axis, 90 degrees along another), thereby minimizing incident radiation and destroying the tumor without exposing healthy tissue. | 08-28-2008 |
| 20080206149 | METHOD, DYE AND MEDICAMENT FOR STAINING THE INTERNAL LIMITING MEMBRANE, EPIRETINAL MEMBRANE, THE VITREOUS AND/OR THE CAPSULE OF AN EYE - The present invention concerns a method of staining the internal limiting membrane, the vitreous and/or the lens capsule of the eye as well as dyes and medicaments suitable for this method. Such dyes, medicaments and methods are needed in ophthalmic surgery, in particular in macular and/or cataract surgery and/or vitrectomy. | 08-28-2008 |
| 20080213188 | NOVEL OPHTHALMIC COMPOSITIONS CONTAINING HUMAN RECOMBINANT LYSOZYME AND USE THEREOF FOR TREATING EYE CONDITIONS AND AS CONTACT LENS SOLUTIONS - An ophthalmic solution comprising: a) a human recombinant lysozyme; b) one or more natural lacrophyl substances; c) water; and d) optionally one or more therapeutic substances. The ophthalmic solution is useful to treat dry eye conditions and eye inflammation and also to condition and/or cleanse contact lenses. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims. | 09-04-2008 |
| 20080219933 | Fluorescence-Mediated Molecular Tomography - This invention relates to a fluorescence-mediated molecular tomographic imaging system, designed to detect near-infrared fluorescence activation in deep tissues. The system can use targeted fluorescent molecular probes or highly sensitive activatable fluorescence molecular probes. Such probes add molecular specificity and yield high fluorescence contrast, to allow early detection and molecular target assessment of diseased tissue, such as cancers, in vivo. The new tomographic imaging system enables three-dimensional localization in deep tissues and quantitation of molecular probes. | 09-11-2008 |
| 20080226562 | Biocompatible fluorescent metal oxide nanoparticles - The invention relates to highly fluorescent metal oxide nanoparticles to which biomolecules and other compounds can be chemically linked to form biocompatible, stable optical imaging agents for in vitro and in vivo applications. The fluorescent metal oxide nanoparticles may also be used for magnetic resonance imaging (MRI), thus providing a multi modality imaging agent. | 09-18-2008 |
| 20080226563 | Non-invasive localization of a light-emitting conjugate in a mammal - Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking the progression of disease or a pathogen within the animal, and for screening putative therapeutic compounds effective to inhibit the disease or pathogen. | 09-18-2008 |
| 20080233050 | Diagnostic and therapeutic optical agents - Disclosed herein are compounds that may be characterized by some as cyanine and indocyanine dye bioconjugates. Compounds disclosed herein may be utilized (e.g., in the form of a pharmaceutically acceptable composition) in a number of medical procedures, such as in the visualization and detection of tumors. | 09-25-2008 |
| 20080233051 | Nanoparticles for two-photon activated photodynamic therapy and imaging - The present invention provides organically modified silica (ORMOSIL) nanoparticles into which have been incorporated two-photon absorption dye molecules. The two photon absorption dye displays a unique aggregation induced fluorescence enhancement behavior. As a result ORMOSIL nanoparticles with high amounts of the dye can be prepared. These particles can be used for imaging. In one embodiment, the nanoparticles can additionally have incorporated therein a photosensitizer. The photosensitizer can be activated by intraparticle fluorescence resonance energy transfer (FRET) from the dye aggregates resulting in enhanced fluorescence and singlet oxygen generation from photosensitizer under two-photon excitation conditions. Such nanoparticles can be used for photodynamic therapy applications. | 09-25-2008 |
| 20080241071 | Quantum Dot Probes - Novel nanoparticulate compositions of luminescent probes, as well as methods of using such compositions and systems comprising such compositions are provided. One such composition comprises at least one probe comprising a quantum dot, at least one metal nanoparticle, and at least one tether that is attached to the quantum dot and to the at least one metal nanoparticle. One such method comprises providing at least one such probe, introducing the at least one probe into a subject; and detecting luminescence from the at least one probe in the subject. One such system comprises at least one such probe and a detector capable of detecting luminescence from the quantum dot, wherein the detector is positioned in relation to the at least one probe such that luminescence can be detected. | 10-02-2008 |
| 20080247958 | Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use - A composition comprising an albumin-based colloid composition having at least one protected thiol region, method of making the same, and method for use, including treating hypovolemic conditions such as capillary leak syndrome and shock, are disclosed. The composition also is modified with an indicator reagent such as chromophores. | 10-09-2008 |
| 20080253968 | IN VIVO EXAMINATION METHOD - It is possible to perform quantitative examination of biological tissue even with a solution composed of a near-infrared fluorescent dye and a polypeptide. An image acquired before administering a reagent is subtracted from an image acquired after administering the reagent to remove regions appearing in both images, such as autofluorescence, thus obtaining an image in which only detected fluorescence affected by administration of the reagent is extracted. Because tumors have many (leaky) blood vessels, regions having many areas of high intensity in the extracted image can be recognized as tumors. | 10-16-2008 |
| 20080260647 | Method for Fluorescence Tomographic Imaging - There is provided a method for determining the concentration of a fluorophore in a medium using moments of order k of the fluorescence signal. The method allows higher fidelity 3-dimensional reconstructions of the fluorophore in the medium. The method can be applied in imaging of fluorophores in biological tissues. | 10-23-2008 |
| 20080279780 | Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer - A chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for using the chlorotoxin conjugate. | 11-13-2008 |
| 20080286207 | Polycyclo Dyes and Use Thereof - The invention relates to a family of fluorescent compounds that comprise a bridged polycyclo moiety. The compounds can be chemically linked to biomolecules, such as proteins, nucleic acids, and therapeutic small molecules. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications, and are particularly useful for the in vivo imaging of regions of interest within a mammal. | 11-20-2008 |
| 20080286208 | Eye treatment - The invention relates to a method of diagnosing the eye and to methods for subsequent treatment following such diagnosis. The method involves diagnosing a deficiency in the anatomy and performance of the upper eyelid recognizing the impact of this deficiency during blinking on problems such as dry eye, contact lens intolerance and ocular discomfort in general. The invention also involves the use of this diagnostic method to provide a treatment modality to alleviate such problems. | 11-20-2008 |
| 20080292555 | Quantitative Two-Photon Flow Cytometry - A method and apparatus of multi-dye analysis of particles using flow cytometer. The method includes dying particles to be detected using two or more dyes; urging the particles through a capillary in a non-uniform flow; exciting a first of the particles within the capillary using a multiphoton excitation laser beam causing the two or more dyes each to fluoresce thereby producing a first output signal and a second output signal respectively; and detecting the first output signal and the second output signal. A second of the particles within the capillary being excited using the multiphoton excitation laser beam causing the two or more dyes each to fluoresce thereby producing a third output signal and a forth output signal respectively. The method finally includes comparing a ratio of the first output signal and the second output signal to a ratio of the third output signal and the forth output signal to detect a desired change in the particles. | 11-27-2008 |
| 20080292556 | Target Vector with Activable Imaging Function - The invention concerns the field of molecular probe architecture for in vivo imaging. More particularly, the invention concerns molecular constructs providing an imaging function activable in intracellular environment, said constructs being further bound to a vector which enables certain cells to be targeted, and said cells to be internalized. The inventive fluorescence probes enable in particular images of certain targeted tissues to be formed, while maintaining a low background noise level and, preferably, while obtaining at the targeted tissue, an imaging signal increasing in time. | 11-27-2008 |
| 20080299044 | Saccharide Fluorescent Substrates, Preparation Method and Uses Thereof - The invention concerns saccharide type fluorescent enzymatic substrates comprising on the same saccharide unit a fluorophor F1 and an inhibitor of the fluorescence of F1, and their use for preparing a diagnostic reagent for in vivo functional imaging, as well as a diagnostic reagent containing at least such an enzymatic substrate. | 12-04-2008 |
| 20080305047 | Chemosensors Based on Quantum Dots and Oxazine Compounds - We identified a mechanism to detect chemical changes with a modified semiconductor nanoparticle (e.g., an oxazine-adsorbed CdSe—ZnS core-shell quantum dot). Our strategy is based on the chemical transformation of chromo-genie ligands adsorbed on the surface of a quantum dot. This activates an energy transfer pathway from the quantum dot to the adsorbed chromogenic ligands, which causes a change (e.g., increase or decrease) in a characteristic of fluorescent emission (e.g., intensity or lifetime). Thus, modified quantum dots acting through this mechanism can efficiently transduce a chemical event or occurrence into a change in optical signal. Our design can be adapted to signal chemical changes by a diversity of target analytes and, thus, it can be used to develop other fluorescent chemosensors based on the unique properties of quantum dots. | 12-11-2008 |
| 20080311047 | Multimetric Biosensors and Methods of Using Same - Multimeric tryptophan biosensors are disclosed, which comprise tryptophan-binding domains conjugated to donor and fluorescent moieties that permit detection and measurement of Fluorescence Resonance Energy Transfer upon tryptophan binding. Such biosensors are useful for real time monitoring of tryptophan metabolism in living cells. | 12-18-2008 |
| 20080317674 | Method and Reagent for Measuring Nitroreductase Enzyme Activity - Disclosed are nitro-substituted squaraine reporter dyes and methods using such dyes for detecting nitroreductase enzyme activity and nitroreductase gene expression in cellular assays. The dyes are of the structure: | 12-25-2008 |
| 20090004115 | IN VIVO CELL TRAFFICKING - Provided herein are methods of monitoring inflammatory cell migration in a mammal. The methods include the steps of: providing a donor mammalian subject; introducing an inflammatory agent into the donor mammal to create a granuloma; isolating granuloma-derived nucleated cells from the granuloma of the donor mammalian subject; labeling the granuloma-derived nucleated cells with an optical agent; providing a recipient mammalian subject with inflamed tissue; introducing the granuloma-derived nucleated cells into a recipient mammalian subject at a site remote from site where the inflammatory agent was introduced; and imaging the recipient mammalian subject using an optical system. The methods may also include analysing the distribution of the labeled granuloma-derived cells in the recipient mammal. | 01-01-2009 |
| 20090004116 | IN VIVO OPTICAL IMAGING - Provided herein are methods for imaging an optically labeled target cell implanted in vivo using a reporter construct that encodes an enzyme that is not endogenous to the target cell. The disclosed methods include the steps of: (a) introducing target cell transformed with non-endogenous enzyme into a mammalian subject; (b) contacting the transformed target cell with a cell-permeable soluble fluorescent dye; and (c) observing a fluorescent signal generated by the target cell present in the mammalian subject. In some embodiments, the non-endogenous enzyme comprises a nitroreductase. In some embodiments, the methods may also include the step of tracking the fluorescent target cells in the mammalian subject over time. | 01-01-2009 |
| 20090004117 | Self-Illiminating Dot Systems and Methods of Use Thereof - Generally, aspects of the present disclosure are directed to conjugate systems, self-illuminating quantum dot conjugates, methods of detecting a target in a host, methods of treating a disease in a host, and the like. | 01-01-2009 |
| 20090010851 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function - The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X | 01-08-2009 |
| 20090041668 | Non-invasive localization of a light-emitting conjugate in a mammal - Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking the progression of disease or a pathogen within the animal, and for screening putative therapeutic compounds effective to inhibit the disease or pathogen. | 02-12-2009 |
| 20090041669 | Light-Emitting Biomarker - The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical or biological, in particular enzymatic, phenomenon, as well as a kit for implementing said method. | 02-12-2009 |
| 20090041670 | Near Infrared Fluorescent Contrast Agent And Method For Fluorescence Imaging - A near infrared fluorescent contrast agent which is excellent in permeability in a living tissue and enables specific imaging of tumor and/or blood vessel, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein R | 02-12-2009 |
| 20090047219 | Visible to near-infrared light probe using energy transfer between luciferase and an organic dye via a sugar chain - An object of the present invention is to produce a luminescent probe that has less biological effects, efficiently emits visible to near-infrared light, which is excellent for the imaging of individuals, and the use thereof. The present invention provides a sugar chain-containing-luciferase derivative, wherein an organic fluorescent dye is bonded to the luciferase through the sugar chain. | 02-19-2009 |
| 20090060843 | Non-Invasive In Vivo Imaging and Methods for Treating Type I Diabetes - The present invention provides novel drug discovery platforms and methods for treating type I diabetes. | 03-05-2009 |
| 20090068113 | AMPHIPHILIC SQUARAINE DYES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF - The present invention relates to amphiphilic squaraine dyes of the general formula (1) as shown below Formula (1) wherein, R | 03-12-2009 |
| 20090074672 | Tumor Boundary Imaging - Tumor boundaries and wound healing are optically imaged by cross-linking a fluorescently-labeled tissue transglutaminase substrate into extracellular matrix. | 03-19-2009 |
| 20090081129 | Bioluminescent Endoscopy Methods And Compounds - Bioluminescent endoscopy methods and compounds, wherein an anatomical object is examined by means of filling, perfusing, intubating, injecting, or otherwise administering a solution containing a bioluminescent substance or a mixture of luciferin and luciferase which produces bioluminescence, wherein a color or monochrome image of the object is constituted using the images and information based on bioluminescent emitted by the bioluminescent substance. Procedures are demonstrated which allow bioluminescent solutions to be perfused into certain tissue regions, such as but not limited to the common biliary duct, genitourinary tract, gastro-intestinal tract, cardiovascular system and lymphatic system wherein said structures may be conveniently visualized during surgery to avoid damage to these structures. Such images may also be combined with visual light images. Methods of detection of cancer cells using bioluminescence are provided. Preferred embodiments disclosed include membrane permeant coelenterazine analogs. | 03-26-2009 |
| 20090098057 | SILICA-CORED CARRIER PARTICLE - A nanoparticulate imaging probe with an oxide core, a biocompatible polymeric shell covalently attached to the oxide core, a dye, and a cleavable spacer that covalently binds the dye to the probe. When the spacer is cleaved, the dye is liberated from the probe. The emissions of the dye are quenched when the dye is bound to the probe and not quenched when the dye is liberated from the probe. The spacer can be, for example, a peptide. The oxide core can be, for example, a silicon oxide core. | 04-16-2009 |
| 20090098058 | METHOD OF INJECTING LIQUID AGENTS AT ACUPUNCTURE POINTS TO ARRIVE INTERNAL ORGANS AND METHOD OF VISUALIZING ARRIVAL OF LIQUID AGENTS - Provided are a method of injecting a visualizing material into a point in the vicinity of the Jung-Wan and a method of visualizing arrival of liquid agent in order to verify that the visualizing material injected arrives at internal organs. A point having the lowest electric resistance is found in the vicinity of Jung-Wan of the subject by using an electro acupuncture point detector. The visualizing material is injected into the point by means of an injecting instrument and then verified at least one point of the pancreas and the threadlike structures on top of the surface of the pancreas. The visualizing material is an alcian blue solution or a nanoparticle-containing solution labeled with fluorescent organic material. | 04-16-2009 |
| 20090123381 | IMAGING AND THERAPEUTIC TARGETING OF PROSTATE AND BLADDER TISSUES - The present invention provides methods for imaging and the treatment of cancer. In certain embodiments, a polyarginine (e.g., R11) may be used to selectively image prostate or bladder cells (e.g., a metastatic prostate cancer). In other embodiments, a DOC-2/DAB2 peptide, optionally conjugated to a cell permeable peptide (e.g., R11) may be used to treat a cancer, such as prostate cancer. | 05-14-2009 |
| 20090123382 | Light emitting microorganisms and cells for diagnosis and therapy of tumors - Provided are diagnostic and pharmaceutical compositions containing a microorganism or a cell containing a DNA molecule encoding a detectable protein or a protein that a detectable signal, such as a luminescent or fluorescent protein. Methods of tumor targeting and tumor imaging using the microorganisms and cells are provided. Also provided are therapeutic methods in which the microorganisms and cells, which can encoded a therapeutic protein, such as a cytotoxic or cytostatic protein, are administered. | 05-14-2009 |
| 20090123383 | Non-Isotopic Detection of Osteoblastic Activity In Vivo Using Modified Bisphosphonates - The present invention is directed to a non-isotopic methods for the in vitro and in vivo detection of hydroxyapatite-positive cells and structures. | 05-14-2009 |
| 20090130024 | Biocompatible N, N-Disubstituted Sulfonamide-Containing Fluorescent Dye Labels - This invention relates to new fluorescent chemical entities, especially fluorescent molecules that comprise biocompatible N,N-disubstituted sulfonamide fluorochromes. This invention also relates to the corresponding reactive versions of such molecules. This invention also relates to the corresponding conjugates with moieties such as peptides, proteins, various biomolecules, carbocyclic and heterocyclic compounds, sugars, and their uses thereof. | 05-21-2009 |
| 20090142274 | Intracellular nanosensors and methods for their introduction into cells - The invention provides ion-selective sensors capable of selectively measuring ions, e.g., Na | 06-04-2009 |
| 20090148386 | ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS - Enzyme substrates and associated technology of the present invention are provided. An enzyme substrate of the invention may comprise a biologically functional fluorescent dye and an enzyme-specific substrate moiety attached in such a way that the functionality of the functional dye is diminished. An enzymatic reaction may cleave at least a portion of the substrate moiety from the enzyme substrate to provide a more functional product dye. This product dye may be nonfluorescent or weakly fluorescent, in general, and relatively fluorescent, in a particular condition, such as when bound to a partner biological molecule or an assembly of partner biological molecules. An enzyme substrate of the present invention may thus be useful in fluorescence detection, and/or in any of a variety of useful applications, such as the detection of enzymatic activity in a cell-free system or in a living cell, the screening of drugs, or the diagnosis of disease. | 06-11-2009 |
| 20090155182 | OPTICAL IN VIVO IMAGING CONTRAST AGENTS AND METHODS OF USE - Provided is an optical in vivo contrast agent comprising a fluorescent polymeric microsphere, wherein the microsphere is impregnated with a dye having an excitation and emission spectrum compatible with in vivo imaging, and wherein the microsphere is coated with a block copolymer. | 06-18-2009 |
| 20090155183 | Sensors for the detection of diols and carbohydrates - The systems and methods disclosed herein include a sensor particle for detecting the presence of a chelatable analyte, such as glucose, wherein the sensor comprises a chromophore and a fluorescent component, such as a quantum dot. The sensor particle further comprises moieties that bind both a clelatable analyte and chromophore reversibly and competitively. In the presence of the chelatable analyte, the moieties bind the analyte, and release the chromophore. The chromophore absorbs photons of one wavelength in a free state but of a different wavelength in a bound state, and is selected to operate with the fluorescent component such that the chromophore absorbs emissions of the fluorescent substance in only one of the bound and unbound states. In certain aspects, the invention comprises methods for detecting the presence of a chelatable analyte in a medium such as water, blood plasma and urine, using the sensor particles of the invention. | 06-18-2009 |
| 20090169482 | SILICA-CORED CARRIER PARTICLE - A nanoparticulate imaging probe with an oxide core, a biocompatible polymeric shell covalently attached to the oxide core, a dye, and a cleavable spacer that covalently binds the dye to the probe. When the spacer is cleaved, the dye is liberated from the probe. The emissions of the dye are quenched when the dye is bound to the probe and not quenched when the dye is liberated from the probe. The spacer can be, for example, a peptide. The oxide core can be, for example, a silicon oxide core. | 07-02-2009 |
| 20090169483 | FLUORESCENT PHOTOPROBE FOR THE IMAGING OF ENDOTHELIN RECEPTORS - The present invention relates to a endothelin receptor antagonist conjugate of the formula (I) wherein R | 07-02-2009 |
| 20090196828 | CONTRAST AGENT COMPRISING A TM2+ CONTAINING LUMINESCENT SUBSTANCE FOR OPTICAL IMAGING - The invention relates to a contrast agent for optical imaging. The inventive contrast agent comprises a luminescent substance, wherein the luminescent substance comprises Tm | 08-06-2009 |
| 20090202442 | Enerceutical activation of the alternative cellular energy (ACE) pathway in therapy of diseases - Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or activated using ultraviolet (UV) light, especially if the reaction is initially triggered by the presence of suitable dyes, such as neutral red. A method is described to further enhance the activation of the ACE pathway in humans and animals deprived of ACE. The method comprises using natural or man-made sources of ACE products (enerceuticals), with or without the inclusion of a suitable dye, such as neutral red; and applying the material(s) to the skin, either directly or separated by an impermeable barrier; and illuminating the enerceutical with a UV light source. The process of activating the ACE pathway is evidenced by UV inducible fluorescence seen within areas of the patients' skin and/or mucus membranes. This fluorescence fades as the ACE pathway becomes fully activated. Activating the ACE pathway can have therapeutic benefits in various infectious and non-infectious diseases. Cited examples include autism, Morgellons disease, herpes virus infections and cellulite. | 08-13-2009 |
| 20090208418 | SUPERANTIBODY SYNTHESIS AND USE IN DETECTION, PREVENTION AND TREATMENT OF DISEASE - Superantibodies having enhanced autophilic, catalytic, and/or membrane-penetrating properties are prepared by affinity-based conjugation of a photoactivatable organic molecule to a target immunoglobulin. The photoactivatable organic molecule bears a chromophoric aromatic hydrocarbon moiety, which has affinity for the immunoglobulin. Upon photolysis, the organic molecule is covalently linked to the immunoglobulin. A preferred organic molecule is a peptide and a preferred aromatic hydrocarbon moiety is a tryptophan residue. The photoactivatable organic molecule need not bear a purine, pyrimidine or azido group to effect binding to the immunoglobulin and/or photoactivation. The superantibodies can enhance the potency and expand the targeting range of target antibodies. Autophilic superantibodies can promote apoptosis of target cells and/or enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Exemplary of such diseases are atherosclerosis and cardiovascular disease. Membrane-penetrating superantibodies can prevent apoptosis by binding to intracellular anti-caspase signal proteins. Compositions containing the superantibodies, as well as methods of making and using them, are disclosed. | 08-20-2009 |
| 20090208419 | Multimodality Imaging of Reporter Gene Expression Using a Novel Fusion Vector in Living Cells and Animals - Novel double and triple fusion reporter gene constructs harboring distinct imagable reporter genes are provided, as well as applications for the use of such double and triple fusion constructs in living cells and in living animals using distinct imaging technologies. | 08-20-2009 |
| 20090214434 | METHOD OF DETECTING AND TREATING ALLOGENIC CELLS RESPONSIBLE FOR ENDOMETRIOSIS - There are presently provided methods for identifying an ectopic allogenic cell in a mammalian host, the methods comprising obtaining a first internal soft tissue image, administering an effective amount of iodine to potentiate the host's immune response to aberrant ectopic tissue, obtaining one or more subsequent internal soft tissue images after said administration and comparing the first internal soft tissue image and the one or more subsequent internal images to identify the ectopic allogenic cell. The methods can also be used for determining or improving the efficiency of treatment of pathology disease or disorder caused by the presence of allogenic commensal or commensal-like cells. Furthermore, the methods can be used to diagnose, and also treat, endometriosis. | 08-27-2009 |
| 20090214435 | Recombinant vector expressing MDR1 shRNA and thymidine kinase and use thereof - A recombinant vector capable of expressing MDR1 shRNA and thymidine kinase, and a use thereof. More specifically, provided is a recombinant vector capable of efficiently expressing MDR1 shRNA and thymidine kinase in a host cell, a transfectant cell comprising the same recombinant vector, a composition for treating neoplastic diseases, comprising the same recombinant vector, and a method for imaging of neoplastic lesions using the same recombinant vector. The recombinant vector of the present invention is capable of achieving efficient intracellular expression of MDR1 shRNA and a thymidine kinase-GFP fusion protein within the host cell and is therefore highly effective for combined therapy of anticancer drugs. Further, the recombinant vector of the present invention enables imaging of neoplastic lesions. Therefore, the recombinant vector of the present invention can be used in combination with other anticancer drugs for treatment of neoplastic diseases. | 08-27-2009 |
| 20090214436 | DICHROMIC FLUORESCENT COMPOUNDS - The present invention provides dichromic fluorescent compounds, as well as processes for making and methods for using the dichromic fluorescent compounds. | 08-27-2009 |
| 20090220430 | Fluorescent Imaging Agents - Provided is a family of intramolecularly quenched imaging agents for use in both in vivo and in vitro imaging that contain at least one enzymatically cleavable oligopeptide and two fluorophores or a fluorophore and a quencher. When subjected to proteolytic cleavage, at least one fluorophore is unquenched and becomes capable of producing a fluorescent signal upon excitation with light of an appropriate wavelength. Also provided are in vivo and in vitro imaging methods using such imaging agents. | 09-03-2009 |
| 20090232741 | Optical Imaging - This invention relates to a method for imaging of wet age-related macular degeneration (AMD) using a contrast agent comprising a vector attached to an optical imaging reporter, wherein the vector has affinity for receptors associated with angiogenesis. The invention further provides such methods for monitoring the effect of treatment of AMD. | 09-17-2009 |
| 20090232742 | METHOD FOR SCREENING AGENT WITH ANGIOGENIC-MODULATING ACTIVITIES USING TELEOST EMBRYO - This invention relates to a method of 3-tier system for screening compounds, herb extract or extract of herb combination in formula with angiogenic-modulating activities using transparent teleost embryos as model. | 09-17-2009 |
| 20090238765 | Fluorescent Contrast Agent - The invention relates to contrast agents for imaging of diseases associated with inflammations. More specifically the invention provides optical imaging contrast agents for imaging of activated leukocytes and methods for imaging of such. The contrast agent changes its fluorescent properties upon reaction with oxidants produced by the activated leukocytes. | 09-24-2009 |
| 20090238766 | BIOLUMINESCENT CONSTRUCT - The invention provides a construct comprising an amino acid sequence attached to a luciferin substrate, wherein the amino acid sequence is not a substrate for either luciferase or caspase-3/7 to render the substrate inactive in the presence of luciferase. The construct is useful, for example, as a negative control for in vitro apoptosis assays and the bioluminescent imaging of drug-induced apoptosis in vivo. The invention also provides methods for screening for novel modulators of an apoptosis-related disease. | 09-24-2009 |
| 20090252687 | ASYMMETRIC FLUORO-SUBSTITUTED POLYMETHINE DYES - The present invention relates to improved conjugates of biological molecules with an improved class of water-soluble, green to near infra-red (NIR) cyanine labelling dyes. The dyes are asymmetric fluoro-substituted polymethines, and exhibit a high degree of photostability and reduced dye-dye quenching, as well as a high fluorescence quantum yield. The conjugates are useful for in vivo optical imaging, as well as fluorescence detection methods. Also disclosed are pharmaceutical compositions containing the conjugates, kits for the preparation of such compositions, and methods of in vivo imaging using the conjugates. | 10-08-2009 |
| 20090263328 | FLUORESCENCE OBSERVATION APPARATUS AND FLUOROSCOPY METHOD - A site of interest to be observed is clearly observed in an image during fluoroscopy of a small laboratory animal, even when the fluorescence is extremely low. The invention provides a fluorescence observation apparatus including a light source that emits excitation light; an optical system that irradiates an image-acquisition site on a small laboratory animal with the excitation light from the light source; a light-blocking unit that blocks light in a prescribed region of the small laboratory animal or in an image of the prescribed region; an image-acquisition unit that acquires a fluorescence image of the small laboratory animal; and a control unit configured to identify a high-fluorescence region having a prescribed fluorescence level or above in the fluorescence image of the small laboratory animal acquired by the image-acquisition unit and to control the light-blocking unit so as to block light at the identified high-fluorescence region. | 10-22-2009 |
| 20090269283 | METHOD AND PRODUCT FOR LOCATING AN INTERNAL BLEEDING SITE - A method is provided for localizing an internal bleeding site whereby a protein or other factor involved in the clotting process is complexed to an imaging agent and injected into a patient believed to be at risk of internal bleeding. A clot in the patient will naturally accumulate a certain concentration of the injected complex, and within a short period of time the concentration becomes sufficient to be detected by an imaging apparatus. The imaging contrast agent may, for example, be an MRI contrast agent, a CT contrast agent, a PET agent, or a fluorescent substance. | 10-29-2009 |
| 20090274629 | Sanitizing Composition and Method of Preparation - The invention provides a sanitizing composition in the form of a viscous liquid or gel suitable for use as a handwash composition comprising alcohol, water and a thickener wherein the viscous liquid or gel has particles suspended therein, wherein said particles provide the composition with a granular texture and are capable of being worn away when rubbed. The particles may deliver one or more agents to the skin e.g. antimicrobial, antibacterial or antiviral agents, emollients and/or moisturizers, fragrances, colourings or UV markers. | 11-05-2009 |
| 20090285761 | Renal Function Analysis Method and Apparatus - A method for measuring a glomerular filtration rate in a mammalian kidney comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the blood stream of a mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the health of the subject's kidney. This method measures volume of plasma distribution based on a fluorescence of a marker molecule relative to a fluorescence of a reporter molecule. | 11-19-2009 |
| 20090285762 | IMAGING METHODS AND COMPOSITIONS COMPRISING FLUORESCENT DYES ASSOCIATED WITH VIRAL COMPONENTS FOR NERVE IMAGING - Disclosed herein are compositions and methods for imaging nerve cells. The composition comprises a fluorescent dye; and a viral component selected from a neurotropic, replication-defective virus, a viral protein of a neurotropic virus, and a capsid of a neurotropic virus. Although the fluorescent dye in itself cannot penetrate nerve cells, the fluorescent dye is bound to the viral component to form a dye/viral component complex that is capable of penetrating nerve cells. | 11-19-2009 |
| 20090304597 | Use of an Active Biological Substance in Abnormal Cellular and Viral Membrane Physiologies - An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including: histones, covalently modified histones, histone-like polypeptides, biologically active histone sequences and histone-like polypeptides as agents for stopping the supply to solid tumours over their blood vessels, for killing cells infected by virus and for killing tumour cells with disturbed lipid asymmetry. | 12-10-2009 |
| 20090304598 | FLUORESCENT MEMBRANE INTERCALATING PROBES AND METHODS FOR THEIR USE - The invention relates to a family of dyes which fluoresce in the UV-VIS, far red and near infrared wavelengths of the spectrum and possess asymmetric lipophilic alkyl chains. The dyes of the invention are soluble in commercially available membrane staining dyes, are useful as probes for rapidly staining lipophilic structures such as membranes in cells or isolated from cells, and are well-retained therein. Methods of utilizing the dyes to detect stained cells both in vivo and in vitro are also disclosed. | 12-10-2009 |
| 20090311193 | METHODS AND REAGENTS FOR IN VIVO IMAGING OF CANCER CELL LINES - Provided are reagents and methods for non-invasive in vivo imaging wherein the reagents comprise targeted carrier molecules conjugated to a NIR reporter molecule. In one aspect the targeted carrier molecule is an antibody, or fragment thereof that has specificity for an antigen in a living body, animal or human. In one embodiment the antibodies are anti-cancer/tumor marker antibodies, organ specific antibodies, tissue specific antibodies, cell type specific antibodies, cell surface specific antibodies, anti-viral antibodies, anti-bacterial antibodies and anti-pathogenic antibodies. The NIR reporter molecules are any fluorescent reporter molecule compatible with in vivo imaging and generally having an excitation wavelength of at least 580 nm. | 12-17-2009 |
| 20090317333 | PROTEIN KINASE A REPORTERS USEFUL IN HIGH THROUGHPUT ASSAYS - Protein kinase A reporters useful for obtaining measurements of protein kinase A activity with high spatial and temporal resolution can be used in high throughput assays to identify potentially therapeutic compounds. | 12-24-2009 |
| 20090317334 | OPTICAL DETECTION METHOD OR IMAGING METHOD OF IMPLANTED CELLS - There is provided a method of an animal model experiment to observe cells implanted to an experimental small animal in which the position or spatial spread only of the implanted cells can be detected and observed with time progress and with sufficient accuracy while a plurality of kinds of the implanted cells can be distinguished from one another. The inventive method of in vivo detecting implanted cells implanted into the body of a small animal comprises steps of preparing cells used as the implanted cells into which a gene expressing a tag of a part of a peptide or a protein on a cell membrane is introduced; implanting the implanted cells to an arbitrary site of the small animal; and detecting the tags in the small animal. The tags may be detected by dosing the small animal with fluorescently labeled antibodies to the tags and imaging the fluorescence from the antibodies. | 12-24-2009 |
| 20100003196 | FLUORESCENT MEMBRANE INTERCALATING PROBES AND METHODS FOR THEIR USE - The invention relates to a family of cyanine dyes which fluoresce in the far red and near infra red wavelengths of the spectrum and preferably possess lipophilic side chains. The dyes of the invention are soluble in commercially available membrane staining vehicles, are useful as probes for rapidly staining lipophilic structures such as membranes in cells or isolated from cells, and are well retained therein. Methods of using the dyes to detect stained cells both in vivo and in vitro are also disclosed. | 01-07-2010 |
| 20100008860 | COLOR-MARKED OLIGOSACCHARIDES OR POLYSACCHARIDES - The invention concerns color-marked oligosaccharides or polysaccharides, procedures for the synthesis of these color-marked oligosaccharides or polysaccharides and their use in the determination of kidney function. | 01-14-2010 |
| 20100008861 | WATER SOLUBLE QUANTUM DOTS - An economic, direct synthetic method for producing water soluble QDs that are ready for bioconjugation is provided. The method can produce aqueous QDs with emission wavelengths varying from 400 nm to 700 nm Highly luminescent metal sulfide (MS) QDs are produced via an aqueous synthesis route. MS QDs are capped with thiol-containing charged molecules in a single step. The resultant MS QDs exhibit the distinctive excitonic photoluminescence desired of QDs and can be fabricated to avoid undesirable broadband emissions at higher wavelengths. This provides a significant improvement over the present complex and expensive commercial processes for the production of QDs. The aqueous QDs are stable in biological fluids over a long period of time. In addition, nontoxic ZnS QDs have been produced with good photoluminescence properties by refluxing the ZnS QD suspensions over a period of time. | 01-14-2010 |
| 20100015056 | Uranium-chelating peptides and uses thereof - The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence. | 01-21-2010 |
| 20100021390 | Fluorescent Analogs Of The Islet Amyloid Polypeptide - The present invention relates to methods and compositions for the investigation of amyloid formation. In preferred embodiments, amyloid formation associated with type II diabetes is monitored by fluorescence spectroscopic measurements of the activity of p-cyano-phenylalanine-substituted islet amyloid polypeptide, and derivatives thereof, under an amyloid-forming condition. In some embodiments, the amyloid-forming condition is associated with a diseased, or putatively diseased, cell or tissue. In some embodiments, the invention provides a method of evaluating the severity of the amyloid-forming condition, and changes therein induced by agents that inhibit, or potentially inhibit, amyloid formation. | 01-28-2010 |
| 20100034749 | Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases - The present invention relates to cationic colloidal preparations and their use for the diagnosis and/or treatment of ocular diseases. | 02-11-2010 |
| 20100040554 | CONJUGATES OF PHOTO-ACTIVATABLE DYES - A new class of photoactivatable dyes provides the ability to study cell-cell communication in live animals non-invasively with high spatiotemporal resolution. The compositions are made up of a macromolecule, a caging group, and a coumarin dye. Upon photolysis, the coumarin dye is released from the macromolecule caging group complex and is freely diffusible in cells and between cells. The compositions are retained in cells very well, having no observable side effects, no susceptibility to metabolism, and the ability to generate bright fluorescence signals after photolysis. Because of their high loading capacity and long cellular retention, they can be selectively uncaged in specific cells. | 02-18-2010 |
| 20100047179 | TARGETED SPLIT BIOMOLECULAR CONJUGATES FOR THE TREATMENT OF DISEASES, MALIGNANCIES AND DISORDERS, AND METHODS OF THEIR PRODUCTION - The present invention is directed to compositions and methods for the production of split-biomolecular conjugates for the directed targeting of nucleic acids and polypeptides. More preferably, the compositions and methods allow for the use of the split biomolecular conjugates for the treatment of diseases, malignancies, disorders and screening. In some embodiments, the split biomolecular conjugates comprise split effector protein fragments conjugated to a probe, and interaction of both probes with a target nucleic acid or target polypeptide, such as a pathogenic nucleic acid sequence or pathogenic protein, brings a the split-effector fragments together to facilitate the reassembly of the effector molecule. Depending on the effector molecule, the protein complementation results in a cellular effect, in particular for the treatment of diseases, malignancies and disorders. | 02-25-2010 |
| 20100055039 | NON-INVASIVE METHODS OF MONITORING ENGRAFTED STEM CELLS AND METHODS FOR ISOLATION OF SKELETAL MUSCLE STEM CELLS - The embodiments of the present disclosure encompass methods for non-invasive in vivo bioluminescence imaging that allow the dynamics of stem cell behavior to be followed in a manner not possible using conventional retrospective static histological analyses. By imaging luciferase-generated bioluminescence activity emanating from isolated stem cells, for example, real time quantitative and kinetic analyses can show that donor-derived muscle stem cells may proliferate and engraft rapidly after injection until homeostasis is reached. In addition, the response of the stem cells to injury and participation in the regenerative response can be monitored over time. Other aspects of the disclosure encompasses methods for determining the suitability of a stem cell for tissue replacement, methods for repairing muscle injury, and methods for isolating muscle stem cells from a tissue sample. | 03-04-2010 |
| 20100061936 | UNNATURAL AMINO ACIDS CAPABLE OF COVALENTLY MODIFYING PROTEIN PHOSPHATASES AND THEIR USE AS GENERAL AND SPECIFIC INHIBITORS AND PROBES - An unnatural amino acid including a phosphate mimicking group for mimicking a phosphate group in phosphoamino acids and a protein phosphatase modifying group for covalently binding protein phosphatases. A probe for detecting disease including a phosphate mimicking group for mimicking a phosphate group in phosphoamino acids and a protein phosphatase modifying group for covalently binding protein phosphatases. A method for detecting the presence of disease by administering the unnatural amino acid, binding the unnatural amino acid with a phosphatase, detecting a signal, and detecting the presence of disease. A method of identifying a known protein phosphatase, and a method of identifying an unknown protein phosphatase. A method of making the unnatural amino acid. | 03-11-2010 |
| 20100068150 | Selective Caspase Inhibitors - Described here are novel, highly selective inhibitors and activity based probes (ABPs) for caspases 3, 7, 8, and 9 and legumain. The compounds selectively inhibit only certain caspases. A positional scanning combinatorial library (PSCL) approach was used to screen pools of peptide acyloxymethyl ketones (AOMKs) containing both natural and non-natural amino acids for activity against a number of purified recombinant caspases. These screens were used to identify structural elements at multiple positions on the peptide scaffold that could be modulated to control inhibitor specificity towards target caspases. Further disclosed are individual optimized covalent inhibitors that could also be equipped with various tags for use as activity based probes, as well as labeled substrates. | 03-18-2010 |
| 20100074847 | Chromophore Probes for Optical Imaging - Chromophore probes that are capable of being taken up by, retained by or bound to a biocompatible molecule to form an imaging construct are provided. Various activation strategies of the resulting imaging construct are also provided. | 03-25-2010 |
| 20100080758 | OPTICAL FLUORESCENT IMAGING - Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared (NIR) spectral range. The NIR is highly sensitive for tumor detection and tracking. The application discloses targeting a tumor-enriched cell surface receptor with a ligand-conjugated fluorescent probe, which specifically allows detection of the tumor relative to the negligible animal autofluorescence. | 04-01-2010 |
| 20100092393 | TUNABLE HYDROGEL MICROPARTICLES - Techniques are provided to produce and use non-spherical colloidal particles with independently tuned size, shape, flexibility, and chemical properties. A pre-polymer mixture for forming hydrogel particles includes a percentage of PEGDA selected to impart a target stiffness to the particles and includes, a percentage of acrylic acid selected to impart an independent target chemical function to the particles. The mixture also includes a percentage of photo-initiator to polymerize PEGDA upon exposure to a light source to impart an independently selected target size or shape or both to the particles. | 04-15-2010 |
| 20100119457 | COMPOSITION OF LABELED AND NON-LABELED MONOCLONAL ANTIBODIES - This invention relates to a composition of labeled and non-labeled monoclonal antibodies directed to a human transmembrane protein for the simultaneous treatment and diagnosis of diseases which are associated with an overexpression of such a protein especially of cancer. The invention further relates to a method of first administering said composition, determine the change of labeled antibody concentration and afterwards administering the non-labeled monoclonal antibodies only such that the minimum required concentration of such non-labeled antibody for a favorable therapeutical effect is achieved and maintained in the treatment, while unfavorable side effects are minimized due to the lower systemic antibody concentration. | 05-13-2010 |
| 20100129293 | Near Infrared Imaging Agent - This invention relates to an in-vivo diagnostic method based on near infrared radiation (NIR radiation) that uses water-soluble dyes and their biomolecule adducts, each having specific photophysical and pharmaco-chemical properties, as a contrast medium for fluorescence and transillumination diagnostics in the NIR range, to new dyes and pharmaceuticals containing such dyes. | 05-27-2010 |
| 20100143258 | TUMOR MARGIN IMAGING AGENTS - In one aspect, the present invention provides a functionalized monodisperse polylysine comprising a linear monodisperse polylysine chain comprising constituent lysine monomer residues containing appended C | 06-10-2010 |
| 20100143259 | FLUORESCENT MICROSPHERES, THE PREPARATION METHOD AND USES THEREOF - The invention discloses the microspheres comprising the following structure in the composition thereof and the uses as tracers and fluorescent standard calibration products. | 06-10-2010 |
| 20100143260 | COATING SYSTEM - Embodiments of the invention include a system comprising: an Acetoxy curable silicone Binder; and an active agent blended with the silicone binder, effective for one or more of radiopacification, lubricity, elution of a secondary compound such as a drug, echogenic properties, thermal or electrically insulative properties or chemical indicators wherein the silicone binder effectiveness is not substantially changed by the active agent. | 06-10-2010 |
| 20100143261 | COMPOSITION FOR THE DIAGNOSIS, PREVENTION OR TREATMENT OF DISEASES RELATED TO CELLS EXPRESSING IL-8 OR GRO-ALPHA, COMPRISING UCB-MSCS - Provided is a gene therapy composition for transferring one of a therapeutical gene, a maker gene, or a mixture thereof to a cell that expresses interleukin-8(IL-8) or GRO-α and induces tropism of mesenchymal stem cells isolated from umbilical cord blood and/or the mesenchymal stem cells expanded from said mesenchymal stem cells (UCB-MSCs), wherein the cell-treating composition includes UCB-MSCs. Provided is a composition for treating disease related to a cell expressing IL-8 or GRO-α, that is, a brain tumor in gene therapy, by using UCB-MSCs. Provided is a composition or kit for diagnosing brain tumors, preventing brain tumors, treating brain tumors, or monitoring brain tumor treatment progression by using UCB-MSCs. | 06-10-2010 |
| 20100150843 | PEPTIDE IMAGING AGENTS - The present invention relates to labelled cMet binding peptides suitable for optical imaging in vivo. The peptides are labelled with an optical reporter group suitable for imaging in the red to near-infrared region. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods, especially of use in the detection, staging, diagnosis, monitoring of disease progression or monitoring of treatment of colorectal cancer (CRC). | 06-17-2010 |
| 20100166663 | PROBE FOR A HAIR CELL, AND LABELLING METHOD FOR A HAIR CELL USING THE PROBE FOR A HAIR CELL - Provided are a novel probe for a hair cell for clearly identifying various conditions of a hair cell, and a labelling method for a hair cell using the probe for a hair cell, more particularly, a probe for a hair cell containing, as an active agent, at least one kind selected from staining compounds represented by one of the general formulae (I) and (II), and a labelling method for a hair cell using the probe for a hair cell. | 07-01-2010 |
| 20100178251 | Dual-Sensitizer-Containing Luminescent Compounds, Conjugates, and Uses Thereof - The invention relates to novel luminescent compositions of matter containing two fluorophores (sensitizers), synthetic methods for making the compositions, macromolecular conjugates of the compositions, and the use of the compositions and their conjugates in various methods of detection. The invention also provides kits containing the compositions and their conjugates for use in the methods of detection. | 07-15-2010 |
| 20100178252 | PRODUCTS AND METHODS FOR DISCLOSING CONDITIONS IN THE ORAL CAVITY - An oral composition capable of identifying a condition within the oral cavity by causing a visual contrast between the condition and the hard and soft tissues of the oral cavity has at least one disclosing agent. The disclosing agent can fluoresce in order to highlight conditions within the oral cavity. | 07-15-2010 |
| 20100178253 | PEPTIDE IMAGING AGENTS - The present invention relates to labelled cMet binding peptides suitable for optical imaging in vivo. The peptides are labelled with a benzopyrylium dye suitable for imaging in the red to near-infrared region. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods, especially of use in the detection, staging, diagnosis, monitoring of disease progression or monitoring of treatment of colorectal cancer (CRC). | 07-15-2010 |
| 20100189657 | INTRAMOLECULARLY QUENCHED FLUOROCHROME CONJUGATES AND METHODS OF USE - The invention provides a quenched fluorochrome conjugate and methods of use thereof in the detection and treatment of disorders characterized by unwanted cellular proliferation including cancer. | 07-29-2010 |
| 20100189658 | Imaging probes - The present invention relates to molecular probes of the formula (I) | 07-29-2010 |
| 20100189659 | DIAGNOSTIC SUBSTANCE AND METHOD FOR THE DIAGNOSIS OF PROSTATE DISEASES - A diagnostic substance for use in a method for diagnosing prostate diseases contains multiple different coupling molecules that respectively bind to signal molecules (target molecules) of a molecular surface structure of a pathological tissue that is associated with a prostate disease. A first of the coupling molecules specifically binds to signal molecules of cancer tissue, and a second of the coupling molecules specifically binds to signal molecules formed in inflamed tissue. First and second markers are respectively associated with the first and second coupling molecules, the first and second markers being detectable, and differentiated from each other, with a detection device. | 07-29-2010 |
| 20100189660 | METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEIN - Sensitive, non-radioactive fatty-acyls of Formula I are useful in in vivo methods for detection and cellular imaging of a fatty-acylated substrate (e.g., protein or polypeptide). | 07-29-2010 |
| 20100196282 | OPTICAL IMAGING AGENTS - The present invention relates to imaging agents suitable for in vivo optical imaging, which comprise conjugates of benzopyrylium dyes with biological targeting moieties, such as peptides Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods. | 08-05-2010 |
| 20100202975 | NOVEL FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS - The invention relates to novel fluorescent derivatives of polyamines having a benzoxadiazole group, to a method for preparing the same and to the use thereof as diagnosis tools for emphasising the polyamine transport system in cancerous cells in order to adapt the treatment thereof, and thus for selecting patients carrying such tumours in order to adapt their treatment. The derivatives are of the formula (I) or a pharmaceutically acceptable salt thereof, in which: R | 08-12-2010 |
| 20100202976 | SUBSTANCE-ENCAPSULATING CARBON NANOHORN AGGREGATE AND PROCESS FOR PRODUCING THE SAME - A substance-encapsulating carbon nanohorn aggregate which has improved chemical stability by isolating the encapsulated substance from outside and which is useful as a targeting material which can be led from the outside of the body or as a contrast medium by holding the encapsulated substance in an aggregated form, and a process for producing the same are provided. The substance-encapsulating carbon nanohorn aggregate is characterized in that the encapsulated substance is aggregated in a central part of the carbon nanohorn aggregate or a neighborhood thereof with being isolated from outside. The process includes aggregating a substance to be encapsulated in a central part or a neighborhood thereof by a heat treatment. | 08-12-2010 |
| 20100209353 | TUMOR TARGETING PROTEIN CONJUGATE AND A METHOD FOR PREPARING THE SAME - The present invention relates to a protein conjugate having excellent tumor targeting capacity and a method for preparing the same, more precisely albumin-bile acid conjugate forming 30-500 nm nano-particles and forming self-aggregates in water system and a method for preparing the same. The albumin-bile acid conjugate of the present invention has excellent tumor targeting capacity and facilitates inclusion of a hydrophobic anticancer agent and can be combined with fore infrared ray fluorescent material. Therefore, this conjugate can be effectively used for the production of a novel nano-particle contrast agent or a nano-particle drug delivery system for the diagnosis and treatment of cancer. | 08-19-2010 |
| 20100209354 | ORGANIC/INORGANIC HYBRID NANOPARTICULATES MADE FROM IRON CARBOXYLATES - The invention relates to nanoparticles made from organometallic hybrid materials made from iron carboxylates, used for example as contrast agents. The particles can also be used for the encapsulation and vectoring of molecules of interest such as active3 pharmaceutical agents, cosmetically interesting compounds and markers. Apart from the intrinsic properties thereof for imaging, said nanoparticles give good results in terms of capacity for loading with medicaments and in biocompatibility. | 08-19-2010 |
| 20100215585 | DYES AND PRECURSORS AND CONJUGATES THEREOF - Novel dyes, precursors to novel dyes, and conjugates of the novel dyes are disclosed, as well as methods of making and using the same. | 08-26-2010 |
| 20100221188 | Coated sensors and methods related thereto - The invention provides coated sensors for detecting the presence of analytes. The sensor comprises one or more fluorescent sources, such as one or more quantum dots or one or more fluorescent dyes, a polymeric matrix, a surface coating, and one or more analyte sensing components. The surface coating may be a conformal polymeric film, permeable to the analyte, which may be deposited via a solventless process such as initiated chemical vapor deposition or photoinitiated chemical vapor deposition. The surface coating may increase the biocompatibility of the sensor, reduce nonspecific protein adsorption, and/or sequester functional sensor components within the sensor. The invention also provides methods for detecting the presence of an analyte with coated sensors of the invention. | 09-02-2010 |
| 20100226861 | TOPICAL COMPOSITION DETECTION - Compositions, devices, methods, and kits are provided for determining the presence of topical compositions on surfaces, such as skin. | 09-09-2010 |
| 20100233091 | Pyrazine Derivatives with Extended Conjugation and Methods of Using the same in Optical Applications - The present invention relates to pyrazine derivatives capable of absorbing and emanating spectral energy in the visible and/or near infrared spectrum. Pyrazine derivatives of the invention may be administered to a patient in the form of a pharmaceutically acceptable composition and utilized in medical (e.g., diagnostic imaging) procedures. | 09-16-2010 |
| 20100233092 | IN-VIVO MONITORING OF CIRCULATING APOPTOTIC CELLS - The present invention provides methods and systems for performing in vivo flow cytometry. In one embodiments, selected circulating cells of interest of a subject are labeled with fluorescent probe molecules. The labeled cells are irradiated in-vivo so as to excite the fluorescent probes, and the radiation emitted by the excited probes is detected, preferably confocally. The detected radiation is then analyzed to derive desired information, such as relative cell count, of the cells of interest. In some embodiments, the circulating cells comprise apoptotic cells whose detection can allow, e.g., non-invasive monitoring of the efficacy of a cancer treatment, such as an anti-tumor or an anti-angiogenic therapy. | 09-16-2010 |
| 20100239502 | IN VIVO EXPRESSION ANALYSIS USING ULTRASOUND-INDUCED TRANSFECTION OF REPORTER CONSTRUCTS - The invention features compositions and methods for in vivo expression analysis. The data presented herein demonstrates that ultrasound-enhanced delivery and/or expression of a composition for expression analysis comprising microbubbles vectors as well as a genetic payload, comprising a “always-on” promoter, a “reference” reporter gene, a “query” promoter and an “answer” reporter gene, enables in vivo analysis of gene expression both without requiring prior preparation (especially genetic modification) of the test subject (animal or patient) and without causing long term or systemic effects on the subject. Such an invention can be used, for example, to query the epigenotypic or phenotypic response of the individual subject to a foreign effector substance such as a pyrogen, pharmaceutical compound, pharmaceutical lead compound, an allergen, an autoimmunogene, a toxin, a polyclonal antibody, a monoclonal antibody, an antigen, a lipid, a carbohydrate, a peptide, a protein, a protein-complex, an amino acid, a fatty acid, a nucleotide, DNA, RNA, PNA, siRNA and micro RNA. | 09-23-2010 |
| 20100247446 | METHOD AND SYSTEM FOR ANALYZING OPTICAL SIGNAL - The present invention is related to a method of analyzing an optical signal which analyzes a signal substance induced by a photosensitive protein, includes the steps of introducing a gene which expresses a luminescent probe to analyze the signal substance into an organism sample, emitting a stimulus light to activate the photosensitive protein, and detecting an optical signal emitted by the organism sample. | 09-30-2010 |
| 20100254910 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 - The presently disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also provided are methods for using the disclosed compositions for diagnosing (i.e., by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activity. | 10-07-2010 |
| 20100260683 | THERMOLABILE LIPOSOME WITH CONTROLLED RELEASE TEMPERATURE - The invention relates to a thermolabile liposome with controlled release temperature for the liposome content, which is essentially formed by at least one phosphatidyl choline with a main transition temperature ranging from 0 to 80° C. and 2 to 15 percent by weight of phosphatidyl oligoglycerin. | 10-14-2010 |
| 20100266506 | Flourescent Dendrimer Compounds and Use of Such Compounds in Multi-Photon Devices or Processes - Fluorescent chemical compound composed of an n-generation dendrimer, n being a non-zero integer, exhibiting: -at least one central nucleus (N) with a valency of m, selected from the group consisting of -at least one first, non-chromophoric unit (X) with a valency of m′, and -at least one second unit (Y) which exhibits two-photon absorption properties, with a valency of m″. | 10-21-2010 |
| 20100266507 | LUMINESCENT COMPOUNDS - Luminescent reporter compounds that are rotaxanes having the structure | 10-21-2010 |
| 20100272650 | SEMICONDUCTOR NANOPARTICLE, AND FLUORESCENT LABELING SUBSTANCE AND MOLECULE/CELL IMAGING METHOD BY USE THEREOF - There is provided semiconductor nanoparticles which exhibit enhanced emission efficiency, excellent emission intensity, reduced variation range of emission characteristics among lots and among particles and are excellent in stability and reproducibility. There is further provided a fluorescent labeling agent and molecule/cell imaging method by use of the same. Semiconductor nanoparticles having an average particle size of 1 to 20 nm is disclosed, comprising a dopant of a heteroatom which is identical in valence electron configuration with a main component atom forming the semiconductor nanoparticles or an atomic pair of the heteroatom, and the dopant is distributed on or near a surface of the semiconductor nanoparticles. | 10-28-2010 |
| 20100272651 | METHOD FOR ASSESSING POTENTIAL FOR TUMOR DEVELOPMENT AND METASTASIS - The present invention generally provides methods for assessing the potential of tumor formation and/or metastasis using a combination (e.g., a ratio) of the number of circulating tumor cells and the number of circulating cells exhibiting autofluorescence within a selected wavelength region (e.g., red autofluorescence). In one aspect, it is directed to a method for providing likelihood of occurrence of a primary and/or a metastatic cancerous tumor in an animal, which comprises inoculating the animal with a plurality of cancer cells, determining a ratio of a number of cancer cells relative to a number of circulating indicator cells (e.g., immature leukocytes) that exhibit autofluorescence in the inoculated animal's blood and correlating the ratio to a likelihood that the animal will develop at least one primary and/or metastatic cancerous tumor, e.g., by way of assigning a probability for tumor development and/or metastasis based on the measured ratio. The method can also be utilized in human studies using, e.g., contrast agents to identify the circulating tumor cells. | 10-28-2010 |
| 20100278745 | COMPOUNDS FOR FLUORESCENCE IMAGING - Methods and compositions involving enzyme-activatable fluorophore polymer imaging agents for photodetection of specific tissues and/or human diseases and disorders are provided. In certain embodiments, the imaging agent comprises a hydrophilic polymer backbone (e.g., poly(L)lysine), a hydrophobic fluorophore, and a hydrophilic solubilizing agent. The solubilizing agent may comprise a quarternary ammonium group (e.g., a 1-methylnicotinic group) to enhance self-quenching of the fluorophore. Various methods for the generation and purification of imaging agents are also provided, including methods involving solid phase probe extraction or ion exchange purification. | 11-04-2010 |
| 20100278746 | Method for Measuring Neurotransmitters in Vivo - A method is provided for in vivo detection of a biochemical substance in an animal by culturing neurofluocytes that stably express a receptor of the biochemical substances by transfecting cells with cDNA of the receptor and a tag that will emit a detectable energy in the presence of the biochemical substance, implanting the neurofluocyte into the animal's brain; and detecting the energy emission of the tag. In a first embodiment, the biochemical substance is a neurotransmitter, the tag is a fluophore, and the step of detecting includes forming an opening in the animal's skull and optically detecting fluorescent emissions using a two-photon laser scanning microscope. Multiple biochemical substances can be simultaneously detected by culturing neurofluocytes that express different receptors and have different fluophor tags that produce fluorescent signals at distinguishable wavelengths. | 11-04-2010 |
| 20100278747 | CARRIER - The invention relates to a carrier for delivering agents to the posterior region of the eye, the carrier comprising a Vitamin E derivative, especially tocopherol. The carrier may also comprise a cell death marker, such as an annexin. | 11-04-2010 |
| 20100284929 | FLUORESCENT IMAGING OF TUMORS USING PHOSPHOLIPID ETHER COMPOUNDS - The invention generally relates to the use of novel fluorescent phospholipid ether compounds and compositions comprising these compounds in fluorescence imaging of tumors. A preferred compound of the present invention has the following structural formula: | 11-11-2010 |
| 20100284930 | FLUORESCENT IMAGING OF SKIN CANCERS USING PHOSPHOLIPID ETHER COMPOUNDS - The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and their use in a variety of diagnostic applications, including fluorescence imaging of tumors. A preferred compound of the present invention has the following structural formula: | 11-11-2010 |
| 20100284931 | FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and their use in a variety of diagnostic applications, including fluorescence imaging of tumors. A preferred compound of the present invention has the following structural formula: | 11-11-2010 |
| 20100284932 | FLUORESCENT EMULSIONS FOR OPTICAL IMAGING - The invention relates to a fluorescent emulsion, to a diagnostic reagent containing the same, and to the use thereof in the preparation of a diagnostic reagent for in vivo fluorescence imaging. | 11-11-2010 |
| 20100290999 | NANOPARTICLES OF LIGHT EMISSIVE POLYMERS AND PREPARATION METHOD THEREOF - Disclosed are nanoparticles of a light emissive polymer, comprising nanoparticles of a cyano-substituted poly(arylene vinylene) polymer; and a biocompatible surfactant adsorbed to the surface of the nanoparticles of the polymer, and preparation method thereof, wherein the method comprises: (1) uniformly mixing a dialdehyde monomer represented by a general formula OHC—Ar | 11-18-2010 |
| 20100291000 | Diagnostic value of systemic ACE pathway activation in the detection by fluorescence of localized pathological lesions - Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or activated using ultraviolet (UV) light, especially if the reaction is initially triggered by the presence of suitable dyes, such as neutral red. Once partially activated, ACE pigments within a localized lesion will fluoresce upon direct exposure to UV light. It is diagnostically useful to screen an individual or animal undergoing localized or systemic activation of their ACE pathway for the presence of lesions elsewhere in the body, which become fluorescent under direct UV illumination, both as a way of detecting an otherwise non-apparent or unnoticed lesion and of confirming that such a lesion contains ACE pigments that can be further activated. The development of direct UV fluorescence in a localized lesion can also be an indication of the therapeutic value of continuing with direct UV illumination of the lesion. | 11-18-2010 |
| 20100297024 | PROMOTER INDUCIBLE BY REACTIVE OXYGEN SPECIES AND VECTOR COMPRISING THE SAME - The invention provides promoters inducible by reactive oxygen species (ROS), capable of driving the expression of a gene of interest, particularly in a tumor cell. More particularly, it refers to promoters inducible by reactive oxygen species, that may be used to drive the expression of a gene of interest, such as a therapeutic gene, or a reporter gene for use in image diagnosis. The promoters comprise at least a fragment of a promoter sequence responsive to said reactive oxygen species, and corresponding to a gene highly expressed in cancer cells, wherein the fragment of the promoter sequence responsive to reactive oxygen species (ROS) is selected from the group of: the VE element of the VEGF promoter, the E6 element of the promoter of the EGR-1 gene, the MMP-1 element and a chimeric promoter containing an E6 element and a VE element. It also provides vectors carrying a human therapeutic or non therapeutic gene of interest, operably linked to said promoter sequence and compositions comprising the same. | 11-25-2010 |
| 20100303727 | OPTICAL IMAGING AGENTS - The present invention relates to imaging agents suitable for in vivo optical imaging, which comprise conjugates of pentamethine cyanine dyes having reduced non-specific binding, e.g. to plasma proteins. This is achieved by control of the nature and location of the sulfonic acid substituents, in particular the sulfoalkyl groups. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods. | 12-02-2010 |
| 20100303728 | CASPASE IMAGING PROBES - The present invention relates to molecular probes of formula (I) | 12-02-2010 |
| 20100303729 | CYANOCHROME FLUOROPHORES - Genetically-engineered cyanochrome fluorophore molecules (fluorophores) with increased fluorescence and with absorbing fluorescence in the blue and green (blue/green) portion of the light spectrum are provided. These fluorophores are derived from the domains of phytochromes, and in particular cyanobacterial phytochromes. Methods for generating these fluorophores and various applications of these fluorophores are also provided. | 12-02-2010 |
| 20100310468 | RECOMBINANT ALBUMINS FUSED WITH POLY-CYSTEINE PEPTIDE AND THE METHODS FOR PREPARING THE SAME - The present invention relates to recombinant albumins fused with poly-cysteine peptide and methods for preparing the same, more precisely recombinant albumins in which cysteines that can be used for drug binding are amplified at N-terminal and C-terminal of the albumin and methods for preparing the same. The recombinant albumin of the present invention demonstrates improved albumin-drug conjugation efficiency when it is used for drug delivery system, indicating that it can effectively deliver a large amount of drug to a target tissue. At the same time, the recombinant albumin of the present invention can be used as an excellent drug deliverer with reduced side effects, compared with the conventional albumin carriers, by regulating the amount of drug conjugated to each unit of albumin by regulating the number of cysteine fused thereto. In addition, the recombinant albumin of the present invention can be used for the screening of a novel drug and for the non-invasive real-time diagnosis and treatment of disease by combining with a fluorescent material or a contrast agent for molecular imaging. | 12-09-2010 |
| 20100322866 | DEVICE, SYSTEM AND METHOD FOR IN-VIVO ANALYSIS - A method for detecting the presence of a substance such as an antigen, the method including the steps of: maintaining a signaling material at a first pH within a liposome; contacting the liposome with a sample having a second pH such that if the substance is present in the sample the liposome will rupture thereby exposing the signaling material to the second pH; and detecting a change in an optical property, such as color, of the signaling material, the change caused by the exposure to the second pH. | 12-23-2010 |
| 20100329989 | In Vivo Labeling of Mammalian Cone Photoreceptors by Intravitreal Injection of Fluorescently Tagged Peanut Agglutinin - A method for specifically labeling of mammalian cone photoreceptors in vivo comprising injecting a mammal with peanut agglutinin conjugated with a fluorescent probe. The peanut agglutinin labels the cone photoreceptor. | 12-30-2010 |
| 20100329990 | LUMINESCENT MARKERS - The invention relates to luminescent proteins, nucleic acids encoding same, compositions and combinations comprising the proteins, and methods using the proteins, nucleic acids, compositions and combinations. In particular, a luminescent protein is provided comprising oncomodulin in which a salt bridge has been introduced to provide greater stability. The protein may be used as a luminescent marker in, for example, luminescent items, immunoassays, and fluorescent energy transfer assays. | 12-30-2010 |
| 20110008262 | DRUG DELIVERY SYSTEM TARGETING TO ESTROGEN RECEPTOR OVER-EXPRESSED CELLS - A vector for targeted delivery of drugs into estrogen receptors over-expressed cells is disclosed. The vector of the present invention is mainly about an active targeting delivery carrier which consists of a plurality of nanoparticles including: (i) a plurality of targeted moiety conjugated to the outer surface of the nanoparticles, the moiety being capable of binding with the estrogen receptor of a target cell, and (ii) bioactive agents encapsulated in the nanoparticles or forming complex with the nanoparticles. The targeted moiety of the present invention can also be conjugated to parent drugs for prodrug design. | 01-13-2011 |
| 20110020239 | METHODS FOR IN VIVO IMAGING OF CELLS - The instant invention provides methods for the in vivo imaging of cells using one or more imaging modalities. | 01-27-2011 |
| 20110020240 | Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics - Provided herein are imaging methods for detecting, diagnosing and imaging pathogenic bacteria or a pathophysiological condition associated therewith using fluorogenic substrates for bacterial enzymes. Fluorescent, luminescent or colorimetric signals emitted by substrates or enzyme products in the presence of the bacteria are compared to controls to detect and locate the pathogenic bacteria. Provided is a method for screening therapeutic agents to treat the pathophysiological conditions by measuring a signal emitted from the fluorogenic substrates or products in the presence and absence of the potential therapeutic agent. In addition, a diagnostic method for detecting a mycobacterial infection in a subject by contacting biological samples with a fluorogenic substrate and imaging for signals emitted from a mycobacterial beta-lactamase product. Provided are fluorogenic substrates CC1, CC2, CHPQ, CR2, CNIR1, CNIR2, CNIR3, CNIR4, CNIR5, CNIR5-QSY22, CNIR7, CNIR9, CNIR10, CNIR-TAT, CDC-1, CDC-2, CDC-3, CDC-4, CDC-5, XHX2-81, XHX2-91, XHX3-26, or XHX3-32 or a derivative thereof. | 01-27-2011 |
| 20110020241 | FLUORESCENT LABELING AGENT CONTAINING QUANTUM DOTS - Disclosed is a fluorescent labeling agent containing quantum dots, which exhibits little fluctuation in luminous properties in accordance with the environment where the fluorescent labeling agent is stored and therefore has high environmental stability, and which has high luminous intensity. Specifically disclosed is a fluorescent labeling agent containing quantum dots, which comprises: (1) a fluorescent labeling agent core part which comprises at least three quantum dots per a fluorescent labeling agent and a protective material; and (2) an organic surface-coating layer which coats the fluorescent labeling agent core part, wherein the fluorescent labeling agent core part has an average particle diameter of 10 to 50 nm. | 01-27-2011 |
| 20110027190 | COMPOSITION OF A FIRST NON-LABELED MONOCLONAL ANTIBODY BINDING TO A TUMOR ANTIGEN AND A NON-CROSS REACTIVE SECOND MONOCLONAL ANTIBODY LABELED WITH A NIR FLUORESCENCE LABEL - This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition. | 02-03-2011 |
| 20110027191 | OPTICAL IMAGING AGENT - The near-infrared wavelengths (700 nm-900 nm) are a suitable optical window for light penetration and deep tissue imaging. The present invention provides a near-infrared fluorescent blood pool contrast agent. The agent is of use to detect and quantify pathological capillary leak in live animals, e.g., serially imaging of traumatized tissue (muscle) as well as tumors. | 02-03-2011 |
| 20110033389 | Modified antibodies for passive immunotherapy - Provided herein are modified therapeutic antibodies containing a protein transduction domain conjugated to a neutralizing antibody. Also provided are methods for generating the modified therapeutic antibodies and methods of using the modified therapeutic antibodies for prevention and treatment of disease. | 02-10-2011 |
| 20110038803 | FLUORESCENT PROBE - A fluorescent probe which specifically and efficiently traps nitrogen monoxide, zinc ion etc. to emit fluorescence is provided. | 02-17-2011 |
| 20110044910 | IN VIVO FLOW CYTOMETRY BASED ON CELLULAR AUTOFLUORESCENCE - The present invention generally provides methods and systems for performing in vivo flow cytometry by using blood vessels as flow chambers through which flowing cells can be monitored in a live subject in vivo without the need for withdrawing a blood sample. In some embodiments, one or more blood vessels are illuminated with radiation so as to cause a multi-photon excitation of an exogenous fluorophore that was previously introduced into the subject to label one or more cell types of interest. In some other embodiments, rather than utilizing an exogenous fluorophore, endogenous (intrinsic) cellular fluorescence can be employed for in vivo flow cytometry. The emission of fluorescence radiation from such fluorophores in response to the excitation can be detected and analyzed to obtain information regarding a cell type of interest. | 02-24-2011 |
| 20110059022 | TWO PHOTON TRACER, METHOD FOR THE PREPARATION THEREOF AND THE USE THEREOF IN SCREENING ANTICANCER AGENTS - Disclosed herein are compounds useful as two-photon tracers. Also, methods are provided for visualizing intracellular glucose uptake, screening anticancer agents, and diagnosing cancer using the compounds. They exhibit preferential uptake by cancer cells, penetrability sufficient to allow bright section images, high water solubility, high pH resistance and low toxicity in addition to applicability to living cells in deep tissues over a long period of time. | 03-10-2011 |
| 20110059023 | NARROWBAND IMAGING USING NEAR-INFRARED ABSORBING NANOPARTICLES - Devices and methods are provided for image identification of contrast agents comprising nanopartiles. The imaging devices and methods may also be configured to identify target tissues from surrounding tissues such as disease conditions (e.g. cancer tumors) through narrow-band imaging of tissue. Contrast agents such as near-infrared absorbing nanoparticles may be introduced to an organism to distinguish target cells, tissues, or structures from normal tissue. The contrast agent is allowed to preferentially accumulate in the target cells, tissues or structures. As the contrast agents are adapted to preferentially absorb one or more wavelengths of light, the reflection of one wavelength or band of wavelengths by the contrast agents is compared to a separate wavelength or band of wavelengths to identify the target cells, tissues, or structures. In this way, the comparisons identify the presence of the preferential accumulation of the contrast agent in the target cells, tissues or structures. | 03-10-2011 |
| 20110070166 | REDUCED DYE PROBES FOR THE DETECTION OF RADICAL OXYGEN SPECIES - Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted π conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended π conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo. | 03-24-2011 |
| 20110081298 | RATIOMETRIC BIOLUMINESCENT SENSOR FOR IMAGINING OXIDATIVE STRESS - This invention provides a novel ratiometric bioluminescent sensor and methods of use thereof. The bioluminescent sensor comprises two luminescent proteins that exhibit different characteristics associated a biological condition, and thereby illuminates differently in response to the biological condition. A ratio between the luminescence of the two luminescent proteins indicates a change in the biological condition. The bioluminescent sensor of the invention can be used to image an oxidative stress or its associated conditions, including a programmed cell death. | 04-07-2011 |
| 20110085986 | Diagnosis and treatment of epithelial cancers using labeled/conjugated progastrin peptides - The current invention provides Progastrin peptides that specifically bind Annexin A2 overexpressed by epithelial cancers. The invention includes isolated homing Progastrin peptides conjugated to an imaging agent and methods of using the same for the diagnosis of epithelial cancers. Also encompassed are Progastrin peptides conjugated to cytotoxic agents such as Camptothecin, Doxorubicin, Paclitaxel and derivatives thereof, and methods of treating epithelial cancer using the same. | 04-14-2011 |
| 20110104069 | MULTI-FUNCTIONAL BIODEGRADABLE PARTICLES FOR SELECTABLE TARGETING, IMAGING, AND THERAPEUTIC DELIVERY AND USE THEREOF FOR TREATING OCULAR DISORDERS - In various embodiments, provided are multi-functional biodegradable particles for selectable targeting, imaging, and delivery of therapeutic agents. Also provided are methods of using the provided particles for treatment of ocular disorders, such as for the treatment of age-related macular degeneration. The provided particles and methods provide a clinician with options for control over, and monitoring of, the delivery of therapeutic agents. | 05-05-2011 |
| 20110104070 | SITE SPECIFIC FLUORESCENCE AND CONTRAST MARKER FOR SAME - A contrast marker for indicating a presence of a target cell in an environment comprises a fluorophore, an NMP, and a short spacer and a long spacer linking the fluorophore to the NMP. The short spacer holds the fluorophore at a quenching distance from the NMP and the long spacer holds the fluorophore at a fluorescence enhancing distance from the NMP. The short spacer is configured to be cleaved by a molecule characterizing the target cells. | 05-05-2011 |
| 20110104071 | METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS - The present invention provides compositions and methods for imaging tumor resections. | 05-05-2011 |
| 20110110864 | FLUORESCENT NANOCRYSTALS ENCAPSULATED IN AN INORGANIC SHELL - The present invention relates to a method of preparing hybrid organo/mineral nanoparticles comprising an organic fluorescent crystalline core encapsulated in an inorganic shell, and to nanoparticles that can be obtained by said method. The method of the present invention comprises the following steps: (i) a sol-gel mixture able to be obtained by a process comprising the addition, in at least one organic solvent, in the presence of water, of a fluorescent organic compound and at least one metal alkoxide is sprayed; (ii) the sprayed sol-gel mixture is dried, by evaporating the solvent and the water that are present in the sol-gel mixture. The nanoparticles of the present invention can be used for example as a tracer in medical imaging or as a chemical sensor. | 05-12-2011 |
| 20110117024 | NANOCARRIER AND NANOGEL COMPOSITIONS - Novel classes of multi-arm polyalkylene oxide-based materials including PEG nanocarriers, nanogel particles, and aggregated nanogel particles are disclosed. These classes of compositions may be associated with therapeutic agents and targeting moieties, or visibility enhancing agents, and may have a modified surface structure. In some embodiments the PEG-based materials can be made to provide relatively high drug loads with improved solubility and targeted delivery. | 05-19-2011 |
| 20110117025 | DEVICE AND METHOD FOR FLUORESCENCE-BASED IMAGING AND MONITORING - A device for fluorescence-based imaging and monitoring of a target comprising: a light source emitting light for illuminating the target, the emitted light including at least one wavelength or wavelength band causing at least one biomarker associated with the target to fluoresce; and a light detector for detecting the fluorescence. | 05-19-2011 |
| 20110117026 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF BIOACTIVE COMPOUNDS - The present invention provides compositions comprising delivery systems comprising a lipid vehicle, a bioactive compound, and a polyanionic carrier macromolecule that is not a carrier polynucleotide, wherein the lipid vehicle encapsulates the polynucleotide of interest and the polyanionic carrier macromolecule, and wherein the delivery system is essentially free of carrier polynucleotides. Compositions also include delivery systems comprising a lipid vehicle and a bioactive agent, wherein the lipid vehicle encapsulates the bioactive agent, and wherein the lipid vehicle comprises a covalent bilayer or a core supported bilayer comprising polycationic lipids. Other compositions provided herein comprise a delivery system comprising a polypeptide of interest and a means for delivering the polypeptide into a cell. Also provided herein are methods for making the delivery systems, methods for delivering bioactive compounds, methods for treating a disease or unwanted condition in a subject with the delivery systems, and methods for detecting apoptosis in a cell. | 05-19-2011 |
| 20110123456 | HOLLOW BIODEGRADABLE NANOSPHERES AND NANOSHELLS FOR DELIVERY OF THERAPEUTIC AND/OR IMAGING MOLECULES - A polymeric hollow nanoshell or nanosphere for release of an agent is described, wherein the hollow nanosphere comprises at least one biodegradable polymer, characterised in that the polymer is cross-linked. The biodegradable mono-disperse nanospheres described are suitable for use as carriers of biomolecules, therapeutic agents and/or imaging agents. | 05-26-2011 |
| 20110129424 | FLUORINATED POLYMERS AND ASSOCIATED METHODS - Compositions comprising a fluorinated polymer and related methods. | 06-02-2011 |
| 20110158913 | Antisense and pretargeting optical imaging - The present invention relates, in part, to detectably labeled oligomer duplexes and their use in optical imaging, including, in vivo optical imaging. The invention includes methods of optical imaging including in vivo pretargeting methods and in vivo antisense optical imaging methods. | 06-30-2011 |
| 20110158914 | FLUORESCENCE IMAGE CAPTURING METHOD AND APPARATUS - A fluorescence image capturing apparatus for capturing a fluorescence image by receiving fluorescence emitted from an observation area administered with a fluorescent agent, in which pharmacokinetic information of the fluorescent agent is obtained and the intensity of the excitation light and/or the charge storage period of the image sensor is controlled based on the pharmacokinetic information of the fluorescent agent. | 06-30-2011 |
| 20110165083 | Peptides that home to tumor lymphatic vasculature and methods of using same - The present invention provides a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. The invention also provides a method of directing a moiety to tumor lymphatic vasculature in a subject by administering to the subject a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. | 07-07-2011 |
| 20110165084 | VIVO DETECTION OF PHOSPHOLIPASE ACTIVATION - The present invention is directed to a phospholipid-based NIR molecular beacon, having a phospholipid moiety; with an NIR fluorophore moiety covalently linked to a phospholipid glycerol backbone and a quencher moiety covalently linked to the phospholipid glycerol backbone. Additionally, provided herein is methods of analyzing a sample for the presence of a phospholipase and methods of identifying the activity of a phospholipase in vivo utilizing phospholipid-based NIR molecular beacon. | 07-07-2011 |
| 20110165085 | TUMOR SELECTIVE FLUORESCENT STAINING AGENT - A tumor cell or tumor tissue-selective fluorescent staining agent comprising a compound represented by the following general formula (I): | 07-07-2011 |
| 20110177003 | PROTEINS THAT FLUORESCE AT INFRARED WAVELENGTHS OR GENERATE SINGLET OXYGEN UPON ILLUMINATION - This invention provides novel truncation mutants of a phytochrome from the bacterium | 07-21-2011 |
| 20110182823 | Compositions and methods for in vivo evaluation of bioluminescence - Compositions and methods are described for normalizing a bioluminescent signal in a live animal. | 07-28-2011 |
| 20110189101 | FLUORESCENT LABELING AGENT AND FLUORESCENT LABELING METHOD - Disclosed is use of zinc oxide nanoparticles as an exciton emission source in vivo or in vitro. Also disclosed is a fluorescent labeling agent comprising a zinc oxide nanoparticle and a substance capable of selectively binding to a target in vivo or in vitro, wherein the substance is bound to the zinc oxide nanoparticle via at least one binder. Further disclosed is a fluorescent labeling agent comprising a zinc oxide nanoparticle of which the surface is coated with a coating film selected from ZnS, Mg | 08-04-2011 |
| 20110195029 | FLUORESCENT EMULSION - The invention relates to a fluorescent emulsion, to its uses and to labelling reagents comprising it. | 08-11-2011 |
| 20110200532 | Fluorescent emulsion of indocyanine green - The present invention relates to a formulation of indocyanine green in the form of a nanoemulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, in which the oily phase comprises indocyanine green, at least one amphiphilic lipid and at least one solubilising lipid. | 08-18-2011 |
| 20110206616 | RECOMBINANT DERIVATIVES OF BOTULINUM NEUROTOXINS ENGINEERED FOR TRAFFICKING STUDIES AND NEURONAL DELIVERY - This invention relates to isolated | 08-25-2011 |
| 20110206617 | MODIFIED POLYSACCHARIDES FOR DRUG AND CONTRAST AGENT DELIVERY - According to one embodiment, the disclosure provides a delivery formulation including a chitosan in which the primary amines are partially modified with 4-imidazole acetic acid monohydrochloride and a therapeutic or imaging material. According to another embodiment, the disclosure provides a method for delivering a material to an epithelial or mucosal tissue comprising increasing the permeability of an epithelial or mucosal tissue by applying to said tissue a delivery formulation including a chitosan in which the primary amines are partially modified with 4-imidazole acetic acid monochlorohydride and a therapeutic or imaging material. | 08-25-2011 |
| 20110206618 | Fluorescent labeling material and flourescent labeling agent - Provided is a fluorescent labeling material, including zinc oxide nanoparticles each surface-modified with an organic compound having an amino group placed at an outer end thereof. Also provided is a fluorescent labeling agent to be used in vivo or in vitro, including the fluorescent labeling material, in which: EDC or the like is bound thereto through the amino group; and a substance capable of selectively binding to a target to be fluorescently labeled, such as an antibody, is linked thereto. | 08-25-2011 |
| 20110223109 | DIAGNOSTIC SUBSTANCE FOR USE IN A METHOD FOR DETERMINING THE AGGRESSIVENESS OF A PROSTATE TUMOR AND DIAGNOSTIC METHOD - In order to determine the aggressiveness of a prostate tumor, a diagnostic substance is administered to a patient that includes a biomarker provided with a first label that is detectable with a detection device and that specifically binds to a VEGF molecule, and that contains a biomarker that binds specifically to a target molecule that occurs uniformly in the endothelium of blood vessels of healthy tissue and the blood vessels of a prostate tumor, and that is provided with a second label that is detectable with the detection device independently of the first label. | 09-15-2011 |
| 20110223110 | STABLE INDIUM-CONTAINING SEMICONDUCTOR NANOCRYSTALS - Nanocrystals having an indium-based core and methods for making them and using them to construct core-shell nanocrystals are described. These core-shell nanocrystals are highly stable and provide higher quantum yields than known nanocrystals of similar composition, and they provide special advantages for certain applications because of their small size. | 09-15-2011 |
| 20110223111 | CALCIUM CARBONATE MICROSTRUCTURES USEFUL IN ENCAPSULATION APPLICATIONS AND A PROCESS FOR THE PREPARATION THEREOF - A facile method to synthesize stable calcium carbonate microstructures is demonstrated which allows in situ encapsulation of sensitive molecules like drugs. The methodology involves a macromolecular assembly of anionic polypeptide with cationic peptide oligomer to concurrently template and hold to stabilize the mineralized structure. The heterogeneously distributed mixture of anionic and cationic residues in the macromolecular assembly, similar to that is found in natural systems assists in recognizing and coassembling Ca | 09-15-2011 |
| 20110229415 | SEMI-SYNTHETIC ANTIBODIES AS RECOGNITION ELEMENTS - The presently-disclosed subject matter is directed to biosensors for detecting molecules of interest, and systems and methods for using same. The biosensors include an antibody and a probe covalently-linked to the antibody. The antibody has an antigen-binding site that selectively binds the molecule of interest and a purine-binding site, which is at a location distinct from that of the antigen-binding site. The probe includes a purine molecule, which is covalently bound at the purine-binding site to the antibody, and a label linked to the purine molecule. Upon binding of the molecule of interest to the biosensor antigen-binding site, the biosensor undergoes a conformational change, which detectably alters a signal of the label such that the molecule of interest can be detected. | 09-22-2011 |
| 20110229416 | AMPHIPHILIC MACROMOLECULES FOR SOLUBILIZING NANOCRYSTALS - Certain embodiments of the invention provide amphiphilic macromolecules and nanocrystals encapsulated by amphiphilic macromolecules. Additionally, certain embodiments of the invention also provide nanocrystals that are water-solubilzed using functionalized AMs capable of coordinating to the nanocrystal surface. | 09-22-2011 |
| 20110250144 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF - The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radio imaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for in targeted chemotherapy. | 10-13-2011 |
| 20110250145 | BIOLUMINESCENCE IMAGING OF MYELOPEROXIDASE ACTIVITY IN VIVO, METHODS, COMPOSITIONS AND APPARATUSES THEREFOR - Methods of imaging distribution of myeloperoxidase activity in a subject are disclosed. These methods include the use of bioluminescent substrates, including luminol and wavelength-shifted analogues of luminol. Bioluminescent myeloperoxidase substrates that emit light at longer wavelengths compared to luminol are shown to be useful for imaging myeloperoxidase activity in vivo. The disclosed methods can be used for imaging sites of inflammation and other pathological conditions associated with abnormal levels of MPO activity in vivo. Methods of synthesis of luminol analogues are also disclosed. | 10-13-2011 |
| 20110256065 | Non-Isotopic Detection of Osteoblastic Activity In Vivo Using Modified Bisphosphonates - The present invention is directed to a non-isotopic methods for the in vitro and in vivo detection of hydroxyapatite-positive cells and structures. | 10-20-2011 |
| 20110262363 | GLUCOSE BIOSENSOR SYSTEM COUPLED WITH AN ANTI-INFLAMMATORY MODULE AND METHODS FOR USING THE SAME - Disclosed are apparatuses for detecting glucose levels in a subject. The apparatuses include a glucose sensor coupled with an anti-inflammatory module. The apparatus is configured to monitor blood glucose by detecting the fluorescence generated by the sensor and simultaneously reduce the tissue inflammation reaction. Also disclosed are biosensor systems including the apparatuses and methods of using the biosensor systems. | 10-27-2011 |
| 20110262364 | Fluorescent Particles Comprising Nanoscale ZnO Layer and Exhibiting Cell-Specific Toxicity - A core-shell nanoparticle having a core that includes a fluorophore and a first oxide of a first metal and a shell that includes a second oxide of a second metal such that the first oxide and the second oxide are different. Also disclosed are methods relating to the core-shell nanoparticle. | 10-27-2011 |
| 20110268660 | METHOD FOR DETECTING DYSPLASIA - The present invention provides a method of imaging useful in the determination of sites of dysplasia in patients suffering from Barrett's oesophagus. The method comprises the use of an optical imaging agent comprising a vector which targets the extracellular domain of EGFR, the vector also being selective for EGFR over Her2. The vector is labelled with an optical reporter suitable for in vivo imaging using light in the green to near-infrared wavelength 500-1200 nm. Also provided are novel optical imaging agents suitable for use in the method. | 11-03-2011 |
| 20110268661 | FLUORESCENT FUSION POLYPEPTIDES AND METHODS OF USE - Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus. | 11-03-2011 |
| 20110268662 | FUNCTIONALIZED NANOCERIA COMPOSITION FOR OPHTHALMIC TREATMENT - The invention provides a composition comprising a plurality of nanoceria particles, a sufficient amount of at least one inhibitor of human carbonic anhydrase II associated with said plurality of nanoceria particles, and a pharmaceutically acceptable carrier containing said plurality of nanoceria particles with associated inhibitor. One preferred inhibitor of human carbonic anhydrase II comprises 4-carboxybenzene sulfonamide. The disclosed composition is useful in treatment of glaucoma. | 11-03-2011 |
| 20110280810 | SURGICAL OPTICAL SYSTEMS FOR DETECTING BRAIN TUMORS - A method of detecting a brain tumor includes administering indocyanine green to a living body; exposing brain tissue in the living body; irradiating the exposed brain tissue with excitation light of indocyanine green; obtaining an image based on fluorescence of the excited indocyanine green in the brain tissue, wherein the image is obtained using an endomicroscope; and identifying portions of the brain tissue corresponding to the brain tumor based on the image. | 11-17-2011 |
| 20110280811 | METHOD OF MEASURING PROPULSION IN LYMPHATIC STRUCTURES - Novel methods and imaging agents for functional imaging of lymph structures are disclosed herein. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye flowing in one or more lymphatic structures. The packets of organic dye may be tracked to provide quantitative information regarding lymph propulsion and function. In particular, lymph flow velocity and pulse frequency may be determined using the disclosed methods. | 11-17-2011 |
| 20110286932 | OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE - The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively. | 11-24-2011 |
| 20110286933 | MONOFUNCTIONAL CARBOCYANINE DYES FOR IN VIVO AND IN VITRO IMAGING - The present invention provides symmetric carbocyanine dyes and dye precursors useful for fluorescence microscopy, and methods of making and using same. | 11-24-2011 |
| 20110286934 | MEMBRANE TRANSDUCTION PEPTIDES, POLYNUCLEOTIDES, AND METHODS - Isolated polypeptides, nucleic acids, and methods relating to cellular internalization of materials are described herein. Generally, the isolated polypeptides include a membrane transduction domain of human tissue factor pathway inhibitor-2 (TFPI-2). In some cases, the isolated polypeptide can be a fusion peptide that includes a membrane transduction domain of human TFPI-2 and a heterologous peptide domain. The nucleic acids include nucleic acids that encode the isolated polypeptides described herein. The methods generally include providing a composition that includes a membrane transduction domain of human TFPI-2 coupled to a material, and contacting the composition with a cell under conditions effective to permit the cell to internalize the composition. | 11-24-2011 |
| 20110293529 | FLUORESCENT NIRF ACTIVATABLE PROBES FOR DISEASE DETECTION - Fluorescent activatable probes for imaging biological processes and disease detection in vitro and in vivo. There is also described a method for detecting the presence of an enzyme. A sample is contacted with a nanoparticle including a monomer, at least one cleavable spacer comprising at least one fluorescence activation site, and at least two dyes of at least two types. The cleavable spacer is attached at one end to the nanoparticle. The at least two types comprise an energy donor type and an energy acceptor type. At least one dye of one type is embedded in the nanoparticle and the cleavable spacer has at least one dye of the other type attached. The at least two dyes comprise at least one matched pair capable of fluorescence resonance energy transfer. Fluorescence is detected by exposing the sample to a light source, and detecting emitted light with a detector. | 12-01-2011 |
| 20110300076 | METHODS FOR PREPARATION OF ZnTe NANOCRYSTALS - Nanocrystals having a ZnTe core and methods for making and using them to construct core-shell nanocrystals are described. These core-shell nanocrystals are highly stable and provide quantum yields and stability suitable for applications such as flow cytometry, cellular imaging, and protein blotting, medical imaging, and other applications where cadmium toxicity is an issue. | 12-08-2011 |
| 20110305641 | Compositions And Methods For Treatment Of Angiogenesis-Associated Ocular Disorders - The invention provides methods and compositions for identifying and quantifying pathological changes on the retina. | 12-15-2011 |
| 20110318273 | FLUORESCENT CONTRAST AGENTS - The invention relates to contrast agents for imaging of diseases associated with inflammations. More specifically the invention provides optical imaging contrast agents for imaging of activated leukocytes and methods for imaging of such. The contrast agent changes its fluorescent properties upon reaction with oxidants produced by the activated leukocytes. | 12-29-2011 |
| 20120009126 | OPTICAL DETERMINATION OF GLUCOSE UTILIZING BORONIC ACID ADDUCTS - The present invention concerns an improved optical method and optical sensing device for determining the levels of polyhydroxyl-substituted organic molecules in vitro and/or in vivo in aqueous media. The range of detection is between about 400 and 800 nm. In particular, a sensory devise is implemented in a mammal to determine sugar levels. Specifically, a dye is combined with a conjugated nitrogen-containing heterocyclic aromatic boronic acid-substituted bis-onium compound in the presence of a sugar, such as fructose or glucose. The viologens are preferred as the aromatic conjugated nitrogen-containing boronic acid substituted compounds. The method is useful to determine sugar levels in a human being. | 01-12-2012 |
| 20120027689 | METHODS AND COMPOSITIONS FOR ALTERING PHOTOPHYSICAL PROPERITES OF FLUOROPHORES VIA PROXIMAL QUENCHING - The invention is directed to fluorophore-containing compositions and configurations wherein proximity between the fluorophore and one or more protective agents (PAs) modifies the lifetime of fluorescent and/or dark states, their frequency of occurrence, and the total lifetime of fluorescence in order to appropriately modify the photophysical characteristics of the fluorophore. The invention is also directed to methods that utilize these compositions and configurations. | 02-02-2012 |
| 20120034168 | Isolated Monoclonal Antibody or Fragment Thereof Binding Prostate Specific Membrane Antigen, Conjugates and Uses Thereof - An isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen (PSMA) preferably in its native form on the surface of tumour cells. A conjugate of the antibody with an active ingredient and modified forms of the antigen-binding antibody fragment are also provided. The complete antibody and the antigen-recognising fragment thereof are used alone or conjugated for the treatment and the diagnosis of tumours or tissues associated to the tumour overexpressing the PSMA antigen, preferably prostatic neoplastic diseases. | 02-09-2012 |
| 20120039813 | INTRINSICALLY COLORED, LUMINESCENT SILK FIBROIN AND A METHOD OF PRODUCING THE SAME - This present invention proposes a method of producing intrinsically colored, luminescent silk fibroin by feeding silkworms with feed comprising the luminescent dyes as well as the appropriate degumming process to remove sericin while retaining the dyes in silk fibroin are also described. Luminescent and functional molecular organic dyes with balanced hydrophobic/hydrophobic properties that can be effectively absorbed into silk glands of the silkworm are also described. | 02-16-2012 |
| 20120064010 | CCR3 and its Ligands Are Therapeutic and Diagnostic Targets for Neovascular Age-Related Macular Degeneration - The results presented herein demonstrate the specific expression of CCR3 in CNV endothelial cells in humans with AMD, and despite the expression of its ligands, eotaxin-1, -2, and -3, neither eosinophils nor mast cells are present in human CNV. The genetic or pharmacological targeting of CCR3 or eotaxins as disclosed herein inhibited injury-induced CNV in mice. CNV suppression by CCR3 blockade was due to direct inhibition of endothelial cell proliferation, and was uncoupled from inflammation as it occurred in mice lacking eosinophils or mast cells and was independent of macrophage and neutrophil recruitment. CCR3 blockade was more effective at reducing CNV than vascular endothelial growth factor-A (VEGF-A) neutralization, which is currently in clinical use, and, unlike VEGF-A blockade, not toxic to the mouse retina. In vivo imaging with CCR3-targeting quantum dots located spontaneous CNV invisible to standard fluorescein angiography in mice before retinal invasion. CCR3 targeting is useful in reducing vision loss due to AMD through early detection and therapeutic angioinhibition. | 03-15-2012 |
| 20120070380 | Ingestible salt grabber - Disclosed herein include embodiments related to compositions, devices, computer systems, computer-implemented methods, and computer program products associated with an ingestible salt grabber. | 03-22-2012 |
| 20120070381 | OPHTHALMOLOGIC COMPOSITION HAVING GELATION ABILITY - Disclosed is a material for use in ophthalmologic organ replacement, which is transparent, has controllable physical properties, and can have physical properties suitable for use as an ophthalmic tissue when the hardness of a gel produced from the material or the fluidability of a sol produced from the material at a specific temperature or lower is varied. Specifically disclosed is an ophthalmologic composition capable of forming a gel, which comprises a polyethylene glycol that is represented by formula 1 and has one end modified with a long-chain alkyl group, a polyethylene glycol that is represented by formula 2 and has both ends modified with a long-chain alkyl group, and a solvent. | 03-22-2012 |
| 20120070382 | FLUORESCENT CONJUGATED POLYMERS WITH A BODIPY-BASED BACKBONE AND USES THEREOF - The present invention provides various fluorescent conjugated polymers with a BODIPY-based backbone. The invention also provides methods of using the polymers of the invention, such as for imaging and detection of cells, tumors, bacteria and viruses. | 03-22-2012 |
| 20120076735 | Nanoparticles for Extravascular Administration - Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and/or diagnostic agents, for use in research and medical applications. | 03-29-2012 |
| 20120076736 | HOST SUPPORTED GENETIC BIOSENSORS - The present invention relates to an in vivo method of monitoring an analyte in a subject. This method involves providing an expression vector that encodes a biosensor molecule, the biosensor molecule comprising an analyte binding domain and a signal domain. The biosensor molecule produces a signal from the signal domain upon binding of the analyte by the analyte binding domain. The signal is detectable by a non-invasive means. The expression vector is introduced locally into in vivo cells of a subject under conditions effective to express the biosensor molecule in the cells. The signal from the expressed biosensor molecule is detected by a non-invasive means, thereby monitoring the analyte in the subject in vivo. | 03-29-2012 |
| 20120100077 | MIXTURE OF AMPHIPATHIC MOLECULES AND METHOD FOR MODIFYING CELL MEMBRANES BY MEANS OF FUSION - Disclosed is a mixture of amphipathic molecules and a method for modifying cells in vivo by way of membrane fusion with these molecules. | 04-26-2012 |
| 20120100078 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring - The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below. | 04-26-2012 |
| 20120107244 | MONOMERIC VARIANTS OF THE TETRAMERIC eqFP611 - Monomeric eqFP611 variants exhibit red fluorescent properties and DNA encoding monomeric eqFP611 variants. | 05-03-2012 |
| 20120114563 | OPTICAL IMAGING AGENTS - The present invention relates to a method of in vivo optical imaging, of the margins around tumours, which comprises an optical imaging contrast agent. The optical imaging agents comprise conjugates of near-infrared dyes with synthetic polyethylene glycol (PEG) polymers having a molecular weight in the range 15-45 kDa. Also disclosed are optical imaging contrast agents, pharmaceutical compositions and kits. | 05-10-2012 |
| 20120128596 | FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and diagnostic methods utilizing these compounds. A preferred compound of the present invention has the following structural formula: (I) | 05-24-2012 |
| 20120134930 | Pyrazine Derivatives for Bioconjugation - Provided are compounds and compositions of general Formula IX: E1-L-Ar-X-PA, that may be utilized in bioconjugation procedures, where Ar is a chromophore and PA is a functional group capable of being attached to any bioactive molecule of interest. The present invention provides Formulas I-III that are capable of being attached to a bioactive vector for the selective delivery of said photoactive pyrazine derivatives to a desired biological target. | 05-31-2012 |
| 20120148499 | PEPTIDES AND APTAMERS FOR TARGETING OF NEURON OR NERVES - The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide or aptamer that specifically binds to the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that specifically bind to neurons or nerves and for compositions thereof. | 06-14-2012 |
| 20120156140 | FLUORESCENT COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 06-21-2012 |
| 20120177578 | COMPOSITIONS, METHODS, AND SYSTEMS COMPRISING FLUOROUS-SOLUBLE POLYMERS - The present invention generally relates to compositions, methods, and systems comprising polymers that are fluorous-soluble and/or organize at interfaces between a fluorous phase and a non-fluorous phase. In some embodiments, emulsions or films are provided comprising a polymer. The polymers, emulsions, and films can be used in many applications, including for determining, treating, and/or imaging a condition and/or disease in a subject. The polymer may also be incorporated into various optoelectronic device such as photovoltaic cells, organic light-emitting diodes, organic field effect transistors, or the like. In some embodiments, the polymers comprise pi-conjugated backbones, and in some cases, are highly emissive. | 07-12-2012 |
| 20120189550 | ORALLY ADMINISTERED BACTERIA AS VEHICLES FOR SYSTEMATIC DELIVERY OF AGENTS - The current invention relates to the use of a bacterial species in the preparation of a composition adapted for oral administration for the delivery of an agent to a site in the body. The site in the body may be an organ or a tumour site. The bacterial species is a food grade, non-pathogenic, gram-positive bacteria capable of anaerobic growth. | 07-26-2012 |
| 20120207683 | EVALUATION PROBE FOR CENTRAL NERVOUS SYSTEM PERMEABILITY, EVALUATION METHOD FOR CENTRAL NERVOUS SYSTEM PERMEABILITY, AND SCREENING METHOD USING AN EVALUATION PROBE FOR CENTRAL NERVOUS SYSTEM PERMEABILITY - Provided is an evaluation probe capable of optically evaluating permeability of a substance through a central nervous system tissue. Also provided is an evaluation method for permeability of a substance through a central nervous system tissue using an evaluation probe for central nervous system permeability. Also provided is a screening method using an evaluation probe for central nervous system permeability. The evaluation probe for central nervous system permeability includes, as an active ingredient, at least one kind of compound represented by the following general formula (1). | 08-16-2012 |
| 20120225021 | STABLE COLLOIDAL GOLD NANOPARTICLES WITH CONTROLLABLE SURFACE MODIFICATION AND FUNCTIONALIZATION - In the present invention, a method of producing stable bare colloidal gold nanoparticles is disclosed. The nanoparticles can subsequently be subjected to partial or full surface modification. The method comprises preparation of colloidal gold nanoparticles in a liquid by employing a top-down nanofabrication method using bulk gold as a source material. The surface modification of these nanoparticles is carried out by adding one or multiple types of ligands each containing functional groups which exhibit affinity for gold nanoparticle surfaces to produce the conjugates. Because of the high efficiency and excellent stability of the nanoparticles produced by this method, the fabricated gold nanoparticle conjugates can have surface coverage with functional ligands which can be tuned to be any percent value between 0 and 100%. | 09-06-2012 |
| 20120230918 | NON-INVASIVE IN VIVO OPTICAL IMAGING METHOD - The present invention relates to a non-invasive method of determining the presence, quantifying the blood level, and/or monitoring or determining the blood clearance of a fluorescent analyte which comprises a fluorescent entity and a second entity, in the blood of a subject, comprising or consisting of the steps: (a) directing excitation light of at least one predetermined wavelength onto a delineated region comprising at least a portion of the pupil of said subject, to excite the fluorescent entity, (b) receiving light emitted from said fluorescent analyte with a wavelength distinguishable from the predetermined wavelength of (a), through the eye of said subject, thereby determining the presence, quantifying the blood level, and/or monitoring or determining the blood clearance of said fluorescent analyte in the blood of said subject. The present invention further relates to a fluorescent analyte or fluorescent label as defined in any one of the preceding claims for use in any one of the preceding methods. The present invention furthermore relates to the use of a fluorescent analyte or fluorescent label as defined in any one of the preceding claims for the preparation of a diagnostic composition which is to be employed in any one of the preceding methods. The present invention furthermore relates to a device for use in any of the methods defined herein. | 09-13-2012 |
| 20120237451 | NOVEL MOLECULAR BEACONS - The invention provides novel compositions and methods for the detection of a target molecule. Specifically, the invention provides a bimolecular beacon composition comprising two nucleic acid molecules, and methods thereof. One of the nucleic acid molecule is operably linked to a reporter detectable label and the other nucleic acid molecule is operably linked to a reference detectable label and a quencher. In some embodiments, at least one of the nucleic acid molecules comprises a single stranded overhang. | 09-20-2012 |
| 20120244078 | OPTICAL IMAGING CONTRAST AGENTS AND USES THEREOF - The invention relates to microbubble contrast agent compositions comprising a gas core encapsulated by a monolayer shell, said shell comprising a first surfactant, a second surfactant having a higher water solubility than said first surfactant, an anchor molecule attached to said shell at the gas-shell interface and an optically-active probe, said probe being detectable by fluorescence, near-infrared, bioluminescence, or other optical imaging methods. Uses of the described compositions for imaging and therapeutic applications are contemplated. | 09-27-2012 |
| 20120251458 | Dyes for Membranes and Biological Structures - The present invention relates to the use of one or more natural dyes, alone or in combination with other dyes for preparation of a composition to stain membranes and biological structures, in order to facilitate their identification during surgical procedures. The present invention relates to the use of one or more natural dyes, alone or in combination with other dyes, to stain membranes and biological structures, in order to facilitate their identification during surgical procedures. | 10-04-2012 |
| 20120251459 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN - Compounds which specifically inhibit legumain, also known as asparaginyl endopeptidase are provided. The compounds have an epoxide or N-Michael acceptor warhead, and have an asparagine side chain attached to a nitrogen atom in the backbone adjacent the warhead. The compounds also preferably comprise a proline residue adjacent the asparagine, and the compound may also contain a third residue and/or a label for cellular or in vivo imaging of active legumain. | 10-04-2012 |
| 20120258048 | OPTICAL FLUORESCENT IMAGING - Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared (NIR) spectral range. The NIR is highly sensitive for tumor detection and tracking. The application discloses targeting a tumor-enriched cell surface receptor with a ligand-conjugated fluorescent probe, which specifically allows detection of the tumor relative to the negligible animal autofluorescence. | 10-11-2012 |
| 20120269734 | Self-Illuminating Dot Systems and Methods of Use Thereof - Generally, aspects of the present disclosure are directed to conjugate systems, self-illuminating quantum dot conjugates, methods of detecting a target in a host, methods of treating a disease in a host, and the like. | 10-25-2012 |
| 20120276014 | MEASUREMENT OF BODY FLUID VOLUMES - The present invention is related generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (IFV). The methods are especially beneficial for subjects suffering from renal failure and particularly those undergoing renal dialysis. ECFV can be measured by administering a first molecule which is non-metabolized and permeable to vessel walls of the vascular system wherein the first molecule is distributed within the total vascular space as well as the interstitial space. TVPV can be measured by administering a second molecule which is non-metabolized and impermeable to vessel walls of the vascular system wherein the second molecule is distributed within only the vascular space. IFV can then be calculated using the equation IFV=ECFV−TVPV. | 11-01-2012 |
| 20120276015 | Optical in vivo Imaging Contrast Agents and Methods of Use - Provided is an optical in vivo contrast agent comprising a fluorescent polymeric microsphere, wherein the micro-sphere is impregnated with a dye having an excitation and emission spectrum compatible with in vivo imaging, and wherein the microsphere is coated with a block copolymer. | 11-01-2012 |
| 20120294807 | FLUORESCENT COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 11-22-2012 |
| 20120294808 | Fluorescent Analogs of Neurotransmitters, Compositions Containing the Same and Methods of Using the Same - A method of imaging using selective fluorescent emitters and compositions for imaging are described. The method can include contacting a specimen with a composition comprising at least one selective fluorescent emitter of Formulas I through IX and irradiating the specimen with an excitation wavelength. The fluorescence emitted by the selective fluorescent emitter can be detected to generate an image. Formulas I through IX are: | 11-22-2012 |
| 20120315220 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use - The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy. | 12-13-2012 |
| 20120321562 | NICOTINIC ACID AND PICOLINIC ACID DERIVED NEAR-INFRARED FLUOROPHORES - This invention relates to new fluorescent chemical entities, including fluorescent molecules that comprise a carboxyl or carbonyl functionalized pyridine moiety. This invention also relates to the corresponding reactive versions of such molecules. This invention also relates to the corresponding conjugates with moieties such as peptides, proteins, various biomolecules, carbocyclic and heterocyclic compounds, sugars, and their uses thereof. | 12-20-2012 |
| 20120321563 | Carbonic Anhydrase Targeting Agents and Methods of Using Same - The invention provides agents that target carbonic anhydrase, which can be used as imaging agents or therapeutic agents. The agents can be used to image tumor hypoxia as well as other physiological processes in a subject. | 12-20-2012 |
| 20120328530 | TOLUIDINE BLUE DERIVATIVES AS PHOTOSENSITISING COMPOUNDS - A compound of formula (III), or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen and/or tumour cells; wherein X is selected from O, S and Se; each of R | 12-27-2012 |
| 20130004429 | USE OF A NEUROFILAMENT PEPTIDE FOR THE TREATMENT OF GLIOMA - The present invention provides a new drug to treat malignant glioma, which is the most prevalent type of primary tumor of the central nervous system (CNS). The present invention indeed shows that the isolated NFL-TBS | 01-03-2013 |
| 20130004430 | FLUORESCENT PHOTOPROBE FOR THE IMAGING OF ENDOTHELIN RECEPTORS - The present invention relates to an endothelin receptor antagonist conjugate of the formula (I) wherein R | 01-03-2013 |
| 20130011337 | THERAPEUTIC AGENT AND DIAGNOSTIC AGENT FOR MITOCHONDRIAL DYSFUNCTION BRAIN DISEASES - To provide a therapeutic agent and a diagnostic agent for mitochondrial dysfunction brain diseases including cerebral infarction as a representative. | 01-10-2013 |
| 20130017154 | Uniform Fluorescent Microsphere with Hydrophobic Surfaces - Fluorescent microspheres for the measurement of blood flow are provided. The microspheres are substantially uniform in diameter and have a hydrophobic surface, which allows them to circulate more freely throughout bloodstream, while reducing immunogenicity, particle aggregation and bioaccumulation. The hydrophobic surface on each microsphere is generally comprised of polymeric material having a limited surface charge. | 01-17-2013 |
| 20130039859 | PASSIVATED NANOPARTICLES - Passivated semiconductor nanoparticles and methods for the fabrication and use of passivated semiconductor nanoparticles is provided herein. | 02-14-2013 |
| 20130039860 | FLUORESCENT IMAGING WITH SUBSTITUTED CYANINE DYES - Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared spectral range. The cyanine compounds of Formula I are presented: | 02-14-2013 |
| 20130039861 | Dye Conjugated Peptides for Fluorescent Imaging - The present application discloses compositions and methods of use of dye conjugated peptides for fluorescent detection, diagnosis and/or imaging. In preferred embodiments, the compositions comprise a DNL complex comprising an anti-hapten antibody or antigen-binding fragment thereof conjugated to an AD moiety and a DDD moiety conjugated to an antibody or antigen-binding fragment thereof that binds to the target antigen, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form the DNL complex. More preferably, the compositions comprise a targetable construct comprising at least one hapten and a fluorescent probe. Binding of the DNL complex to the target antigen and of the hapten on the targetable construct to the DNL complex results in fluorescent labeling of the target antigen. Most preferably, fluorescent imaging is of use in intraoperative, intraperitoneal, laparoscopic, endoscopic or intravascular procedures for detection of diseased tissues. | 02-14-2013 |
| 20130052137 | PARA AMINO BENZOIC ACID BASED NANOTUBES - The invention relates to nanotubes and processes for making them and intermediates of a drug moiety or its derivative/s as a structural moiety with side chain/s capable of promoting self aggregation. The side chain/s are mono or a multiple of alkyl chain/s that are substituted or unsubstituted capable of creating self aggregating assemblies. A p-amino benzoic acid (PABA) moiety or derivative as a structural moiety of 4-alkylamido-N-pyridin-2yl-benzamide with a lauric or stearic side chain. 4-alkylamido-N-pyridin-2yl-benzamide and 4-Amino-N-pyridine-2 yl-benzamide, N-(Pyridine-2-yl)-4-dodecanamido-benzamide and N-(Pyridin-2-yl)-4-stearamidobenzamide are intermediates useful for in vivo Conjugation of an active ingredient, illustrated by Rhodamine B. With Rhodamine B as an active ingredient, nano-tubes prepared with lauric side chain, which show red fluorescence and is useful for in vivo tracking. | 02-28-2013 |
| 20130052138 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 - The presently disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also provided are methods for using the disclosed compositions for diagnosing (i.e., by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activity. | 02-28-2013 |
| 20130058871 | METHOD AND SYSTEM FOR MAPPING SYNAPTIC CONNECTIVITY USING LIGHT MICROSCOPY - A mammalian Green Fluorescent Protein (GFP) Reconstruction Across Synaptic Partners (mGRASP) method and system is provided by optimizing synaptic transmelectron microscopicbrane carriers for mammalian synapses. The method and system in one form integrates molecular and cellular approaches with a novel computational strategy to reliably reconstruct neurons in 3D. The method and system allows mGRASP to be applied to both long-range and local microcircuits, analysis of synaptic distribution at the level of single neurons and dendritic compartments within neural cells. | 03-07-2013 |
| 20130058872 | Bioluminescent Endoscopy Methods and Compounds - Bioluminescent endoscopy methods in which bioluminescent generating system components are combined ex vivo immediately prior to injection or infusion into a tissue area of interest to enable bioluminescent viewing of the tissue. The bioluminescent generating system components are combined by simultaneous injection into a Y tube or other in-line mixing chamber receiving fluid inputs from two or more fluid conduits and providing a fluid output to at least one fluid conduit. The mixed components which are the output of such multi lumen mixing system is injected into a hollow viscus organ or otherwise applied to organs and/or tissues of the body. | 03-07-2013 |
| 20130064776 | LABELLED SILICA-BASED NANOMATERIAL WITH ENHANCED PROPERTIES AND USES THEREOF - The present invention relates to labelled silica-based nanoparticles with enhanced properties, to process for preparing them and to uses thereof. | 03-14-2013 |
| 20130078188 | ACTIVATABLE CELL PENETRATING PEPTIDES WITH QUENCHED FLUOROPHORES - The invention provides compositions useful as molecular probes. In particular, the invention provides activatable cell penetrating peptides comprising a fluorescence donor and a fluorescence acceptor. Exemplary fluorescence donors and fluorescence acceptors include compounds derived from cyanine. Also provided are ratiometric, multispectral, and excitation lifetime imaging methods for detecting the molecular probes provided herein. | 03-28-2013 |
| 20130095042 | SILICA-BASED NANOPARTICLES AND METHODS OF STIMULATING BONE FORMATION AND SUPPRESSING BONE RESORPTION THROUGH MODULATION OF NF-KB - Osteoporosis, is an exceedingly common malady that leads to bone fracture and results from an imbalance in the rate of osteoblastic bone formation with respect to osteoclastic bone degradation. Nanotechnology has raised exciting possibilities for the development of novel therapeutic agents. Embodiments of the disclosure provide silica-based fluorescent nanoparticles endowed with natural bone targeting capabilities and expressing potent pro-osteoblastogenic and concomitant anti-osteoclastogenic activities in vitro and the capacity to increase bone mineral density in vivo. Embodiments of the disclosure can achieve their stimulatory effects on osteoblasts, and inhibitory effects on osteoclasts, in part by suppressing NF-KB signal transduction. Embodiments of the present disclosure provide for derivatives of silica-based nanoparticles that represent a novel class of dual anti-catabolic and pro-anabolic agents that may be applicable to the amelioration of numerous osteoporotic conditions. | 04-18-2013 |
| 20130101517 | DEVELOPMENT OF PHOTOSTABLE NEAR-IR CYANINE DYES FOR IN VIVO IMAGING - A compound of structural formula (I): | 04-25-2013 |
| 20130101518 | METHOD AND APPARATUS FOR KIDNEY FUNCTION ANALYSIS - A method and apparatus for determining physiological data related to an animal, such as kidney diagnostics data, is provided. The method includes injecting a mixture of a first and a second molecule into an animal (e.g., a human patient), determining a molecular ratio of the molecules, and determining the physiological data based on the molecular ratio. The apparatus includes a number of finger receiving apertures, a light generation circuit, a light detection circuit, a pulse counting circuit, and a user interface. | 04-25-2013 |
| 20130101519 | Diagnostic Method for Atherosclerosis - The invention relates to a method of identifying/monitoring active atherosclerotic plaques associated with blood vessel walls wherein the plaques comprise activated macrophages having accessible binding sites for a ligand. The method comprises the steps of administering to a patient being evaluated for atherosclerosis an effective amount of a composition comprising a conjugate of a ligand and a chromophore capable of emitting light under predetermined conditions, allowing sufficient time for the ligand conjugate to bind to the activated macrophages, subjecting the blood vessels to the predetermined conditions using a catheter-based device, and identifying active plaques by detecting light emitted by the chromophore using a catheter-based device or by using an external imaging technique. The invention also relates to a similar method wherein a chemical moiety capable of emitting radiation is conjugated to the ligand. | 04-25-2013 |
| 20130121924 | FLUORESCENCE DETECTION OF POISON OAK OIL - The invention herein disclosed provides for compositions, methods for synthesizing said compositions, and methods for using said compositions, wherein the compositions and methods may be used to bind to and/or deactivate a poison oak oil, such as urushiol. The compositions and methods can be used to treat and/or reduce an inflammatory reaction and/or hypersensitivity to natural compounds found in poison oak, poison ivy, poison sumac, mango, lac tree, and cashew nut. | 05-16-2013 |
| 20130121925 | OPTICAL DETERMINATION OF GLUCOSE UTILIZING BORONIC ACID ADDUCTS - The present invention concerns an improved optical method and optical sensing device for determining the levels of polyhydroxyl-substituted organic molecules in vitro and/or in vivo in aqueous media. The range of detection is between about 400 and 800 nm. In particular, a sensory devise is implemented in a mammal to determine sugar levels. Specifically, a dye is combined with a conjugated nitrogen-containing heterocyclic aromatic boronic acid-substituted bis-onium compound in the presence of a sugar, such as fructose or glucose. The viologens are preferred as the aromatic conjugated nitrogen-containing boronic acid substituted compounds. The method is useful to determine sugar levels in a human being. | 05-16-2013 |
| 20130121926 | DYE COMPOSITIONS AND DYE SYNTHESES - The present invention relates to sulfonated optical dye compositions, especially dyes suitable for biological applications in vitro, and for in vivo imaging. Improved dye compositions and intermediates are provided, which enable the suppression of undesirable newly-identified impurities. Also provided is the use of the improved dye compositions in the preparation of conjugates with biological targeting molecules. | 05-16-2013 |
| 20130129631 | Fluorescent Probe for Imaging Lymph Nodes - Disclosed is a near-infrared fluorescent imaging agent comprising an indocyanine-based fluorescent dye and a liposome. The near-infrared fluorescent imaging agent of the present invention demonstrates high fluorescence intensity and a long anchoring time in sentinel lymph nodes, thereby making it useful for detecting sentinel lymph nodes in sentinel lymph node navigation surgery. Also disclosed is an indocyanine green derivative that is particularly suitable for use in the near-infrared fluorescent imaging agent of the present invention. | 05-23-2013 |
| 20130136697 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES - The invention discloses injectable hydrogels which are in the form of crosslinked nano beads or particle in the size range 5 nm to 10 μm, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents and their methods of preparation. The said gel is formed by reaction of the PAMAM dendrimer with asymmetrical end groups with other polymer wherein the other polymer is selected from the group of linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel disclosed in the present invention is formed as small crosslinked particles in the size range 25 nm to 10 μm and is suitable for injectable delivery of hydrogel to any of the body orifices, tissues by intramuscular or subcutaneous route and ocular delivery for the purpose of therapeutic treatment and imaging. | 05-30-2013 |
| 20130136698 | INTEGRATED PHOTOACTIVE AGENTS AND USES THEREOF - The present invention discloses a number of photoactive compounds designed to bind and inhibit serine proteases. Compounds disclosed herein may be utilized in a number of appropriate medical diagnostic and/or therapeutic procedures such as the monitoring of hemostasis, imaging and/or treatment of vulnerable plaques, and/or tumor imaging and/or treatment. | 05-30-2013 |
| 20130142732 | RECOMBINANT FLUORESCENT NANOPARTICLES - A recombinant fluorescent protein nanoparticle having high fluorescence intensity and a method of detecting a target material using the same are provided. The protein nanoparticle has higher fluorescence intensity than a fluorescent protein, and is resistant to denaturation of the fluorescent protein at room temperature, thereby having higher structural stability than the fluorescent protein itself. In addition, since a self-assembled protein is used as a fusion partner of the fluorescent protein, the protein nanoparticle is biocompatible and safe. Moreover, when a linker peptide is additionally inserted into the protein nanoparticle, a suitable distance between the self-assembled protein and the fluorescent protein is maintained, thereby considerably increasing fluorescence intensity of the protein nanoparticle. The probe-binding protein nanoparticle can control distances between the fluorescent proteins on the surface thereof, thereby maximizing fluorescence intensity. | 06-06-2013 |
| 20130142733 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES - In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymers and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 06-06-2013 |
| 20130142734 | TARGETED DELIVERY SYSTEMS FOR DIAGNOSTIC APPLICATIONS - Targeting of imaging probes specifically to diseased tissues such as cancer is attractive because it potentially allows the improvement of tumor detection. One of the problems associated with conventional, low molecular weight imaging probes is the limited tumor:background ratio. To circumvent this, imaging probes may be conjugated to polymeric carriers to target solid tumors by either passive accumulation of macromolecules into tumor tissues due to the “enhanced permeability and retention” effect (EPR effect) or active targeting through the incorporation of cell-specific recognition ligands that mediate binding to cancer-specific antigens. This invention describes an innovative targeting strategy for the selective delivery of diagnostic agents into solid tumors by means of polymer-NIR fluorochrome conjugates modified with targeting ligands that bind to antigens or receptors that are uniquely expressed or over-expressed on the target cells relative to normal tissues. | 06-06-2013 |
| 20130149251 | OPTICAL SENSOR CONJUGATES FOR DETECTING REACTIVE OXYGEN AND/OR REACTIVE NITROGEN SPECIES IN VIVO - The present invention provides methods and compositions based on optical sensor conjugates that are useful for detecting reactive oxygen, reactive nitrogen, or both species that are a direct result of inflammation caused by tissue damage. | 06-13-2013 |
| 20130149252 | SWITCHING FLUORESCENT NANOPARTICLE PROBE AND FLUORESCENT PARTICLE IMAGING METHOD USING SAME - The present invention provides a novel fluorescent nanoparticle imaging probe having a switching function (a function to quench a fluorescent dye during nanoparticle preparation, and emit fluorescence during imaging). A switching fluorescent nanoparticle probe comprising: a molecular assembly composed of an amphiphilic block polymer having a hydrophilic block chain and a hydrophobic block chain; and a fluorescent dye encapsulated in the molecular assembly, wherein (a) the hydrophilic block chain comprises, as an essential hydrophilic structural unit, a unit selected from a sarcosine unit and an alkylene oxide unit, (b) the hydrophobic block chain comprises, as an essential hydrophobic structural unit, a unit selected from the group consisting of an amino acid unit and a hydroxylic acid unit, and (c) the fluorescent dye is a cyanine compound represented by the formula (I): | 06-13-2013 |
| 20130156705 | BIVALENT MULTIFUNCTIONAL LIGANDS TARGETING A[BETA] OLIGOMERS AS TREATMENT FOR ALZHEIMER'S DISEASE - Bivalent multifunctional Aβ oligomerization inhibitors (BMAOIs) that target multiple risk factors involved in Alzheimer's disease are provided. The BMAOIs are useful for the treatment and/or prevention of Alzheimer's disease, as well as for diagnostic imaging of Aβ plaques in brain tissue. The BMAOIs comprise i) an Aβ oligomer (ApO)-inhibitor moiety which may have antioxidant activity (e.g. curcumin, curcumin derivatives, curcumin hybrids, resveratrol, etc.); ii) a cell membrane/lipid raft (CM/LR) anchoring moiety (e.g. cholesterol, cholesterylamine, a steroid, etc.); and iii) a spacer or linker moiety that stably links i) | 06-20-2013 |
| 20130164220 | COLLAGEN MIMETIC PEPTIDES FOR TARGETING COLLAGEN STRANDS FOR IN VITRO AND IN VIVO IMAGING AND THERAPEUTIC USE - The present invention provides both a caged collagen mimetic peptide (CCMP) having the formula: L-S-Z | 06-27-2013 |
| 20130164221 | USE OF BACTERIAL BETA-LACTAMASE FOR IN VITRO DIAGNOSTICS AND IN VIVO IMAGING, DIAGNOSTICS AND THERAPEUTICS - Provided herein are methods for detecting, quantifying, differentiating, diagnosing and imaging pathogenic bacteria or condition associated therewith using substrates for bacterial enzymes. Fluorescent, luminescent or colorimetric signals emitted by substrates or enzyme products in the presence of the bacteria are compared to controls to detect and locate the pathogenic bacteria. Provided is a method for screening therapeutic agents to treat the pathophysiological conditions by measuring a signal emitted from the substrates or products in the presence and absence of the potential therapeutic agent and a diagnostic method for detecting a mycobacterial infection in a subject by contacting biological samples with a substrate and imaging for signals emitted from a mycobacterial beta-lactamase product. Also provided are fluorogenic substrates or substrates comprising a colored dye or a chemical reagent effective to induce a color or pH change. | 06-27-2013 |
| 20130171074 | TARGETING COMPOUNDS - The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided. | 07-04-2013 |
| 20130183247 | FLUORESCENT CYANINE-POLYAMINE DERIVATIVES AS A DIAGNOSTIC PROBE - The invention relates to fluorescent derivatives of cyanines conjugated with a polyamine group, having formula (I), or a pharmaceutically acceptable salt thereof. The invention also relates to the method for preparing said derivatives, diagnostic compositions containing same and the use thereof as a diagnostic probe for the detection of cancer tumours, in particular in vivo. | 07-18-2013 |
| 20130189188 | TEMPERATURE-MODULATED FLUORESCENCE TOMOGRAPHY - Aspects of the disclosure relate to fluorescence imaging, and more particularly to the use of temperature modulation in a tissue site with a modulator such as high intensity focused ultrasound to modulate the emission signal emitted by temperature-sensitive optical fluorescence reporters. | 07-25-2013 |
| 20130195764 | Nanoparticle Targeting to Ischemia for Imaging and Therapy - The invention provides compositions and methods that provide a solution to the difficulties in diagnosing ischemia, e.g., identifying specific affected anatomical areas, and treating ischemic tissue so as to minimize damage and promote healing of damaged tissue in a subject such as a human or other animal. | 08-01-2013 |
| 20130195765 | METHOD FOR TREATING AND DIAGNOSING CANCER BY USING CELL-DERIVED MICROVESICLES - Disclosed is a method for the treatment and/or diagnosis of cancer, using bacterial cell-derived microvesicles, which is highly effective in cancer therapy with a significant reduction in side effects. Also, a method is provided for delivering of a drug therapeutic or diagnostic for a disease, using bacterial cell-derived microvesicles loaded with the drug, thereby treating and diagnosing the disease effectively and specifically. | 08-01-2013 |
| 20130202536 | FLUOROPHORE CHELATED LANTHANIDE LUMINESCENT PROBES WITH IMPROVED QUANTUM EFFICIENCY - The invention relates to novel luminescent compositions of matter containing a fluorophore, synthetic methods for making the compositions, macromolecular conjugates of the compositions, and the use of the compositions in various methods of detection. The invention also provides kits containing the compositions and their conjugates for use in the methods of detection. | 08-08-2013 |
| 20130202537 | COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE - The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide that associates with (e.g., specifically binds to) the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that associate with (e.g., specifically bind to) neurons or nerves and for compositions thereof. | 08-08-2013 |
| 20130209367 | PARTICLE AND CONTRAST AGENT HAVING THE PARTICLE - There is provided an ICG-loaded polymer nanoparticle that is dynamically stable, prevents the leakage of contained ICG and the resulting discoloration, and has a high molar absorbance coefficient. The particle contains a hydrophilic dye having a sulfonate group and a hydrophobic polymer, and the particle further contains at least one of a lipid having a positively charged region, a nicotinic acid derivative and a thiamine derivative. | 08-15-2013 |
| 20130209368 | NEAR INFRARED FLUORESCENT PARTICLES AND USES THEREOF - The present invention provides particles comprising either a water-soluble polymer or a phospholipid, wherein at least one near infrared (NIR) fluorescent probe and optionally at least one active agent such as a targeting moiety, capable of selectively recognizing a particular cellular marker, are non-covalently bound to the outer surface of the particles. Pharmaceutical compositions comprising these particles may be used, inter alia, for detection and treatment of tumors in the gastrointestinal tract | 08-15-2013 |
| 20130216482 | METHODS AND COMPOSITIONS FOR NON-INVASIVE, DYNAMIC IMAGING OF INTESTINAL MOTILITY - Described are methods and composition for use in non-invasive imaging of intestinal structure and function. These methods can be used to identify, diagnose, assess, monitor and direct therapies for gastrointestinal diseases and disorders. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye excreted in bile into the intestinal tract to provide quantitative information regarding intestinal propulsion and function. | 08-22-2013 |
| 20130224120 | MULTIMODAL DIAGNOSTIC TECHNOLOGY FOR EARLY STAGE CANCER LESIONS - Disclosed herein are compositions of a multimodal detection agent and methods of fabricating the same. The multimodal detection agent comprises a plurality of metallic nanoparticles attached to a surface of a polymeric carrier. The detection agent further comprising one or more target-specific binding agents attached to the metallic nanoparticles or the polymeric carrier. | 08-29-2013 |
| 20130224121 | PARTICLE CONTAINING HYDROPHOBIC DYE HAVING CYANINE STRUCTURE, AND CONTRAST AGENT CONTAINING THE PARTICLE - Provided is a particle which can stably hold a dye in itself even in an aqueous solution such as serum, in order to solve such a problem of a particle containing ICG, which has been conventionally used in a contrast agent or the like, that the ICG is a dye having a hydrophilic functional group and hence the ICG leaks out of the particle in an aqueous solution such as serum. More specifically, provided is a particle including a hydrophobic dye having a cyanine structure, in which the hydrophobic dye is represented by the following chemical formula (1). | 08-29-2013 |
| 20130230464 | Imaging Probe Including Nanoparticle - An imaging probe can include a photoluminescent carbon nanostructure configured to emit a wavelength of light detectable through living tissue, and a targeting moiety including a first binding partner configured to interact with a second binding partner. | 09-05-2013 |
| 20130230465 | BENZOCYANINE COMPOUNDS - Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 09-05-2013 |
| 20130230466 | CYANINE COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 09-05-2013 |
| 20130230467 | POLYMERIZED MICELLES FOR DIAGNOSIS - The invention relates to polymerized micelles of size inferior to 100 nm for in vivo diagnosis, in particular of cancer. The polymerized micelles of the invention comprise a diagnostic agent and an amphiphilic polymer obtainable by the polymerization of an amphiphilic monomer, said monomer comprising: a lipophilic chain comprising a polymerizable vinylic or diacetylenic group, and a hydrophilic head comprising a polyoxyethylene or polyoxypropylene chain. The invention finds application in the pharmaceutical field, in particular. | 09-05-2013 |
| 20130251637 | FLUORESCENT COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 09-26-2013 |
| 20130251638 | Switchable Nucleic Acid Aptamer Probe and Uses Thereof in Tumor Living Cell Detection and in Vivo Detection - The present invention relates to nucleic acid-based detection field, in particularly to a switchable nucleic acid aptamer probe and use thereof. The switchable nucleic acid aptamer probe includes a probe main body as well as a fluorescence generating unit and a fluorescence quenching unit which are respectively connected to two ends of the probe main body. The probe main body includes a nucleic acid aptamer fragment with a function of specifically recognizing target tumor cell and a nucleic acid fragment partially complemented with the nucleic acid aptamer fragment. The nucleic acid aptamer fragment and the nucleic acid fragment are linked by a connection fragment with a length of 7˜15 nm so as to form a hairpin structure. The ability of competitive hybridization of the nucleic acid fragment with the nucleic acid aptamer fragment is weaker than that of the target tumor cell. The use of the probe of the invention can be at least one of specific detection of tumor living cell in buffer solution, effective detection of tumor living cell in serum, and real-time fluorescence imaging and in vivo detection of tumor in living body. The probe of the invention holds relatively high stability, specificity and sensitivity, and its use is easy to operation, fast, sensitive, specific and of low cost. | 09-26-2013 |
| 20130251639 | Novel Cyclodecapeptide Compounds For Use As Drugs - The invention relates to novel cyclodecapeptide compounds having formula (I) for use as drugs and, more specifically, for use in the diagnosis, prevention and/or treatment of neurodegenerative diseases, such as Wilson's disease and Alzheimer's disease, and for use in the diagnosis, prevention and/or treatment of poisoning with metal ions, such as copper and mercury ions. The invention also relates to pharmaceutical compositions comprising at least one compound having formula (I) as an active principle. | 09-26-2013 |
| 20130251640 | PROTEASE DEGRADABLE POLYPEPTIDES AND USES THEREOF - Provided herein are polypeptides that are selectively cleaved by cathepsin E. Also provided are methods of detecting cathepsin E. The methods comprise contacting cathepsin E with the polypeptides provided herein and detecting fluorescence. Further provided are methods of diagnosing cancer or pre-cancerous conditions in a subject. Also provided herein is a multilayered nanoparticle or a composition comprising the multilayer nanoparticle, wherein the multilayered nanoparticle comprises a negatively charged nanoparticle core or capsule coated with alternating positive and negative layers. Optionally, the positive layer comprises a positively charged protease degradable polypeptide. Optionally, the negative layer comprises a negatively charged therapeutic agent or a therapeutic agent and a means for providing the agent with a negative charge. For example, optionally, the therapeutic agent is linked to a negatively charged polymer. Further provided are methods of treating or preventing a disease characterized by expression of a protease in a subject using the nanoparticle. | 09-26-2013 |
| 20130266517 | Humanized Antibodies That Recognize Alpha-Synuclein - The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease. | 10-10-2013 |
| 20130272966 | RET2IR CONJUGATES, RET2IR CONJUGATE SYSTEMS AND METHODS OF USE THEREOF - Embodiments of the present disclosure include conjugate systems, methods of using conjugate systems, RET | 10-17-2013 |
| 20130272967 | Nicotinic Acid and Picolinic Acid Derived Near-Infrared Fluorophores - This invention relates to new fluorescent chemical entities, including fluorescent molecules that comprise a carboxyl or carbonyl functionalized pyridine moiety. This invention also relates to the corresponding reactive versions of such molecules. This invention also relates to the corresponding conjugates with moieties such as peptides, proteins, various biomolecules, carbocyclic and heterocyclic compounds, sugars, and their uses thereof. | 10-17-2013 |
| 20130280172 | FLUORESCENT IMAGING WITH SUBSTITUTED CYANINE DYES - Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared spectral range. The cyanine compounds of Formula I are presented: | 10-24-2013 |
| 20130287699 | Luciferin Derivatives from Bicyclic Reactants and Aminothiol Derivatives and Methods of Use Thereof - The present disclosure features a condensation reaction and a luciferin-unmasking reaction that can be carried out under physiological conditions. In general, the condensation reaction involves reacting a bicyclic reactant with an aminothiol derivative, generating a luciferin or luciferin derivative. A luciferin can provide detectable luminescence. A luciferin derivative can be unmasked to provide detectable luminescence in a luciferin-unmasking reaction. The present disclosure provides bicyclic reactants and aminothiol derivatives suitable for use in the condensation reaction. The condensation and luciferin-unmasking reactions find use in a variety of applications, which are also provided. | 10-31-2013 |
| 20130287700 | COMPOUNDS FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISORDERS ON THE OLFACTORY EPITHELIUM - Subject of the present invention are compounds with high affinity for the Aβ protein, α-synuclein or for Tau-PHF aggregates, which are suitable as preferably fluorescent probes for the in vivo diagnosis of neurodegenerative disorders like e.g. Alzheimer's disease and Parkinson's disease. The compounds are characterized by suitable physicochemical properties (excitation wavelength, emission wavelength, Stokes shift, extinction) as well as a high affinity and selectivity for the target proteins. | 10-31-2013 |
| 20130287701 | METHOD OF DETECTING RISK OF CANCER - The invention provides an ex vivo method for detecting the risk of cancer in a patient, comprising the step of: (iii) detecting the expression level of the genes identified herein as ELN, RGS-1, SOCS-3, PTGS-2, JUN, ATF-3, CTGF, IGF-2 and RBMS-1, in a sample of genetic material isolated from a patient, wherein the combined expression level indicates the risk of cancer in the patient from whom the sample was isolated. | 10-31-2013 |
| 20130287702 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER CELLS - A molecular probe for use in detecting, monitoring, and/or imaging cancer cells and/or cancer cell metastasis, migration, dispersal, and/or invasion includes a targeting agent and a detectable moiety. The targeting agent specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of an immunoglobulin (Ig) superfamily cell adhesion molecule that is expressed by a cancer cell or another cell in the cancer cell microenvironment. | 10-31-2013 |
| 20130295019 | LIGANDS AND METHODS FOR LABELING BIOMOLECULES IN VIVO - Disclosed are tris(triazolylmethyl)amine ligands, and kits and methods for labeling and/or imaging a biomolecule of interest in a subject or living system. | 11-07-2013 |
| 20130315834 | NANOPROBE COMPRISING GOLD COLLOID NANOPARTICLES FOR MULTIMODALITY OPTICAL IMAGING OF CANCER AND TARGETED DRUG DELIVERY FOR CANCER - The present invention is directed to a nanoparticle loaded with a light sensitive molecule and a method of preparing the nanoparticle, wherein the nanoparticle is a colloidal gold nanoparticle and the light sensitive molecule is non-covalently adsorbed to the surface of the nanoparticle. The present invention is also directed to a nanoprobe comprising the nanoparticle and further comprising a targeting moiety covalently coupled to the surface of the nanoparticle. Additionally, the present invention is directed to an imaging method comprising administering the nanoprobe to a subject and collecting imaging data of the subject or part of the subject with optical multimodality imaging. A method of treating cancer in a subject comprising administering the nanoprobe and performing photodynamic therapy on the subject is further disclosed. | 11-28-2013 |
| 20130315835 | SILICA NANOPARTICLES DOPED WITH MULTIPLE DYES FEATURING HIGHLY EFFICIENT ENERGY TRANSFER AND TUNABLE STOKES-SHIFT - The present invention relates to silica nanoparticles comprising at least two dyes. Said dyes have a respective relationship of donor-acceptor couple in an energy transfer process and have a molar absorption coefficient ≧10,000 M | 11-28-2013 |
| 20130315836 | NOVEL CELL-PENETRATING MARKERS OF APOPTOSIS - Provided herein are compounds useful for selectively labeling an apoptotic cell, and methods and assays using such compounds for the detection of an apoptotic cell in vivo or in a biological sample obtained from a subject. | 11-28-2013 |
| 20130315837 | DYE-CONTAINING NANOPARTICLE FOR PHOTOACOUSTIC CONTRAST AGENT - An object of the present invention is to increase the dye content in nanoparticles and to improve the signal intensity per particle. According to the nanoparticle including at least a silicon naphthalocyanine or a derivative thereof and a surfactant, wherein the proportion of the silicon naphthalocyanine or the derivative thereof is 70% or more by weight in relation to the other component of the particle exclusive of the surfactant, the dye content in the nanoparticles can be increased and the signal intensity per particle can be improved without weakening the signal intensity per dye molecule (light absorptivity) | 11-28-2013 |
| 20130323179 | NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS - Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier. | 12-05-2013 |
| 20130323180 | COMPOSITION OF A FIRST NON-LABELED MONOCLONAL ANTIBODY BINDING TO A TUMOR ANTIGEN AND A NON-CROSS REACTIVE SECOND MONOCLONAL ANTIBODY LABELED WITH A NIR FLUORESCENCE LABEL - This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition. | 12-05-2013 |
| 20130330278 | MULTICOLORED pH-ACTIVATABLE FLUORESCENCE NANOPLATFORM - The present invention relates to pH-tunable, highly activatable multicolored fluorescent nanoplatforms and methods of using the nanoplatforms in a variety of applications including, but not limited to, investigating fundamental cell physiological processes such as pH regulation in endocytic vesicles, endosome/lysosome maturation, and effect of pH on receptor cycling and trafficking of subcellular organelles. | 12-12-2013 |
| 20130336895 | FOLATE TARGETED ENHANCED TUMOR AND FOLATE RECEPTOR POSITIVE TISSUE OPTICAL IMAGING TECHNOLOGY - A method of differentiating tumors from healthy cells in tissue is disclosed. The method includes the steps of providing a marker-folate conjugate, placing the marker-folate conjugate in contact with the tissue and viewing the tissue. | 12-19-2013 |
| 20130336896 | SWITCHING-TYPE FLUORESCENT NANOPARTICLE PROBE, AND FLUORESCENT MOLECULAR IMAGING METHOD USING SAME - [Problem] To provide a novel fluorescent nanoparticle imaging probe having a switching function (a function to quench a fluorescent dye in a blood component and emit fluorescence in a tumor or an inflamed site to be imaged). | 12-19-2013 |
| 20130344002 | FOLATE TARGETED ENHANCED TUMOR AND FOLATE RECEPTOR POSITIVE TISSUE OPTICAL IMAGING TECHNOLOGY - A method of differentiating tumors from healthy cells in tissue is disclosed. The method includes the steps of providing a marker-folate conjugate, placing the marker-folate conjugate in contact with the tissue and viewing the tissue. | 12-26-2013 |
| 20140004049 | NANOPROBES FOR SENSING OF REACTIVE OXYGEN AND REACTIVE NITROGEN SPECIES | 01-02-2014 |
| 20140004050 | SELF-QUENCHING ACTIVATABLE COX-2-SPECIFIC MULTI-MODAL MOLECULAR PROBES FOR DIAGNOSIS OF CANCERS, INFLAMMATION, AND IMMUNE SYSTEM DISORDERS | 01-02-2014 |
| 20140010760 | Hypoxia-Targeted Polymeric Micelles For Cancer Therapy And Imaging - The present invention provides a composition and method for targeting hypoxic tumor areas for detection or treatment or a treatment adjuvant for cancer. Specifically, a hypoxia targeting moiety is conjugated to a polymeric micelle containing imaging agents, therapeutic agents, or therapeutic adjuvants. | 01-09-2014 |
| 20140010761 | FORM OF HEXYL-5-AMINOLEVULINATE HYDROCHLORIDE AND METHODS OF USING THE SAME - This invention relates to a novel crystalline polymorph of hexyl-5-aminolevulinate hydrochloride, referred to hereinafter as Form C, which is useful as precursor of a photo sensitizer in the photodynamic diagnosis and treatment of metabolically active cells related to diseases such as cancer of the uterus, cervix, vagina, rectum, colon, lower gastrointestinal tract; infection associated with cancer caused by human papilloma virus; non-cancerous lower gastrointestinal tract a human; inflammatory bowel disease; ulcerative colitis; Crohn's disease; inflammatory bowel syndrome; dysplasia of the female reproductive system; anus; penis; rosacea; and acne and which is suitable for use as the active ingredient of a commercial pharmaceutical product. The invention relates further to methods of preparing Form C and using it in the described pharmaceutical compositions. | 01-09-2014 |
| 20140010762 | IMAGING AGENTS - An imaging agent for cells which produces an intracellular imaging signal proportional to the amount of hCE-1 in the cells independently of the amount of hCE-2 and/or hCE-3 in the cells, said imaging agent being a covalent conjugate of (a) an imaging agent and (b) an alpha mono- or di-substituted amino acid ester, wherein (a) is directly linked to (b), or (a) is indirectly linked to (b) by a linker radical, and wherein said direct or indirect linkage is via the amino group of (b), and wherein the amino group is not directly linked to a carbonyl group, and wherein the said alpha mono- or di-substituted amino acid ester part is selectively hydrolysable to the corresponding carboxylic acid part by the intracellular carboxylesterase enzyme hCE-1 relative to the intracellular enzymes hCE-2 or hCE-3. | 01-09-2014 |
| 20140010763 | ACTIVATABLE FLUOROGENIC COMPOUNDS AND USES THEREOF AS NEAR INFRARED PROBES - Novel fluorogenic compounds designed such that upon a chemical event, compounds capable of emitting NIR light are generated, are disclosed. The compounds comprise two or more acceptor-containing moieties and a cleavable donor-containing moiety, being in complete pi-electrons conjugation and being such that no delocalization of pi-electrons is enabled. Also disclosed are fluorescent compounds generated upon subjecting the fluorogenic compounds to a chemical event (e.g., deprotonation). Also disclosed are uses of the fluorogenic compounds as NIR probed with a Turn-ON mechanism in monitoring presence and/or level of various analytes. | 01-09-2014 |
| 20140017173 | Process of Evaluating Blood-Brain Barrier Permeability of Stroke Rat by Using Fluorescent Substance - A process of evaluating blood-brain barrier permeability of a stroke rat by using fluorescent substance is disclosed. This process uses an Evans blue dye having spontaneous fluorescence properties, in combination with the use of a new non-invasive in vivo imaging system (IVIS), to obtain fluorescent signals so as to assess the change in the blood-brain barrier permeability of rodents after a cerebral artery stroke model surgery. In operation, an Evans blue dye is injected into a stroke rat of middle cerebral artery occlusion model. A non-invasive in vivo imaging system is used to detect the fluorescence distribution of the whole brain, and obtain images combined by the fluorescence images and optical images for the whole brain tissue. Thereby, the change in the blood-brain barrier permeability of the stroke rat can be completely realized. | 01-16-2014 |
| 20140017174 | METHODS AND COMPOSITIONS FOR DETERMINING RESPONSIVENESS TO TREATMENT WITH A TNF-ALPHA INHIBITOR - The present invention is directed to methods and compositions useful for predicting the efficacy of a TNFα inhibitor for treating an inflammatory bowel disease (IBD). The invention includes, in one embodiment, determining the level of expression of TNFα by delivering a labeled anti-TNFα antibody on to the cells of the intestinal mucosa of a subject having IBD, whereby the TNFα level of expression can be used to predict whether the subject will be responsive or not to the antibody therapy. Levels of TNFα may be determined in vivo or ex vivo. The invention further provides methods of locally administering a TNFα antibody, e.g., topically to the intestinal mucosa, for the treatment of IBD. | 01-16-2014 |
| 20140017175 | PENTABLOCK POLYMERS - Novel pentablock polymers comprising PGA-PCL-PEG-PCL-PGA or PEG-PCL-PLA-PCL-PEG, wherein PEG is polyethylene glycol, PCL is poly(ε-caprolactone), PGA is poly(glycolic acid), and PLA is poly(lactic acid). | 01-16-2014 |
| 20140023590 | NOVEL BLOCK COPOLYMER AND MICELLE COMPOSITIONS AND METHODS OF USE THEREOF - Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R′ is —H or —CH | 01-23-2014 |
| 20140023591 | HETEROMULTIVALENT NANOPARTICLE COMPOSITIONS - A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety. | 01-23-2014 |
| 20140023592 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS - A compound comprising three components A, B, and C, which components are covalently bound forming the compound having the structure A-B-C wherein
| 01-23-2014 |
| 20140030193 | CUINSE/ZNS NIR-QUANTUM DOTS (QDS) FOR BIOMEDICAL IMAGIING - Applications in nanomedicine, such as diagnostics and targeted therapeutics, rely on the detection and targeting of membrane biomarkers. Disclosed herein are functionalized quantum dots exhibiting greater stability in water, methods of making the functionalized quantum dots and methods of in vivo imaging using the functionalized quantum dots. | 01-30-2014 |
| 20140037553 | BACTERIUM-BASED MICROROBOT CAPABLE OF TARGETING CANCER TISSUE - To provide a bacterium-based microrobot which can be specifically targeted to cancer in vivo, the present invention provides a drug delivery system for cancer tissue, comprising a bacterium, and a microbead encapsulated with at least one drug, wherein biotin is bound to a surface of the bacterium and a surface of the microbead is coated with streptavidin. | 02-06-2014 |
| 20140044646 | Labeled, Non-Peptidic, Multivalent Integrin Antagonist Compounds; Methods for Synthesis and Uses Thereof - Disclosed are multivalent, integrin-receptor antagonists that are useful in a variety of therapeutic, prophylactic, and/or diagnostic imaging modalities. In illustrative embodiments, such compounds have been prepared and utilized in the imaging, detection, localization, and/or quantitation of one or more samples of biological interest. Similarly, these compounds, as well as formulations comprising them, find utility in the prevention, treatment, and/or amelioration of one or more symptoms of a disease, abnormal condition, dysfunction, etc., including, for example proliferative diseases such as cancer in affected animals. In certain embodiments, fluorescently- or radio-labeled-non-peptidic, multivalent integrin α | 02-13-2014 |
| 20140050666 | SCAVENGER RECEPTOR UPTAKE FOR FABRY DISEASE ENZYME REPLACEMENT THERAPY - The present invention relates to a composition comprising a lysosomal enzyme conjugated to a negatively charged scavenger receptor ligand. In some embodiments, the lysosomal enzyme is conjugated to the scavenger receptor ligand by way of a linker. The present invention also relates to a composition comprising lysosomal enzyme encapsulated by a liposome, said liposome externally comprising a negatively charged scavenger receptor ligand. The invention further encompasses a method of treating a lysosomal storage disease with the compositions listed above. The invention further encompasses a method of treating a lysosomal storage disease with an acylated, acetylated, or aconitylated lysosomal enzyme. | 02-20-2014 |
| 20140050667 | RENAL FUNCTION ANALYSIS METHOD AND APPARATUS - A method for measuring a glomerular filtration rate in a mammalian kidney comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the blood stream of a mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the health of the subject's kidney. This method measures volume of plasma distribution based on a fluorescence of a marker molecule relative to a fluorescence of a reporter molecule. | 02-20-2014 |
| 20140056817 | PHOTODYNAMIC THERAPY OR DIAGNOSTIC AGENT, USING INFRARED-SPECTRUM LIGHT - It is intended to provide a therapeutic and/or diagnostic agent that can be used in photodynamic therapy (PDT) or photodynamic diagnosis (PDD) capable of utilizing infrared-spectrum light such as near-infrared light (NIR), infrared light, or far-infrared light, which attains a deep body penetration. The present invention provides a photodynamic therapeutic or diagnostic agent or a photodynamic therapeutic or diagnostic kit for cancer or infectious disease, comprising: a particle (e.g., a lanthanide particle) that emits upconversion luminescence by infrared-spectrum light such as near-infrared light having a wavelength of 0.7 μm to 2.5 μm; and a photosensitizer (e.g., porphyrin) or a 5-aminolevulinic acid group. | 02-27-2014 |
| 20140056818 | PROCESS FOR DELIVERING ENCAPSULATED NEUTRAL BIOIMAGING MOLECULES, COMPLEX, AND PROCESS THEREOF - The present disclosure relates to delivering neutral bioimaging molecules encapsulated within icosahedral DNA capsules in vivo and in vitro. The present disclosure also discloses the entrapment of neutral bioimaging molecules like FITC dextran within the cavity of a DNA polyhedron without any molecular recognition or chemical conjugation between host (DNA icosahedron) and cargo (like FITC Dextran). This DNA polyhedron is structurally well defined and shows high encapsulation efficiency. The present disclosure also relates to complex formed due to the encapsulation of neutral bioimaging agents within icosahedral DNA capsules. | 02-27-2014 |
| 20140072515 | CYANINE COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 03-13-2014 |
| 20140072516 | METHODS FOR DETECTING ENZYME ACTIVITY USING FLUORESCENCE LIFETIME IMAGING - Disclosed are methods of detecting enzymatic activity on a fluorophore-labeled substrate using by monitoring the fluorescence lifetime of the fluorophore. | 03-13-2014 |
| 20140079642 | NANOPARTICLES BASED FOR DERMAL AND SYSTEMIC DELIVERY OF DRUGS - The present invention relates to a poly(lactic glycolic) acid (PLGA) nanoparticle associated with therapeutic agents for a variety of therapeutic applications. | 03-20-2014 |
| 20140079643 | PROTEIN SKELETAL MODULE WHICH INCREASES THE BINDING AFFINITY AND BINDING SPECIFICITY OF ACTIVE POLYPEPTIDES - The present invention relates to a novel protein skeletal module which increases the binding affinity or binding specificity of active polypeptides. More particularly, the present invention relates to a protein skeletal module comprising polypeptides consisting of the 1 | 03-20-2014 |
| 20140086843 | BIFUNCTIONAL HYDROXY-BISPHOSPHONIC ACID DERIVATIVES - The present invention relates to a bifunctional hydroxy-bisphosphonic acid derivative of formula (I) below: | 03-27-2014 |
| 20140086844 | LUMINESCENT COMPOUNDS - Dyes and photoluminescent compounds based on polymethine dyes that contain at least one alkyl-phosphonate or substituted alkyl-phosphonate group, including the synthetic precursors, methods of synthesis, and applications thereof. Certain embodiments include heterocyclic ring systems and polymethine linkages selected such that the resulting polymethine dye is a cyanine dye, a merocyanine dye or a styryl dye. | 03-27-2014 |
| 20140086845 | METHOD FOR IMAGING A SITE OF ARTHRITIS IN AN ANIMAL - The present disclosure demonstrates that a nanovesicle comprising a membrane-associated lysosomal protein (saposin C; “SapC”) incorporated into a phospholipid has a high fusogenic affinity for phosphatidylserine-rich domains on the surfaces of target cell membranes. It is believed that the nanovesicles target surface exposed phosphatidylserine on the membranes of cells associated with arthritis, allowing for detection of local tissue damage associated with arthritis. In plasma membranes, phosphatidylserine is normally present only on the inner leaflet but is “flipped” to the outer leaflet upon the presence of cell damage. Incorporation of the fluorophore in the nanovesicles allows for the in vivo visualization of the fluorophore in targeted tissue and provides a technique to detect and evaluate the onset and progression of arthritic disease in an animal. Furthermore, the use of the nanovesicle in optical imaging methods provides great promise for analyzing events occurring early in the pathogenesis of arthritis and arthritic disease. | 03-27-2014 |
| 20140093457 | Compositions, methods and kits for remineralization and inhibition of dental caries in teeth - Methods, compositions and kits are provided for enhancing remineralization of a tooth or bone containing hydroxyapatite and inhibiting caries progression or loss of hydroxyapatite using a bisphosphonate or pyrophosphonate. The tooth or tooth surface contains a trauma or defect, for example the tooth contains a caries that is identified using a detectable probe. The bisphosphonate or pyrophosphonate is contacted to the tooth and/or oral cavity and binds to the hydroxyapatite material in the tooth or bone and prevents loss of hydroxyapatite material or strengthens the hydroxyapatite. The amount and extent of enhanced remineralization or of inhibition of caries progression and loss of hydroxyapatite are determined by techniques including photography, light microscopy and fluorescence microscopy. | 04-03-2014 |
| 20140093458 | IN VIVO SELECTION OF THERAPEUTICALLY ACTIVE ANTIBODIES - The present invention relates to non-invasive methods of in vivo selecting an antibody against a desired target on the surface of a mammalian cell of a subject by applying near-infrared fluorescence imaging (NIRF) as well as uses of NIRF in such methods. In addition, kits for the use in these methods comprising a panel of potentially therapeutic effective fluorescence labeled antibodies and means for NIRF imaging are provided. | 04-03-2014 |
| 20140099264 | MEANS AND METHODS FOR IN VIVO TESTING OF THERAPEUTIC ANTIBODIES - The present invention provides methods and means for identifying a cancer-patient disposed to respond favourably to a therapeutic antibody as well as methods for in vivo selecting a xenograft tumor model which is most qualified for preclinical testing of a therapeutic antibody. These methods apply near-infrared fluorescence imaging which is an excellent imaging technology because of its simplicity, fast scanning times and non-hazardous radiation. | 04-10-2014 |
| 20140105825 | Systems, Methods, and Apparatus for Imaging of Diffuse Media Featuring Cross-Modality Weighting of Fluorescent and Bioluminescent Sources - In certain embodiments, the invention relates to systems and methods for in vivo tomographic imaging of fluorescent probes and/or bioluminescent reporters, wherein a fluorescent probe and a bioluminescent reporter are spatially co-localized (e.g., located at distances equivalent to or smaller than the scattering mean free path of light) in a diffusive medium (e.g., biological tissue). Measurements obtained from bioluminescent and fluorescent modalities are combined per methods described herein. | 04-17-2014 |
| 20140105826 | REDUCED DYE PROBES FOR THE DETECTION OF RADICAL OXYGEN SPECIES - Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted π conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended π conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo. | 04-17-2014 |
| 20140112871 | NUCLEIC ACID PROBES AND METHODS OF USING THE SAME - The present invention provides a composition comprising a fluorescent nucleic acid probe that can be cleaved by enzymatic and non-enzymatic means, and methods of using the same. Advantageously, the nucleic acid probe may be used to detect and quantify nucleic acid cleavage in vitro, in situ, ex vivo, and in vivo. | 04-24-2014 |
| 20140120038 | NANOPARTICLES FOR IMAGING AND TREATING CHLAMYDIAL INFECTION - Compositions of nanoparticles and targeting moieties for imaging and treating Chlamydial infection are provided, including nanoparticles conjugated to folic acid and comprising at least one antibiotic effective against | 05-01-2014 |
| 20140127137 | SMMR (SMALL MOLECULE METABOLITE REPORTERS) FOR USE AS IN VIVO GLUCOSE BIOSENSORS - Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin. | 05-08-2014 |
| 20140134109 | METHOD FOR DETECTING AMYLOID AGGREGATES USING STYRYLPYRIDAZINE-ONE DERIVATIVES - The present invention relates to a composition for detecting beta amyloid aggregates and a composition for diagnosing beta amyloid aggregation disease, comprising a 2-styrilpyridizine-3(2H)-one derivative or its pharmaceutically acceptable salt, to a diagnostic kit for diagnosing beta amyloid aggregation disease comprising said composition and to a method for detecting beta amyloid aggregates using said compositions to provide information for beta amyloid aggregation disease diagnosis. | 05-15-2014 |
| 20140134110 | OPTICAL IMAGING PROBES - The present invention relates to methods of visualising cells especially although not exclusively in vivo using a dye, such as a dendrimer-dye molecule or polybranched-dye molecule which is internalised by the cells and thus permits subsequent visualisation by confocal fluorescence endomicroscopy or other optical detectors. There is also provided internally quenched probes for use in visualising cells especially although not exclusively in vivo by confocal fluorescence endomicroscopy and the use of internally quenched probes in combination with confocal fluorescence endomicroscopy, for visualising cells by virtue of internalisation and dequenching of a probe by the cells. In a particular embodiment the cells are activated neutrophils, such as within the lung of a subject. | 05-15-2014 |
| 20140134111 | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF BONE RELATED DISEASES - Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and a bisphosphonate bone targeting agent, and processes of preparing same, are disclosed. | 05-15-2014 |
| 20140140930 | NON-PEPTIDIC QUENCHED FLUORESCENT IMAGING PROBES - Methods and materials for the imaging of cells and tissues containing active proteases such as cathepsin are disclosed. The present materials include activity based probes that bind to an enzyme and are subsequently cleaved. Cleavage results in covalent attachment of a fluorescent signal to a target protease due to removal of a quenching group which, when present on the probe causes altered or no fluorescence. The probes are non-peptidic, small molecule scaffolds linked to a reactive acyloxymethyl ketone group, a fluorophore and a quencher. The probes are cell permeable and may use, for example, a QSY21 (CAS 304014-13-9) quencher and a cyanine dye. The probes form covalent bonds with the active site of cysteine cathepsins, proteases that are upregulated at the tumor boundaries with normal tissue and at sites of inflammation. | 05-22-2014 |
| 20140140931 | ANTIOXIDANT, NEUROPROTECTIVE AND ANTINEOPLASTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT ON AN AMPHIPHILIC SPACER OR AN AMPHIPHILIC POLYMER - This invention relates to antioxidant, neuroprotective and antineoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer. Methods of synthesizing the antioxidant derivatives of camptothecin and anti-oxidant derivatives of camptothecin analogs, NSAIDs and statins, spontaneous emulsification or nanoprecipitation thereof to produce antioxidant, neuroprotective and anti-neoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer and their use in treating cancerous diseases are also provided. A further aspect of this invention is the use of these neuroprotective and anti-neoplastic nanoparticles for the preparation of delivery devices of other pharmaceuticals and/or drugs. | 05-22-2014 |
| 20140154184 | TIME-GATED FLUORESCENCE IMAGING WITH SI-CONTAINING PARTICLES - A method for imaging leverages the fluorescence lifetime of a fluorescent Si-containing particle to distinguish from background fluorescence. A particle is introduced into tissue. An excitation light pulse is applied to excite luminescence from the fluorescent Si-containing particle. Time-gated measuring of a responsive luminescence signal identifies the particle. In preferred embodiments the particle is coated or encapsulated with an organic material. The fluorescence lifetime of particles can be controlled during manufacture, such as by oxidation levels, quenching treatments, or by aging. This permits introducing and using groups of particles in imaging that have unique lifetimes and multiple time gating can be used to identify different particles or to monitor the change in lifetime of a single set of particles as they respond to a biochemical stimulus. The particles can also be functionalized for affinity to particular tissues and can be loaded with treatment molecules. | 06-05-2014 |
| 20140161727 | OPTICAL-IMAGING PROBE FOR DETECTING SENTINEL LYMPH NODES WHICH CONTAINS A COMPOSITE OF POLY-GAMMA-GLUTAMIC ACID AND AN OPTICAL-IMAGING DIE - The present invention relates to an optical imaging probe for detecting a sentinel lymph node, which contains a complex of poly-gamma-glutamic acid and an optical imaging dye, and more particularly to an optical imaging probe for detecting a sentinel lymph node, which contains a poly-gamma-glutamic acid/optical imaging dye complex that, when injected subcutaneously in vivo, remains in the sentinel lymph node for a relatively long period of time and has a low tendency to migrate to other lymph nodes. The present invention provides a poly-gamma-glutamic acid/fluorescent dye complex, which contains no radiopharmaceutical and is harmless to the human body. The use of the poly-gamma-glutamic acid/fluorescent dye complex makes it possible to accurately detect the position of a sentinel lymph node in real time without concerns about radioactive contamination. | 06-12-2014 |
| 20140161728 | COMPOSITION FOR DETECTING BIOFILMS ON VIABLE TISSUES - A staining composition for use in making biofilm detectable on viable tissue wherein the composition preferentially stains the biofilm and comprises a staining agent in a quantity effective to stain said biofilm and render it detectable. | 06-12-2014 |
| 20140161729 | COFLUORONS AND METHODS OF MAKING AND USING THEM - The present invention is directed to method of using a collection of monomers capable of forming multimers as a fluorescence reporter in different applications such as ligand detection/screening, disease diagnosis, drug discovery or screening, fluorescent labeling and imaging, or other fluorescent methodologies. Each monomer in the collection includes one or more ligand elements useful for binding to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the ligand elements directly or indirectly through a connector. Association of linker elements of different combinations of monomers, with their ligand elements bound to the target molecule to form a multimer, will generate a unique fluorescent signature different from that produced by those monomers either alone or in association with each other in the absence of the target molecule, when subjected to electromagnetic excitement. | 06-12-2014 |
| 20140178309 | PROTECTION OF CELLS FROM ALU-RNA-INDUCED DEGENERATION AND INHIBITORS FOR PROTECTING CELLS - A method of protecting a cell includes inhibiting an inflammasome, MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NFκB of the cell. Administering an inhibitor of MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NFκB can protect the cell from Alu-RNA-induced degeneration. Protecting a cell, such as an retinal pigment epithelium (RPE), can be therapeutically useful in the context of age-related macular degeneration and geographic atrophy. | 06-26-2014 |
| 20140193340 | Luciferin Amides - This disclosure relates to luciferin amides of formula (I) shown below: | 07-10-2014 |
| 20140193341 | HUMAN INDUCED NEURONAL CELLS - A method for reprogramming a fibroblast into a human induced neuronal cell (hIN) is described. The method comprises expressing heterologous reprogramming factors Bm2, Myt11, Zic1, Olig2, Asc11 or any combination thereof, in said fibroblast, and culturing the fibroblast in a medium comprising BDNF, NT3, GeM or any combination thereof. Biomarkers describing the obtained hiN cells are also presented. In another aspect, methods for screening compounds using the hiN cells is described. | 07-10-2014 |
| 20140193342 | ENZYME DIRECTED ASSEMBLY OF PARTICLE THERANOSTICS - Provided herein is a method for enzymatically triggered assembly of polymeric nanostructures for detection of cancer-associated enzymes in vivo. By detecting enzymatic signals associated with disease, one can sensitively determine the site, and extent of disease within a patient. | 07-10-2014 |
| 20140193343 | MEASUREMENT OF BODY FLUID VOLUMES - The present invention is related generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (IFV). The methods are especially beneficial for subjects suffering from renal failure and particularly those undergoing renal dialysis. ECFV can be measured by administering a first molecule which is non-metabolized and permeable to vessel walls of the vascular system wherein the first molecule is distributed within the total vascular space as well as the interstitial space. TVPV can be measured by administering a second molecule which is non-metabolized and impermeable to vessel walls of the vascular system wherein the second molecule is distributed within only the vascular space. IFV can then be calculated using the equation IFV=ECFV−TVPV. | 07-10-2014 |
| 20140199245 | OLIGONUCLEOTIDE-BASED PROBES FOR DETECTION OF BACTERIAL NUCLEASES - The present invention relates to a rapid detection of microbial-associated nuclease activity with chemically modified nuclease (e.g., ribonuclease) substrates, and probes and compositions useful in detection assays. Accordingly, in certain embodiments, the present invention provides a probe for detecting a microbial endonuclease comprising a substrate oligonucleotide of 2-30 nucleotides in length, a fluorescence-reporter group operably linked to the oligonucleotide, and a fluorescence-quencher group operably linked to the oligonucleotide. The fluorescence-reporter group and the fluorescence-quencher group are separated by at least one RNAse-cleavable residue, e.g., RNA base. | 07-17-2014 |
| 20140212359 | PHOTOSTABLE AIE LUMINOGENS FOR SPECIFIC MITOCHONDRIAL IMAGING AND ITS METHOD OF MANUFACTURING THEREOF - AIE (aggregation-induced emission)-active TPE derivatives, TPE-TPP, TPE-MitoR and TPE-IQ are contemplated. These specific TPE derivatives are useful as fluorescent agents for mitochondrial imaging and as apoptosis inducers. Possessing high specificity to mitochondria, superior photostability and appreciable tolerance to microenvironment change, TPE derivatives are well-suited imaging agents for mitochondrial targeting and morphological change tracking. Because of their synthetic flexibility, TPE derivatives can be further modified as dual-functional probes for an array of applications such as sensing of ROS, metal ions, or pH change in mitochondria. | 07-31-2014 |
| 20140212360 | Imaging Beta-Amyloid Peptides and Inhibition of Beta-Amyloid Peptide Aggregation - The present invention is in the field of pharmaceuticals and chemical industries. In particular, the present invention relates to methods for labeling, imaging and detecting the beta-amyloid (Aβ) peptides, oligomers, and fibrils in vitro by using carbazole-based fluorophores. A further aspect of the present invention relates to a method of reducing and preventing aggregation of beta-amyloid peptides for Alzheimer's disease (AD) as well as of treating and/or preventing Alzheimer's disease by using carbazole-based fluorophores. | 07-31-2014 |
| 20140219925 | POLYMER PARTICLES OR NANO-VECTORS AND USE THEREOF AS A DRUG AND/OR DIAGNOSTIC AGENT - Novel polymer nanovectors or particles and use thereof as medication and/or diagnostic agents. | 08-07-2014 |
| 20140241992 | NANOSTRUCTURE, APPLIED DEVICE AND PREPARATION METHOD THEREOF - A nanostructure is described. The nanostructure includes a nanoparticle, a shell encompassing the nanoparticle, and a gap having a width ranging from 1.0 nm to 6.0 nm and located between the nanoparticle and the shell to enable the nanostructure to generate a fluorescence. | 08-28-2014 |
| 20140241993 | FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR INTRA-OPERATIVE VISUALIZATION OF CANCER - A chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for using the chlorotoxin conjugate. | 08-28-2014 |
| 20140248218 | ROS-SENSITIVE FLUORESCENT PROBES - Herein are provided, inter alia, compositions including boronic esters, which in the presence of H | 09-04-2014 |
| 20140255312 | CYANINE COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 09-11-2014 |
| 20140255313 | Compositions and Methods for Detecting Protease Activity in Biological Systems - The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications. | 09-11-2014 |
| 20140255314 | METHOD FOR INDUCING PHYSIOLOGICAL ADJUSTMENT USING HIGH DENSITY DISPLAY OF MATERIAL - The present invention relates to a method of regulating or inducing specific physiological conditions or functions using one or more materials displayed on a nano-assembly matrix at high density in cells or in vivo. Specifically, the present invention relates to a method of effectively inducing specific physiological regulation in cells or in vivo by the high-density display of bioactive materials. According to the method of the invention, physiological regulation in cells or in vivo can be optionally induced by regulating the assembly and disassembly of nano assembly (unit) matrix or the display or trapping of specific materials on nano assembly (unit) matrix. | 09-11-2014 |
| 20140255315 | ACF DETECTION METHOD - The present invention provides a method for detecting ACF by analyzing a test region of large intestine tissue at the molecular level. Namely, the present invention relates to a method for detecting aberrant crypt foci (ACF) that comprises detecting an ACF detection marker in a test region of large intestine tissue, by using one or more types of molecules for which ACF-specific expression increases as the ACF detection marker, the molecule being selected from the group consisting of Met, Cdh1, Ctnnb1, and GSTp; an ACF detection marker for detecting the ACF in human-derived large intestine tissue, that is Met, Cdh1, Ctnnb1, or GSTp; and, a method for evaluating risk of colorectal cancer and colorectal adenoma in human subjects based on the results of detecting ACF in a test region of large intestine tissue of the subjects using the aforementioned ACF detection method. | 09-11-2014 |
| 20140255316 | BIOMARKERS AND USE THEREOF - A nanoparticle includes a nanosheet coated partially or totally with at least one layer of inorganic material and its use as a fluorophore or a fluorescent agent. | 09-11-2014 |
| 20140271481 | MATRIX-INCORPORATED FLUORESCENT POROUS AND NON-POROUS SILICA PARTICLES FOR MEDICAL IMAGING - A silica particle for medical imaging includes a bridged silane fluorescent dye incorporated throughout the particle matrix. Copolymerization of a bridged silane fluorescent dye (e.g., (R′O) | 09-18-2014 |
| 20140271482 | SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS - The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds. | 09-18-2014 |
| 20140271483 | TARGETED POLYMERIC CONJUGATES AND USES THEREOF - Polymeric conjugates comprising a polymeric backbone having attached thereto a bone targeting moiety and a therapeutically active agent, wherein the bone targeting moiety is attached to one end of the polymeric backbone via a branching unit such that a molar ratio of the bone targeting moiety to the polymer is at least 2:1, are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of bone related disorders are also disclosed. | 09-18-2014 |
| 20140271484 | Methods of Imaging Inflammatory Diseases by Ligands Conjugated to Fluorescent Compounds - The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods of imaging of inflammatory diseases using the compounds. | 09-18-2014 |
| 20140271485 | USE OF COELENTERAZINE FOR IMAGING INSULIN-GENERATING BETA-CELLS - There is a need for a broadly applicable, strain non-specific, bioluminescent imaging tool that will enable researchers to study a β-cell mass in the context of development, disease or transplantation. The disclosure, therefore, encompasses embodiments of a method of identifying a non-diabetic pancreatic β-cell, the method comprising the steps of: delivering to a pancreatic β-cell a composition comprising a coelenterazine; allowing the β-cell to generate a coelenterazine-dependent bioluminescent signal; and identifying the cell as a non-diabetic pancreatic β-cell by detecting the emitted coelenterazine-dependent bioluminescent signal. | 09-18-2014 |
| 20140271486 | Quantum Dots for Diagnostic Imaging - Methods for detecting disease in a patient are disclosed. The methods involve administering to the patient a quantum dot-analyte conjugate, which includes an analyte that binds to a marker for the disease in the patient's gastrointestinal tract. The analyte is conjugated to a quantum dot having a characteristic emission wavelength. Using an endoscopic modality, a physician can illuminate portions of the patient's gastrointestinal tract and detect the presence of the marker based on emission of the quantum dot. Also disclosed are methods of predicting a response to a treatment in a patient. | 09-18-2014 |
| 20140271487 | PRUSSIAN BLUE-INSPIRED CONSTRUCTS FOR MULTIMODAL IMAGING AND THERAPY - The invention describes a coordination polymer construct for multimodal imaging and therapy. The construct consists of a core particle made of a novel coordination polymer. The core is coated with a biocompatible coating that stabilizes the particles in a physiological environment. The biocompatible coating can contain attached targeting agents, imaging agents and therapeutic agents or combinations one or more of the targeting, imaging and therapeutic agents. When administered to a subject or a subject-derived specimen, the resulting coordination polymer core-shell construct enables multimodal imaging and therapy, which improves the diagnostic and treatment outcomes of the conditions or diseases where it is administered. The invention describes the novel material, base for the construct, methods for the preparation of the said construct and its use as a multimodal imaging and therapy agent. | 09-18-2014 |
| 20140271488 | Chiral compounds of varying conformational rigidity and methods of synthesis - Synthesis of compounds having varying degrees of conformational rigidity is obtained via a low cost, high yield and efficient synthetic reactions. The library of compounds is structurally diverse having at least one or more chiral centers and providing large numbers of compounds having building block diversity and substantial scaffold diversity. The compounds further provide a novel method for obtaining candidate therapeutic agents for prevention, treatment or diagnosis of diseases. | 09-18-2014 |
| 20140271489 | POLYMERIC DEPOTS FOR LOCALIZATION OF AGENT TO BIOLOGICAL SITES - Provided herein are polymeric particles and compounds and processes that can be used to prepare polymer-based particles and methods of using those particles to localize or concentrate a subsequently delivered agent to an in vivo site. | 09-18-2014 |
| 20140286873 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 09-25-2014 |
| 20140286874 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring - The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below. | 09-25-2014 |
| 20140301950 | IMAGING AGENT FOR DETECTION OF DISEASED CELLS - The present invention provides compositions and methods for imaging, for example, tumor resections. | 10-09-2014 |
| 20140301951 | POROUS NANOPARTICLE SUPPORTED LIPID NANOSTRUCTURES - Various exemplary embodiments provide protocell nanostructures and methods for constructing and using the protocell nanostructures. In one embodiment, the protocell nanostructures can include a core-shell structure including a porous particle core surrounded by a shell of lipid bilayer(s). The protocell can be internalized in a bioactive cell. Various cargo components, for example, drugs, can be loaded in and released from the porous particle core of the protocell(s) and then delivered within the bioactive cell. | 10-09-2014 |
| 20140301952 | MEASUREMENT OF BODY FLUID VOLUMES - The present invention relates generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (IFV). The methods are especially beneficial for subjects suffering from renal failure and particularly those undergoing renal dialysis. ECFV can be measured by administering a first molecule which is non-metabolized and permeable to vessel walls of the vascular system, wherein the first molecule is distributed within the total vascular space as well as the interstitial space. TVPV can be measured by administering a second molecule which is non-metabolized and impermeable to vessel walls of the vascular system, wherein the second molecule is distributed within only the vascular space. IFV can then be calculated using the equation IFV=ECFV−TVPV. | 10-09-2014 |
| 20140308210 | REAL TIME IMAGING DURING SOLID ORGAN TRANSPLANT - A method of determining the patency of a donor organ or at least one vessel to a donor organ in a donor subject includes administering a fluorescent dye to the donor subject, applying a sufficient amount of energy to the vessel such that the fluorescent dye fluoresces, obtaining a fluorescent image of the donor organ or the vessel attached to a donor organ, and observing the image to determine if a fluorescent signal is continuous through the vessel. A continuous fluorescent signal in the donor organ or vessel indicates the respective donor organ or vessel is patent | 10-16-2014 |
| 20140308211 | MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION CHARACTERISTICS - A polynucleotide encoding a biosensor polypeptide comprising a modified circularly-permuted thermostable luciferase and a linker linking the C-terminal portion of the thermostable luciferase to the N-terminal portion of the thermostable luciferase. The modified circularly-permuted thermostable luciferase is modified relative to a parental circularly-permuted thermostable luciferase. The linker contains a sensor region capable of interacting with a target molecule in a cell. The modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the parental circularly-permuted thermostable luciferase in the presence of the target molecule. Alternatively, the modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the modified circularly-permuted thermostable luciferase in the absence of the target molecule. | 10-16-2014 |
| 20140308212 | EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISEASE - Compositions comprising a therapeutic agent encapsulated by an edible plant-derived microvesicle are provided. Methods of treating an inflammatory disorder and methods of treating a cancer are further provided and include administering an effective amount of a composition comprising a therapeutic agent encapsulated by an edible plant-derived microvesicle to a subject. Further provided are methods of diagnosing a colon cancer that include the steps of administering an edible plant-derived microvesicle incorporating a detectable label to a subject and then determining an amount of the detectable label in an intestine of the subject. | 10-16-2014 |
| 20140314677 | SUBSTITUTED SILAXANTHENIUM RED TO NEAR-INFRARED FLUOROCHROMES FOR IN VITRO AND IN VIVO IMAGING AND DETECTION - The invention provides a family of fluorescent compounds. The compounds are substituted silaxanthenium compounds that can be chemically linked to one or more biomolecules, such as a protein, nucleic acid, and therapeutic small molecule. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications. The dyes are particularly useful for in vitro, in vivo and ex vivo imaging applications. | 10-23-2014 |
| 20140328762 | Fluorogenic Peptide Probes and Assays - Fluorogenic peptide probes specific for a target molecule are provided. Exemplary fluorogenic peptide probes include a peptide labeled with a fluorogenic label, wherein the fluorogenic peptide probe has an unstructured three dimensional conformation in the absence of the target molecule and a structured three dimensional conformation in the presence of the target polypeptide. The structured three dimensional conformation includes an alpha-helix that forms a coiled-coil with the target molecule allowing generation of a detectable signal from the fluorogenic label in response to an exciting amount of radiation. | 11-06-2014 |
| 20140328763 | BIOACTIVE AMPHIPHILIC POLYMER STABILIZED NANOPARTICLES WITH ENHANCED STABILITY AND ACTIVITY - The present invention relates to nanoparticle compositions and treatment of cardiovascular disease using nanoparticles to target Class A and B scavenger receptors. This invention further relates to methods of detecting cells that express scavenger receptors, detecting atherosclerotic lesions, and targeting bioactive amphiphilic macromolecules to cells that express scavenger receptors. | 11-06-2014 |
| 20140328764 | Biocompatible Nanoparticles with Aggregation Induced Emission Characteristics as Fluorescent Bioprobes and Methods of Using the Same for In Vitro and In Vivo Imaging - The development of fluorescent bioprobes comprising organic fluorescent compounds that exhibit aggregation induced emission (AIE) properties, methods of producing the same, and their practical applications for in vitro and in vivo bioimaging. | 11-06-2014 |
| 20140341810 | ANTAGONISTS FOR ABDOMINAL VASOPRESSIN V2 RECEPTOR AND USES THEREOF - Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V | 11-20-2014 |
| 20140341811 | Nanoparticles and Uses Thereof - A nanoparticle conjugate for intracellular delivery of a therapeutic agent, wherein the conjugate comprises a nanoparticle, a cationic agent and the therapeutic agent. Pharmaceutical compositions, medicaments and therapeutic uses thereof are also provided. | 11-20-2014 |
| 20140348753 | HETEROCYCLE-FUNCTIONALIZED LUMINOGENS EXHIBITING AGGREGATION-INDUCED EMISSION - The development of a series of fluorescent materials including heterocycle-functionalized luminogens with aggregation-induced/enhanced emission (AIE/AEE), long wavelength emission, and high solid state fluorescence quantum efficiency is contemplated. The described fluorescent materials are promising candidates in selective luminescence-based chemosensor for Hg | 11-27-2014 |
| 20140348754 | Method of Delivering Therapeutics and Imaging Agents to the Brain by Nanoparticles that Cross the Blood Brain Barrier - Described herein are methods of delivering a nanoparticle to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle. For example, the targeting agent may include a ligand specific for a receptor expressed by brain endothelial cells and a linker that connects the ligand to the external surface of the nanoparticle core. Additionally, the linker can promote disassociation of the ligand from the nanoparticle when inside a cell. | 11-27-2014 |
| 20140356293 | FLUORESCENT COMPOSITIONS WITH ENHANCED FLUORESCENCE AND METHODS BASED THEREON - Fluorescent compositions with enhanced fluorescent intensity are provided. Methods for using the fluorescent compositions in medical imaging are also provided. The enhanced fluorescent compositions can be a mixture or solution comprising a fluorescent dye and a light-scattering emulsion or fluorescence-enhancing diluent. The fluorescent dye, e.g., indocyanine green (ICG), is activated by near-infrared radiation. The fluorescence-enhancing diluent can be milk, infant formula, intravenous fat emulsions, soy bean oil, egg phospholipids, Intralipid, Liposyn, Nutralipid, Soyacal, Travamulsion, SMOFlipid, Clinoleic, Lipovenoes and/or combinations thereof. The fluorescent intensity of the enhanced fluorescent composition can be 5 to 20 or more times greater than that of the fluorescent dye in solution without added fluorescence-enhancing diluent. | 12-04-2014 |
| 20140369935 | LIPOSOME COMPOSITE BODY - An object of the present invention is to provide a drug delivery system capable of sustainedly releasing a drug noninvasively at any given point in time. The present invention relates to a liposome complex comprising a liposome membrane-constituting substance bonded to a light-absorbing compound having an absorption wavelength in the near-infrared region, selected from the group consisting of indocyanine green dyes, phthalocyanine dyes, squarylium dyes, croconium dyes, and diimmonium dyes. | 12-18-2014 |
| 20140369936 | COMPOSITIONS AND METHODS FOR MONITORING BIOMETRIC INDICATORS - Methods of measurement of biometric indicators in a mammalian subject are described. Biometric indicators of interest include hematocrit, plasma volume, volume of distribution, and glomerular filtration rate. The methods are especially applicable to subjects with rapid blood loss and to subjects with unstable hematocrits. Hematocrit may be measured by administering an injectate with a dynamic fluorescent marker and a static fluorescent marker, or a single static marker with two fluorescent tags, into the vascular system of the subject, and monitoring the emission intensities of the markers or fluorescent tags over a period of time. Hematocrit may then be calculated using a calibrated spectrometric analyzer by determining the raw ratio of the markers at T0, calculating the apparent hematocrit, and applying a correction factor. | 12-18-2014 |
| 20140377184 | Methods and Compositions Related to Targeting Tumors and Wounds - Disclosed are compositions and methods useful for targeting tumors, sites of injury and blood clots. The compositions and methods are based on peptide sequences that selectively bind to and home to tumors, sties of injury and blood clots in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tumors, sites of injury and blood clots. | 12-25-2014 |
| 20150010475 | CRLF-2 BINDING PEPTIDES, PROTOCELLS AND VIRAL-LIKE PARTICLES USEFUL IN THE TREATMENT OF CANCER, INCLUDING ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - The present invention relates to the use of which are attached or anchored phospholipid biolayers further modified by CRLF-2 and CD 19 binding peptides which may be used for delivering pharmaceutical cargos, to cells expressing CRLF-2 and CD 19, thereby treating cancer, in particular, acute lymphoblastic leukemia (ALL), including (B-precursor acute lymphoblastic leukemia (B-ALL). Novel CRLF-2 binding peptides and CLRF-2 and CD19-binding viral-like particles (VLPs) useful in the treatment of cancer, including ALL are also provided. | 01-08-2015 |
| 20150030542 | METHODS FOR MEDICAL IMAGING - The invention relates to methods of identifying, detecting, and locating a tissue(s), nodule(s) or mass(es) and its draining lymph nodes that is/are suspected to be abnormal, typically a neoplasm (i.e., cancer, malignancy, premalignancy) in an individual undergoing an invasive procedure (i.e., surgery or endoscopy) or a non-invasive procedure (ie. radiology). The method involves the use of, for example, indocyanine green (ICG). The uptake of this dye is different by diseased tissues and lymph nodes compared to non-diseased tissues when administered at the appropriate combination of dose and time and monitored with an appropriate device that can excite and capture the signal. | 01-29-2015 |
| 20150030543 | Formulas for Diagnosing and Treating Hormone-Dependent Cancers and Cancers of the Organs Responsible for Steroid Hormone Synthesis - The present invention relates to a formulation of a therapeutic or diagnostic agent in the form of a nano-emulsion, to its preparation method and to the use of this formulation for treating or diagnosing hormone-dependent cancers or cancers of organs synthesizing steroidal hormones. | 01-29-2015 |
| 20150030544 | Enzymatic Nanosensor Compositions and Methods - Disclosed herein are compositions including a nanosensor that is sensitive to an analyte such that the nanosensor emits a fluorescent signal upon detecting the analyte, and a catalytic agent that catalyzes a reaction in which a target substrate is converted into one or more products, such that at least one of the one or more products is the analyte. In addition, methods of using the nanosensor-catalytic agent compositions to detect a target substrate are disclosed. | 01-29-2015 |
| 20150037258 | INFECTION INDICATING MEDICAL DEVICES - Provided herein is an implantable medical device capable of self-reporting microbial growth adjacent the site of the implanted device. | 02-05-2015 |
| 20150037259 | POLYELECTROLYTE-COATED POLYMER DOTS AND RELATED METHODS - Polymer nanoparticles and related methods include polymer dots having a coating including a polyelectrolyte polymer. The polymer dots can have a polyelectrolyte coating that can improve colloidal stability of the particles as compared to polymer dots not having the coating. A method of preparing a population of nanoparticles. The methods can include, e.g., providing the population of nanoparticles having a condensed semiconducting polymer; and combining, in a first aqueous solution comprising polyelectrolytes, the population of nanoparticles having the condensed semiconducting polymer to form a population of nanoparticles having a polyelectrolyte coating surrounding the condensed semiconducting polymer of each of the nanoparticles in the population. The methods can include a step of forming the condensed semiconducting polymer using nanoprecipitation or miniemulsion techniques. The polyelectrolyte coating can completely surround the condensed semiconducting polymer. | 02-05-2015 |
| 20150037260 | CHEMICAL REACTION BY COMBINATION OF GAS-PHASE AND WET-CHEMICAL METHODS - The invention provides a new apparatus ( | 02-05-2015 |
| 20150044140 | PROTEASE-RESISTANT COMPOUNDS USEFUL AS SHUTTLES THROUGH THE BLOOD-BRAIN BARRIER AND SHUTTLE-CARGO CONSTRUCTS - The peptides of formula (I) R | 02-12-2015 |
| 20150044141 | SYNTHESIS AND APPLICATION OF NOVEL IMAGING AGENTS CONJUGATED TO DPA 713 ANALOGS FOR IMAGING INFLAMMATION - The present invention provides analog compounds of DPA-713 which specifically bind the translocator protein (TSPO), which is upregulated in activated leukocytes, some malignant tumors and tissues involved in steroid biogenesis. These compounds are linked via a linking moiety to a variety of imaging agents, including, for example, near infra-red dyes. The compounds of the present invention are useful for both pre-clinical near-IR fluorescence imaging (NIRF) and use in optically-guided interventions including NIRF endoscopy. Methods of use in diagnosis and treatment of TSPO related disease are also provided. | 02-12-2015 |
| 20150044142 | FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and diagnostic methods utilizing these compounds. A preferred compound of the present invention has the following structural formula: | 02-12-2015 |
| 20150044143 | FLUORESCENT MEMBRANE INTERCALATING PROBES AND METHODS FOR THEIR USE - The invention relates to a family of dyes which fluoresce in the UV-VIS, far red and near infrared wavelengths of the spectrum and possess asymmetric lipophilic alkyl chains. The dyes of the invention are soluble in commercially available membrane staining dyes, are useful as probes for rapidly staining lipophilic structures such as membranes in cells or isolated from cells, and are well-retained therein. Methods of utilizing the dyes to detect stained cells both in vivo and in vitro are also disclosed. | 02-12-2015 |
| 20150056142 | NEAR-INFRARED-II FLUORESCENT AGENTS, METHODS OF MAKING NEAR-INFRARED-II FLUORESCENT AGENTS, AND METHODS OF USING WATER-SOLUBLE NIR-II FLUORESCENT AGENTS - Embodiments of the present disclosure provide for compositions including organic, water-soluble NIR-II fluorescent agent that emit radiation at about 1.0 to 1.7 μm, methods of making the composition, methods of imaging a disease and related biological events, methods of imaging, monitoring and/or assessing a disease and related biological events, and the like. | 02-26-2015 |
| 20150056143 | LIGHT-GUIDING HYDROGEL DEVICES FOR CELL-BASED SENSING AND THERAPY - A hydrogel-lightguide based sensory system susceptible to a stimulus signal produced by ambient and stimulating sensory cells embedded in a hydrogel body of the system. Sensory cells generate an optical signal (in response to a user-defined triggering with excitation light or, alternatively, due to bioluminescence) the properties of which, determined based on detection of such signal with an optical detector device, provide characterization of the stimulus and information required for user-defined activation of emitter cells encapsulated in the hydrogel. When activated, emitter cells generate matter and/or light directed to interact with the ambient. | 02-26-2015 |
| 20150071859 | TUMOR-SPECIFIC MINICIRCLES FOR CANCER SCREENING - The present disclosure encompasses embodiments of nucleic acid minicircle vectors most advantageous for the detection of tumor cells. In particular, the minicircles of the disclosure incorporate a tumor-specific promoter operably linked to a nucleotide sequence desired to be selectively expressed in a tumor cell or a tissue comprising a population of tumor cells. In embodiments of the disclosure, the minicircle vectors comprise a tumor-specific promoter operably linked to a nucleotide sequence encoding a polypeptide useful as a reporter. Accordingly, when expressed by a recipient tumor cell, the reporter may be detectable, thereby providing information such as a visual image of the tumor cell and/or its location in a tissue of the subject human or non-human animal. Tumor-specific minicircle vectors driving the expression of either secreted embryonic alkaline phosphatase or firefly luciferase and their utility validated for detecting tumors after systemic administration using blood- and/or imaging-based assays are disclosed. | 03-12-2015 |
| 20150071860 | CYCLIC PEG COATINGS INCREASE THE BLOOD CIRCULATION TIME OF PARTICLES USED IN DRUG DELIVERY APPLICATIONS - A micelle comprising a diblock polymer with a cyclic polyethylene glycol block and a hydrophobic block is provided. The micelle may be used in conjunction with one or a combination of therapeutic agents, targeting agents, and imaging agents. The micelle may be incorporated in a pharmaceutical composition. | 03-12-2015 |
| 20150079004 | METHODS FOR INCREASING SWALLOWING EFFICACY - In a general embodiment, a method for increasing efficacy of a swallow response is provided. The method includes providing a thickened composition having a xanthan gum thickening component, and orally administering the composition to an individual having, or at risk of having, a swallowing impairment. In an embodiment, the efficacy of the swallow response is increased by reducing an amount of pharyngeal residue in the individual's piriform sinuses, valleculae, and/or pharyngeal wall during or after the individual swallows the composition. | 03-19-2015 |
| 20150093333 | COMPOSITIONS, METHODS AND USES FOR PEPTIDES IN DIAGNOSIS, PROGRESSION AND TREATMENT OF CANCERS - Embodiments herein report compositions, systems, methods, and uses for diagnosing and/or treating a condition in a subject. In certain embodiments, one or more peptides can be used as biomarker detectors for predicting onset or progression of disease. Some embodiments of the present invention report peptides capable of associating with MVs for predicting onset or progression of cancer in a subject. Other embodiments include methods of generating and or modifying peptides of use herein. Yet other embodiments herein report biomarker detectors capable of detecting agents associated with cancer progression, for example, metastasis. | 04-02-2015 |
| 20150093334 | Vault and Vault like Carrier Molecules - A method of using vaults as carrier molecules to deliver one or more than one substance to an organism, or to a specific tissue or to specific cells, or to an environmental medium. A vault-like particle. A method of preventing damage by one or more than one substance to an organism, to a specific tissue, to specific cells, or to an environmental medium, by sequestering the one or more than one substance within a vault-like particle. A method of delivering one or more than one substance or a sensor to an organism, to a specific tissue, to specific cells, or to an environmental medium. According to another embodiment of the present invention, there is provided a method of making vault-like particles, and making vault-like particles comprising one or more than one substance, or one or more than one sensor. | 04-02-2015 |
| 20150098905 | METHODS TO DETECT A FUNGAL CELL - The present invention relates to targeting agents and methods: of using the targeting agents to detect a fungal cell in a subject. | 04-09-2015 |
| 20150104394 | CHARACTERIZATION OF BIOLOGICAL TISSUES AT A CELLULAR LEVEL USING RED AND FAR-RED FLUORESCENT DYES - A method for observing the morphology of a biological tissue is disclosed. The method involves using a fluorescent dye on the biological tissue, where the fluorescent dye is selected from patent blue V, isosulfan blue, toluidine blue, hypericin, indocyanine green, MVAC, or doxorubicin, and using a microscopic linear or non-linear imaging system to form an image of the biological tissue, where the fluorescence of the dye reveals the morphology of the tissue at cellular scale. | 04-16-2015 |
| 20150104395 | System and Method for Diagnosis of Astrocytic Brain Tumor - Methods and systems for distinguishing an astrocytic human brain rumor from a non-astrocytic human brain tumor (FIG. | 04-16-2015 |
| 20150104396 | METHOD FOR DETECTING CANCER USING ICG FLUORESCENCE METHOD - A method of detecting an accessory cancer lesion, comprising an administration step wherein indocyanine green is administered to a living body, an irradiation step wherein a target organ suspected of having cancer is surgically exposed and irradiated with excitation light of indocyanine green, an imaging step wherein a near-infrared fluorescence intensity distribution image from the excited indocyanine green in the target organ is obtained, and an identification step wherein an area having the near-infrared fluorescence in the intensity distribution image, excluding the area detected in preoperative examination or intraoperative macroscopic observation, is identified as an accessory cancer lesion. | 04-16-2015 |
| 20150110719 | HYDROGEL BASED DELIVERY AND SENSOR - Described are catheters associated with a hydrogel for release of a molecule of interest. The molecule of interest may be an antibody. Further described are sensors useful for detecting the presence or amount of an analyte, and associated methods. A sensor for use in detecting the presence or amount of an analyte may comprise a catheter having one or more apertures. The sensor may also include means for detecting binding of the analyte to an antibody. | 04-23-2015 |
| 20150110720 | FLUORESCENT FUSION POLYPEPTIDES AND METHODS OF USE - Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus. | 04-23-2015 |
| 20150118162 | TWO-PHOTON FLUORESCENT PROBES FOR IMAGING OF TOTAL SULFIDE IN LIVE CELL AND TISSUE, AND QUANTITATIVE ESTIMATION OF TOTAL SULFIDE CONCENTRATION USING THE SAME - The present disclosure relates to a two-photon fluorescent dye for imaging total sulfide in vivo and a method for quantitatively estimating total sulfide concentration in vivo using the same. The two-photon fluorescent dye, which includes a compound of [Chemical Formula 1], can detect hydrosulfide on and image total sulfide and allows quantitative estimation of total sulfide concentration in vivo. | 04-30-2015 |
| 20150118163 | Methods of Preparing Ophthalmic Formulations and Uses of Same - The present invention relates to a process for preparing an ointment comprising subjecting a mixture of a fluorescent molecular rotor compound, mineral oil, and grinding media to ball milling agitation and combining this mixture with a hydrophobic vehicle for an ointment. The invention also relates to an ophthalmic formulation comprising a pharmaceutically acceptable carrier and a compound of the following structural Formula (I), or a pharmaceutically acceptable salt thereof: | 04-30-2015 |
| 20150125396 | OCULAR DETECTION OF AMYLOID PROTEINS - Described are methods for the detection, in the eye of an individual, of protein aggregates or other misfolded proteins associated with disease using peptide or peptide mimic probes that preferentially associate with the protein aggregates or misfolded proteins, which can be accomplished non-invasively. | 05-07-2015 |
| 20150125397 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IMMUNE CELL RECEPTORS AND AUTOANTIGENS - Engineered multivalent and multispecific binding proteins that bind immune cell receptors and/or autoantigens are provided, along with methods of making and uses in the prevention, diagnosis, prognosis and/or treatment of disease. | 05-07-2015 |
| 20150147277 | COMPOSITIONS AND METHODS FOR ASSESSING GUT FUNCTION - Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction. | 05-28-2015 |
| 20150297720 | PHOTODYNAMIC DIAGNOSTIC AGENT AND PHOTOBLEACHING INHIBITOR - The objects of the present invention are to inhibit photobleaching of porphyrins as well as to provide a superior photodynamic diagnostic agent and a photodynamic diagnostic method employing the photobleaching inhibitor for porphyrins. The present invention provides a photodynamic diagnostic agent containing a precursor of porphyrins and a gallic acid. The present invention also provides a photobleaching inhibitor for porphyrins containing a gallic acid. | 10-22-2015 |
| 20150306252 | TWO-PHOTON PROBE FOR DETECTING COPPER(II) ION AND QUANTITATIVE ESTIMATION OF COPPER(II) ION IN HUMAN TISSUE USING THE SAME - The present disclosure relates to a two-photon probe for in-vivo imaging, having high selectivity for copper(II) ion, and a method for quantitatively estimating copper(II) on (Cu | 10-29-2015 |
| 20150306253 | DUAL EMISSIVE METAL NANOPARTICLES AS RATIOMETRIC PH INDICATORS - In some aspects, the present disclosure provides a dual emissive pH response noble metal nanoparticle which produces a ratiometric fluorescence signal based upon changes in the pH. In another aspect, the noble metal nanoparticle may be used in bioimaging applications as well as to detect in vivo changes of pH. | 10-29-2015 |
| 20150306254 | COMPOSITIONS AND METHODS FOR DETECTING COMPLEMENT ACTIVATION - Provided herein, inter alia, are compositions and methods of using the same for detecting complement activation. | 10-29-2015 |
| 20150314019 | FUNCTIONALIZED ULTRABRIGHT FLUORESCENT SILICA PARTICLES - A method for synthesizing ultrabright fluorescent silica particles with hydrophilic functional groups, comprising the steps of: (i) forming a first mixture comprising a plurality of nano-sized silica particles and a gelation agent; (ii) forming a second mixture by combining the first mixture with a surfactant, a plurality of fluorescent dye molecules, and water, wherein fluorescent dye molecules are encapsulated within a plurality of pores of the nano-sized silica particles; (iii) forming a third mixture by adding a co-source of silica to the second mixture, wherein the co-source of silica prevents leakage of the encapsulated fluorescent dye molecules from the pores of the nano-sized silica particles and provides hydrophilic functional groups to the silica particles while preserving the fluorescence of the silica particles; (iv) optional further functionalization of the obtained nanoparticles with functional molecules, exemplified by carboxylic groups and folic acid, and (v) removing excess fluorescent dye from the third mixture. | 11-05-2015 |
| 20150320681 | PROTOCELLS AND THEIR USE FOR TARGETED DELIVERY OF MULTICOMPONENT CARGOS TO CANCER CELLS - Various embodiments provide materials and methods for synthesizing protocells for use in targeted delivery of cargo components to cancer cells. In one embodiment, the lipid bilayer can be fused to the porous particle core to form a protocell. The lipid bilayer can be modified with targeting ligands or other ligands to achieve targeted delivery of cargo components that are loaded within the protocell to a target cell, e.g., a type of cancer. Shielding materials can be conjugated to the surface of the lipid bilayer to reduce undesired non-specific binding. | 11-12-2015 |
| 20150322078 | BENZOPYRYLIUM COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 11-12-2015 |
| 20150328330 | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF BONE RELATED DISEASES - Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and a bisphosphonate bone targeting agent, and processes of preparing same, are disclosed. | 11-19-2015 |
| 20150335766 | CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES - A composition comprising a tricyclic indole compound. The composition has a higher purity and better impurity profile than known compositions comprising said tricyclic indole compound and as a consequence has superior properties, particularly when said compound is destined for use in vivo as a therapeutic or diagnostic agent. | 11-26-2015 |
| 20150338425 | TREATMENT AND PROGNOSIS OF LYMPHANGIOLEIOMYOMATOSIS - Embodiments disclosed herein relate to treatment methods, diagnosis methods, drug efficacy evaluation methods and prognosis evaluation methods of lymphangioleiomyomatosis (LAM) and a disease associated with a mutation in a tuberous sclerosis complex (TSC) gene. The methods comprising analyses of the levels of lysophosphatidylcholine (LPC) in a biological sample of a subject, or comprising analyses of images of the location and signal intensity of isotope-labeled choline in the subject. | 11-26-2015 |
| 20150343093 | CONTROLLED DEATH OF IMPLANTED CELLS - A method is provided, including implanting a chamber containing cells in a subject, and subsequently administering, to the subject, a drug capable of killing the cells. For example, the drug may be administered after the cells cease to function for their intended purpose, or if the cells escape from the implanted chamber. Alternatively, the drug may be administered to kill the cells while the cells are in the implanted chamber. Other embodiments are also described. | 12-03-2015 |
| 20150344525 | A DUAL-TARGETED THERAPEUTIC PEPTIDE FOR NASOPHARYNGEAL CARCINOMA, NANOPARTICLES CARRYING SAME AND USES THEREOF - Disclosed is a dual-targeted therapeutic peptide for nasopharyngeal carcinoma formed by covalently linking a targeted therapeutic peptide for nasopharyngeal carcinoma, a peptide linker and a targeted therapeutic peptide with an α-helical structure for nasopharyngeal carcinoma. Also disclosed is a nanoparticle containing the peptide. The peptide and the nanoparticle can be used to treat nasopharyngeal carcinoma. | 12-03-2015 |
| 20150352184 | METHOD AND COMPOSITIONS FOR GENETIC AND RETINAL DISEASE - An inventive method for treatment or prevention of vascular diseases of the retina is provided. A Norrin compound is optionally administered to a subject either directly and/or as expressed by a cell. The presence of the compound is either protective of or therapeutic for a pathological condition of the retina. Preferred pathological conditions are those linked to the absence of or mutation of norrin protein and are preferably Norrie disease, FEVR, or macular degeneration. | 12-10-2015 |
| 20150352229 | APPARATUS FOR FACILITATING CELL GROWTH IN AN IMPLANTABLE SENSOR - Apparatus is provided that contains cells for implantation into a human subject. The apparatus includes a substantially non-degradable three-dimensional scaffold having surfaces to which the cells are attached, and a hydrogel, which is attached to the cells. The scaffold, the cells, and the hydrogel are arranged such that the cells are sandwiched in spaces between the hydrogel and the surfaces of the scaffold, thereby allowing mobility and proliferation of the cells in the spaces between the hydrogel and the surfaces of the scaffold, and preventing the mobility and the proliferation of the cells to locations outside of the spaces between the hydrogel and the surfaces of the scaffold. | 12-10-2015 |
| 20150352230 | SYNTHESIS AND ISOLATION OF DENDRIMER BASED IMAGING SYSTEMS - The present invention relates to novel methods of synthesis and isolation of antibodies conjugated with modular dendrimer nanoparticles. In particular, the present invention is directed to antibodies conjugated with novel modular dendrimer nanoparticles having precise numbers of imaging agents, methods of synthesizing the same, compositions comprising such antibodies conjugated with such modular dendrimer nanoparticles, as well as systems and methods utilizing the conjugates (e.g., in imaging settings) (e.g., in diagnostic and/or therapeutic settings) (e.g., for the delivery of therapeutics, imaging, and/or targeting agents). | 12-10-2015 |
| 20150352264 | POLYMERIC VASCULAR STENT AND IN VIVO VISUALIZATION THEREOF - This invention is directed to vascular stents that can be visualized in vivo through the use of fluorescent imaging. | 12-10-2015 |
| 20150353603 | ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF - Provided herein are compositions and methods for selectively targeting an endometriosis cell. | 12-10-2015 |
| 20150353604 | COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE - The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide that associates with (e.g., specifically binds to) the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that associate with (e.g., specifically bind to) neurons or nerves and for compositions thereof. | 12-10-2015 |
| 20150353609 | MONOMERIC AND BRIGHT INFRARED FLUORESCENT PROTEINS - The invention described herein features variants related to infrared fluorescent proteins, in particular to mutants of a phytochrome from the bacterium | 12-10-2015 |
| 20150359908 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE - Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or tissue retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) cargo moieties (portion D | 12-17-2015 |
| 20150359912 | J-Aggregate Forming Nanoparticle - There is provided herein a nanovesicle having a bilayer comprising a saturated first phospholipid and no more than about 15 molar % of a second phospholipid covalently conjugated to a J-aggregate forming dye. | 12-17-2015 |
| 20150361145 | FLUORESCENT FUSION PROTEIN - A fluorescent fusion protein is provided. The fluorescent fusion protein of the invention comprises a first fluorescent protein with first emission wavelength, a second fluorescent protein with second excitation wavelength and second emission wavelength, and a linker peptide linking the first fusion protein and the second fusion protein, wherein the first emission wavelength overlaps the second excitation wavelength so that the second fluorescent protein exhibits the second emission wavelength after receiving energy. The fluorescent fusion protein of the invention exhibits a stronger fluorescence in the absence of bilivirdin (BV). | 12-17-2015 |
| 20150374828 | GLUCOSE-SENSITIVE NANOPARTICLE FOR CANCER DIAGNOSIS AND THERAPY - Disclosed are glucose-sensitive nanoparticles which includes a phenylboronic acid derivative and a biocompatible polymer, and is prepared as an amphiphilic conjugate having chemical binding between the phenylboronic acid derivative and the biocompatible polymer. The use of the composition can effectively collect glucose in the cancer tissue, thereby simultaneously performing diagnosis and therapy of cancer. | 12-31-2015 |
| 20160000724 | CONTROLLED RELEASE NANOPARTICLES AND METHODS OF USE - Provided herein are nanoparticles that include a lipid layer and a compartment surrounded by the lipid layer. The lipid layer may include a lipid and a lipoprotein. The lipid may include a POPE lipid covalently attached to a hydrophilic polymer by a disulfide bond. The lipoprotein may include a trigger protein. The concentration of the first lipid may be between 1 mol % and 30 mol %. The disulfide bond of the first lipid is stable under conditions that include 10% human serum and is broken under conditions that include 50 micromolar glutathione. The hydrophilic polymer may include a PEG molecule. The trigger protein may include an amino acid repeat region, such as (GPX)n. The trigger protein may include a peptide bond that is cleaved by a gelatinase (e.g., gelatinase-B protease), or a member of the ADAM family of proteases (e.g., ADAM10 protease). Also provided are methods of using the nanoparticles. | 01-07-2016 |
| 20160000938 | REAGENT FOR DIAGNOSIS OF OSTEOARTHRITIS COMPRISING PEPTIDE PROBE OF APOPEP-1 - Disclosed is a reagent for diagnosing osteoarthritis or predicting the prognosis of osteoarthritis, the reagent containing a peptide having the amino acid sequence (CQRPPR) of SEQ ID NO: 1 as an active ingredient. The present peptide can be used to accurately diagnose osteoarthritis in its early stage based on the molecular imaging technique. The present peptide has a small molecular weight, and thus has advantages of fast clearance from the blood, effective permeation into the tissue, low immunogenicity, and low-production cost. Further, the present reagent can diagnose osteoarthritis in its early stage in which the destruction of cartilage is in a reversible phase and thus can be recovered to a normal state, thereby significantly contributing to effective treatment of osteoarthritis. | 01-07-2016 |
| 20160008291 | PEPTIDE-BASED HYDROGEL PARTICLES AND USES THEREOF | 01-14-2016 |
| 20160015775 | Lipopeptides for Use in Treating Liver Diseases and Cardiovascular Diseases - The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease. | 01-21-2016 |
| 20160015833 | HETEROMULTIVALENT PARTICLE COMPOSITIONS - A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety. | 01-21-2016 |
| 20160015835 | LUCIFERIN DERIVATIVES FROM BICYCLIC REACTANTS AND AMINOTHIOL DERIVATIVES AND METHODS OF USE THEREOF - The present disclosure features a condensation reaction and a luciferin-unmasking reaction that can be carried out under physiological conditions. In general, the condensation reaction involves reacting a bicyclic reactant with an aminothiol derivative, generating a luciferin or luciferin derivative. A luciferin can provide detectable luminescence. A luciferin derivative can be unmasked to provide detectable luminescence in a luciferin-unmasking reaction. The present disclosure provides bicyclic reactants and aminothiol derivatives suitable for use in the condensation reaction. The condensation and luciferin-unmasking reactions find use in a variety of applications, which are also provided. | 01-21-2016 |
| 20160018398 | COMPOSITIONS AND METHODS FOR DETECTING ORAL NEOPLASM - Methods and kits for assessing the presence of, and for detecting cancer, notably oral cancer, are disclosed. Such methods and kits use one or more lectins operably linked to a fluorophore, wherein the lectin binds differentially to cancerous and non-cancerous tissues, and wherein the fluorophore facilitates visualizing the differential binding. The lectins are applied to the oral mucosa of a subject, the fluorophore is exposed to light, and cancerous regions of the mucosa are visualized. In certain embodiments, the lectin specifically binds to one or more of a β-galactoside, an α- or β-N-acetylglucosamine, or a sialic acid moiety. | 01-21-2016 |
| 20160018404 | MULTILAYER FLUORESCENT NANOPARTICLES AND METHODS OF MAKING AND USING SAME - A multilayer, fluorescently responsive material (FRM)-containing nanoparticle and compositions comprising such nano-particles. The nanoparticles can be made using a layer-by-layer deposition method. The nanoparticles can be used in imaging methods such as, for example, cellular imaging methods. | 01-21-2016 |
| 20160022578 | POLYPEPTIDE BASED BLOCK COPOLYMER AND THE PROCESS FOR THE PREPARATION THEREOF, AND THE POLYMER MICELLES USING THE SAME - The present disclosure relates to a polypeptide based block copolymer having biodegradability due to peptidase, and a process for the preparation thereof, and polymer micelles using the same. The block copolymer according to the present disclosure is a block copolymer of a polyethylene glycol-based compound having properties such that the solubility for water is different depending on the pH, but cannot form micelles due to a self-assembly phenomenon; and a polyglutamic acid-based compound formed using an aminolysis reaction of glutamic acid and tertiary amine in which the end of one alkyl group is substituted with NH | 01-28-2016 |
| 20160022681 | METHODS OF INCREASING LYMPHATIC TRANSPORT - Provided herein are methods of treating a lymphatic transport dysfunction or condition in a subject. Also provided are methods of preventing or reducing a flare in a subject with a lymphatic transport dysfunction or condition. Further provided are methods of monitoring lymphatic transport in a subject and methods of selecting a treatment protocol for a subject with a lymphatic transport dysfunction or condition. Further provided are methods of detecting a flare in a subject with a lymphatic transport dysfunction or condition. | 01-28-2016 |
| 20160025711 | FLUORESCENT MARKERS AND METHODS FOR IMAGING DISEASES - Methods and fluorescent probes that detect the presence of diseased cells such as cancer. The fluorescent probes are cloaked, turn-on probes having the fluorescence reporter released only in the presence of enzymes typically over-expressed in diseased and cancerous tissue. Probes include a fluorescent napthalimide reporter with a quinoidal moiety cloak. | 01-28-2016 |
| 20160030598 | Reaction-Based Fluorescent Probes for Detecting Zinc - Disclosed are compounds and methods useful in the detection of e.g., Zn | 02-04-2016 |
| 20160039792 | ACTIVITY-BASED PROBE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - Activity-based probe compounds for use in labeling a cysteine protease are provided. The compounds are targeted to the protease through a specific targeting element. The compounds additionally include a detectable element, such as a fluorescent label, a radiolabel, or a chelator. In some cases, the compounds additionally include a quenching element that is released upon reaction with the protease. Also provided are compositions comprising the compounds and methods for using the compounds, for example in labeling a protease in an animal and in visualizing a tumor in an animal. | 02-11-2016 |
| 20160041177 | COMPOSITIONS AND METHODS FOR MAKING AND USING OXYGEN SENSING NANOFIBERS AND SCAFFOLDS - To address the need for scaffold-based oxygen concentration monitoring, a single-component, self-referenced oxygen sensor was made into nanofibers. Electrospinning process parameters were tuned to produce a biomaterial scaffold with specific morphological features. The ratio of an oxygen sensitive phosphorescence signal to an oxygen insensitive fluorescence signal was calculated at each image pixel to determine an oxygenation value. A single component boron dye-polymer conjugate was chosen for additional investigation due to improved resistance to degradation in aqueous media compared to a dye polymer blend. Standardization curves show that in fully supplemented media, the fibers are responsive to dissolved oxygen concentrations less than 15 parts per million. Spatial and temporal ratiometric gradients were observed in vitro radiating outward from the center of a dense adherent cell grouping. Sensor activation in ischemia and cell transplant models in vivo show oxygenation decreases on the scale of minutes. | 02-11-2016 |
| 20160045609 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE - A delivery system for active agents, and methods of making and using the systems, are provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum. | 02-18-2016 |
| 20160045620 | USE OF NANOMETER-SIZED PRODRUGS OF NSAIDs TO TREAT TRAUMATIC BRAIN INJURY - The present invention describes methods of delivering derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) and nanospheres thereof as well as therapeutic agents to the injured brain tissue in subjects with traumatic brain injury. The invention also provides methods of treating traumatic brain injury and related conditions. The invention further provides methods of diagnosing traumatic brain injury. | 02-18-2016 |
| 20160045621 | COMPLEX OF MANNOSYL SERUM ALBUMIN, METHOD OF PREPARING THE SAME, OPTICAL IMAGING PROBE AND KIT COMPRISING THE SAME - The present invention relates to a complex prepared by conjugating indocyanine green to mannosyl serum albumin in order to overcome shortcomings such as low light stability and low in vivo stability of indocyanine green that is a fluorescent dye reagent that is used during surgical operations, a preparation method thereof, an optical imaging probe comprising the same, and a kit comprising the probe. | 02-18-2016 |
| 20160045622 | IN VIVO CELL IMAGING - This disclosure relates to the live imaging of native intracellular proteins in eukaryotic cells, typically mammalian cells, by means of a fluorescent bead coupled to a ligand, a cell penetrating peptide and a cell export peptide adapted to interact with cell secretory proteins to remove non-bound fluorescent beads. | 02-18-2016 |
| 20160053318 | MARKERS OF ENDOTHELIAL PROGENITOR CELLS AND USES THEREOF - The present invention provides markers of endothelial progenitor cells (EPCs) and use of those markers and reagents that bind thereto to detect EPC cells or diagnose, prognose, treat or prevent EPC-associated conditions. | 02-25-2016 |
| 20160060356 | ANTI-FAP ANTIBODIES AND METHODS OF USE - The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same. | 03-03-2016 |
| 20160067357 | DETECTION OF HIGH RISK DRUSEN - In some aspects, methods of detecting complement activation in vivo, e.g., in an eye, are provided. In some aspects, methods of detecting high risk drusen are provided. In some aspects, presence of one or more high risk drusen in an eye indicates increased likelihood of developing AMD, GA, or advanced AMD or increased likelihood of rapid progression of AMD. In some embodiments, methods comprise detecting drusen containing or in close proximity to complement activation. In some embodiments methods comprise detecting one or more drusen having inflamed endothelium underlying or in close proximity thereto. In some embodiments methods comprise detecting eye-derived extracellular microvesicles, e.g., exosomes, in a body fluid. In some embodiments methods comprise detecting Th17 cells or a Th17 biomarker in a body fluid. In some embodiments the Th17 biomarker is a cytokine. Methods may be applied individually or in any combination. In some embodiments any of the methods further comprises treating a subject at risk of developing AMD, GA, or advanced AMD or at increased likelihood of rapid progression of AMD with a complement inhibitor. In some aspects, agents useful for performing one or more of the methods are described. | 03-10-2016 |
| 20160067358 | TUMOR SPECIFIC ANITBODY CONJUGATES AND USES THEREFOR - Provided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Provided are antibody/nanoparticle conjugates. Also provided are compositions and delivery agents that include the disclosed antibodies, conjugates, fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject. | 03-10-2016 |
| 20160067359 | COMPOSITION HAVING DYE AND CONJUGATE OF POLYETHYLENEGLYCOL AND ADDITIVE AND CONTRAST AGENT FOR PHOTOACOUSTIC IMAGING HAVING THE SAME - The present invention provides contrast agents for photoacoustic imaging which exhibit high degrees of accumulation in tumor and low degrees of retention in the blood and can be administered into the blood. The contrast agents for photoacoustic imaging include a conjugate of a dye and a polyethyleneglycol represented by Formula (1), (5), (6), or (7) and an additive represented by Formula (301). | 03-10-2016 |
| 20160082131 | Activatable Membrane-Interacting Peptides and Methods of Use - The present disclosure provides activatable and detectable membrane-interacting peptides that, following activation, can interact with phospholipid bilayers, such as cell membranes. The present disclosure also provides methods of use of such compounds. The compounds of the present disclosure are of the general structure X | 03-24-2016 |
| 20160083426 | NON-BENZENOID AROMATIC SYSTEMS FOR IMAGING, MONITORING AND THERAPY - This invention is directed to non-benzenoid aromatic compounds. Other aspects include methods of using non-benzenoid aromatic compounds for imaging and phototherapeutic uses thereof. Non-benzenoid compounds provided herein generally have one or more substituent groups which allow tailoring of the spectral properties or provide photoreactivity or targeting ability. | 03-24-2016 |
| 20160089447 | Cell Penetrating Peptides for Intracellular Delivery of Molecules - A cell-penetrating peptide characterized in that it comprises an amino acid sequence X | 03-31-2016 |
| 20160090376 | PYRAZINE DERIVATIVES WITH EXTENDED CONJUGATION AND METHODS OF USING THE SAME IN OPTICAL APPLICATIONS - The present invention relates to pyrazine derivatives capable of absorbing and emanating spectral energy in the visible and/or near infrared spectrum. Pyrazine derivatives of the invention may be administered to a patient in the form of a pharmaceutically acceptable composition and utilized in medical (e.g., diagnostic imaging) procedures. | 03-31-2016 |
| 20160095838 | TARGETED POLYMERIC CONJUGATES AND USES THEREOF - Polymeric conjugates comprising a polymeric backbone having attached thereto a bone targeting moiety and a therapeutically active agent, wherein the bone targeting moiety is attached to one end of the polymeric backbone via a branching unit such that a molar ratio of the bone targeting moiety to the polymer is at least 2:1, are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of bone related disorders are also disclosed. | 04-07-2016 |
| 20160106851 | Groundbreaking Platform Technology for Specific Binding to Necrotic Cells - A system comprising a targeting molecule for binding necrotic cells; to the system for use as a medicament; to use of the system for diagnosis; to the system for use in treatment of diseases involving necrotic cell death, to a dosage comprising the system; to a method for determining localization of the composition within a sample using said system; and, to a method for treatment of cancers and/or diseases involving necrotic cell death using said system. In particular the invention relates to compositions targeting necrotic cells. | 04-21-2016 |
| 20160106867 | NEAR INFRARED LABEL AND METHODS OF USE THEREOF - The present invention provides compounds useful as novel near-infrared labels, compositions containing these compounds, and methods of using the near-infrared labels to identify targets in vitro, in situ and in vivo. The invention also provides small or large molecule conjugates between targeting agents and NIR labels, as well as methods and kits thereof, that can be used in diagnostics and treatment of diseases related to microbes in mammalian animals. | 04-21-2016 |
| 20160106868 | OXYGEN FREE RADICAL DETECTION - Ratiometric techniques can be used to determine activity levels of reactive oxidation species (“ROS”) in a target area (in vitro or in vivo) to indicate inflammatory responses and/or infection. Target areas may be a tissue surface, a wound, and/or a body cavity. A ROS-sensitive bioluminescent agent and ROS-insensitive fluorescent reference dye are conjugated to surfaces, biocompatible particles, or polymer carriers. The compounds may be constituted as a spray, solution for injection, a wound dressing, medical implants, and/or medical device. The bioluminescent compound and reference fluorescent intensity ratios can be calculated to reflect the extent of localized ROS activities. | 04-21-2016 |
| 20160106869 | FLUORESCENT SOLID LIPID NANOPARTICLES COMPOSITION AND PREPARATION THEREOF - The present invention discloses a solid lipid nanoparticle (SLN) comprising: a) a solid lipid core comprising at least a glyceride and/or at least a fatty acid; b) a mixture of amphiphilic components forming a shell around said core a); c) an alkaline-earth complex with a compound of formula I and/or II: d) at least a fluorescent dye selected from: a cyanine fluorescent dye and/or a polyetherocyclic compound selected from: coumarin, pyrano, quinoline, pyranoquinoline, indole and pyranoindole derivates in acid form or a pharmaceutically acceptable salt thereof. These nanoparticles allow a prolonged blood circulation half-life, show enhanced photostability and improved fluorescence signal. The dye is preserved from degradation and improves the fluorescent quantum yield. | 04-21-2016 |
| 20160120814 | Method for Preparing Protein Cage, and In Situ Method for Preparing Hydrophobic Additive-supported Core-shell Structured Polymer-protein Particles - The present invention relates to a method for preparing a protein cage which comprises: a 1 | 05-05-2016 |
| 20160121002 | Bioorthogonal Turn-on Probes - This present application relates to fluorescent tetrazine-containing compounds consisting of a single pi-system. For example, a compound of Formula (I): or a salt thereof, wherein: F is a fluorophore, L is a conjugated linker, and Tz is a substituted or unsubstituted tetrazine; wherein the linker bridges the Tz and F moieties in a single conjugated pi-system. Also provided herein are methods of using the compounds provided herein for biomedical imaging. | 05-05-2016 |
| 20160129136 | NOVEL COMPOSITIONS AND USES THEREOF - Compositions comprising one or more nanoparticles, wherein the nanoparticles encapsulate fluorescence dyes are disclosed. In one embodiment, the nanoparticle comprises triterpene. In another embodiment, the nanoparticle comprises triterpene and fatty ester. Methods for performing a diagnostic or a therapeutic procedure comprising administering to a subject an effective amount of the compositions of the present invention or carbocyanine dyes are also provided. | 05-12-2016 |
| 20160129137 | COMPOSITION FOR MONITORING AGED TISSUES, COMPRISING BACTERIA, AND USE THEREOF - A recombinant bacterium for detecting aged tissues and a method of detecting aged tissues in a subject, and a composition for delivering a drug to aged tissues are provided. | 05-12-2016 |
| 20160136088 | SILICA HYDROGEL COMPOSITE - This invention relates to a silica hydrogel composite obtainable by mixing silica particles, comprising an encapsulated agent, with a silica sol, wherein obtained hydrogel composite is shear-thinning. The present invention also relates to use of the silica hydrogel composite according to the invention for an injectable, flowing or extrudable formulation. The present invention further relates to a method for preparing the silica hydrogel. | 05-19-2016 |
| 20160136241 | METHODS OF PREPARING AND USING SERICIN HYDROGEL - A method for preparing a sericin hydrogel, the method including: 1) weighing a cocoon of a fibroin-deficient mutant silkworm, | 05-19-2016 |
| 20160136302 | POLYETHYLENE GLYCOL BASED OLIGOMERS FOR COATING NANOPARTICLES, NANOPARTICLES COATED THEREWITH, AND RELATED METHODS - In a composition aspect of the invention, a nanoparticle coating comprises repeating polyacrylic acid monomers covalently bound together in an aliphatic chain having a plurality of carboxylic acid functional groups and modified carboxylic acid functional groups extending therefrom. A first portion of the modified carboxylic acid functional groups are modified by a PEG oligomer having a terminal methoxy functional group and a second portion of the modified carboxylic acid functional groups are modified by a PEG oligomer having at least one terminal sulfur moiety. | 05-19-2016 |
| 20160151517 | Probes for Imaging of Hypoxia | 06-02-2016 |
| 20160152670 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | 06-02-2016 |
| 20160168383 | CYANINE COMPOUNDS | 06-16-2016 |
| 20160175464 | BRANCHED AMPHIPATHIC BLOCK POLYMER AND MOLECULAR AGGREGATE AND DRUG DELIVERY SYSTEM USING SAME | 06-23-2016 |
| 20160176819 | ASYMMETRICALLY CHARGED NIR FLUOROPHORES | 06-23-2016 |
| 20160176931 | RED GENETICALLY ENCODED CALCIUM INDICATORS AND METHODS OF USE | 06-23-2016 |
| 20160193332 | Activatable Antibodies That Bind Epidermal Growth Factor Receptor And Methods Of Use Thereof | 07-07-2016 |
| 20160194690 | FLUOROPHORE CHELATED LANTHANIDE LUMINESCENT PROBES WITH IMPROVED QUANTUM EFFICIENCY | 07-07-2016 |
| 20160199515 | Compositions Comprising Fluorescent Dyes Associated With Viral Components For Nerve Imaging | 07-14-2016 |
| 20160199516 | METHOD OF PREPARATION OF BIODEGRADABLE NANOPARTICLES WITH RECOGNITION CHARACTERISTICS | 07-14-2016 |
| 20160200826 | Anti-Jagged 1/Jagged 2 Cross-Reactive Antibodies, Activatable Anti-Jagged Antibodies And Methods Of Use Thereof | 07-14-2016 |
| 20160250355 | METHODS AND DIAGNOSTIC KIT FOR VISUALIZING BODY TISSUES AND COMPONENTS THEREIN | 09-01-2016 |
| 20160250605 | MIXING DEVICE, MIXING TUBE, DRUG SOLUTION INJECTING SYSTEM, AND DRUG SOLUTION MIXING METHOD | 09-01-2016 |
| 20160251436 | Anti-PD-1 Antibodies | 09-01-2016 |
| 20160375153 | SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS - The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for incorporating the compounds as used for the targeted imaging of tumors. Conjugation of the amino acid linking groups increase specificity and detection of the compound. Methods and compositions for use thereof in diagnostic imaging are contemplated. | 12-29-2016 |
| 20170232120 | DENDRIMER COMPOSITIONS AND USE IN TREATMENT OF NEUROLOGICAL AND CNS DISORDERS | 08-17-2017 |
| 20170233745 | UREIDOPYRIMIDONE SUPRAMOLECULAR COMPLEXES FOR COMPOUND DELIVERY INTO CELLS | 08-17-2017 |
| 20180021446 | SYSTEMS FOR STABILIZING AND DELIVERING ACTIVE AGENTS | 01-25-2018 |
| 20180021460 | PROBES AND METHODS FOR DETECTING AMYLOIDOGENIC PROTEINS | 01-25-2018 |
| 20180022878 | Facile Assembly of Soft Nanoarchitectures and Co-Loading of Hydrophilic and Hydrophobic Molecules via Flash Nanoprecipitation | 01-25-2018 |
| 20190142752 | STABLE NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS METHODS AND SYSTEMS | 05-16-2019 |
| 20190142956 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF FIBROSIS | 05-16-2019 |
| 20190142976 | COMPOSITIONS AND METHODS FOR ASSESSING GUT FUNCTION | 05-16-2019 |
| 20220133914 | OPTICALLY HEAT-GENERATING COMPOSITE MATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER AND PHARMACEUTICAL COMPOSITION - The present invention provides a photo-exothermic composite material represented by Formula (I) of CNM-(Y | 05-05-2022 |
